

CONSENSUS REPORT

Diagnosis, treatment and prevention of infective endocarditis: Turkish consensus report-2019*

İnfektif endokarditin tanısı, tedavisi ve önlenmesi: Ulusal uzlaşısı raporu-2019*

ID Serap Şimşek Yavuz, M.D.,¹ ID Ahmet Rüçhan Akar, M.D.,² ID Sinan Aydoğdu, M.D.,³ ID Deneş Berzeg Deniz, M.D.,¹
 ID Hakan Demir, M.D.,⁴ ID Tuncay Hazırolan, M.D.,⁵ ID Mehmet Ali Özatik, M.D.,² ID Necla Özer, M.D.,³
 ID Murat Sargın, M.D.,² ID Emine Nursen Topcuoğlu, M.D.,⁶ ID Nesrin Turhan, M.D.,⁷ ID Mehmet Birhan Yılmaz, M.D.,³
 ID Özlem Azap, M.D.,¹ ID Seniha Başaran, M.D.,¹ ID Yasemin Çağ, M.D.,¹ ID Atahan Çağatay, M.D.,¹ ID Güle Çınar, M.D.,¹
 ID Sibel Doğan Kaya, M.D.,¹ ID Lokman Hızmalı, M.D.,¹ ID Mehmet Emirhan Işık, M.D.,¹ ID Nurgül Kılıçaslan, M.D.,¹
 ID Şirin Menekşe, M.D.,¹ ID Meliha Meriç-Koç, M.D.,¹ ID Serpil Öztürk, M.D.,¹ ID Ayfer Şensoy, M.D.,¹
 ID Yasemin Tezer-Tekçe, M.D.,¹ ID Elif Tükenmez-Tigen, M.D.,¹ ID Yeşim Uygun-Kızmaz, M.D.,¹
 ID Mutlu Şeyda Velioğlu-Öcalmaz, M.D.,¹ ID Ayşegül Yeşilkaya, M.D.,¹ ID Emel Yılmaz, M.D.,¹ ID Nezih Yılmaz, M.D.,¹
 ID Fatma Yılmaz-Karadağ, M.D.,¹

¹Turkish Society of Clinical Microbiology and Infectious Diseases, Infective Endocarditis and Other Cardiovascular Infections Study Grup (Istanbul University, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Başkent University, İstanbul Medeniyet University, Ankara University, Kartal Koşuyolu High Speciality Training and Research Hospital, Kırşehir Ahi Evran University, Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Bezmialem Vakıf University, Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, Ankara City Hospital, Marmara University, Uludağ University, Yozgat Bozok University, Göztepe Training and Research Hospital), İstanbul, Turkey; ²Turkish Society of Cardiovascular Surgery (Ankara University, Ankara City Hospital, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital), İstanbul, Turkey; ³Turkish Society of Cardiology (Ankara City Hospital, Hacettepe University, Dokuz Eylül University), İstanbul, Turkey; ⁴Turkish Society of Nuclear Medicine (Kocaeli University), Ankara, Turkey; ⁵Turkish Society of Radiology (Hacettepe University), Ankara, Turkey; ⁶Turkish Dental Association (İstanbul University), Ankara, Turkey; ⁷Federation of Turkish Pathology Societies, Cardiovascular System Study Group (Ankara City Hospital), Ankara, Turkey

Summary– Infective endocarditis (IE) is a rare but still important as an infectious disease due to high rate of morbidity and substantial mortality. Although IE is not a notifiable disease in Turkey, and an incidence study has not been performed, the incidence may be higher than that in the developed countries due to frequent predisposing cardiac conditions and higher rates of nosocomial bacteremia, which may lead to IE in risk groups. IE generally affects the elderly in developed countries but it is frequently encountered among young individuals in Turkey. In order to reduce mortality and morbidity, it is critical to diagnose IE, to determine the causative agent, and to start treatment rapidly. Most patients cannot be diagnosed at the first visit, about half can be diagnosed after 3 months, and the disease often goes unnoticed. In patients diagnosed with IE, the rate of the identification of a causative organism is significantly lower in Turkey than that in developed countries. Some im-

Özet– İnfektif endokardit (İE) nadir görülmesine karşın, yol açtığı morbiditeler ve yüksek mortalite hızı nedeniyle halen önemini koruyan bir enfeksiyon hastalığıdır. Türkiye’de İE’nin bildirimi zorunlu bir hastalık olmamasına ve yapılmış bir insidans çalışması bulunmamasına karşın, gerek İE yakınlığını artıran durumların, gerekse riskli hastalarda İE ile sonuçlanabilen nozokomiyal bakteriyemi oranlarının daha fazla olması nedeniyle, ülkemizdeki İE insidansının daha yüksek olması beklenir. Gelişmiş ülkelerde genellikle yaşlı insanları etkileyen İE, ülkemizde halen genç insanları etkileyebilmektedir. Bu hastalığın mortalite ve morbiditesinin azaltılması için, hızlıca tanınması ve etkeninin belirlenerek, etkene yönelik tedavisinin yapılması kritik öneme sahiptir. Ancak hastaların çoğuna ilk başvurularında tanı konulamamakta, yaklaşık yarısında tanı 3 aydan sonra konulabilmekte ve hastalık sıklıkla gözden kaçmaktadır. İE tanısı konulmuş hastalarda, bu enfeksiyona neden olan mikroorganizmaların belirlenme

Received: January 15, 2020 Accepted: January 31, 2020

Correspondence: Dr. Serap Şimşek Yavuz. İstanbul Tıp Fakültesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, İstanbul, Turkey.

Tel: +90 505 - 269 64 12 e-mail: serapsimsekyavuz@gmail.com

© 2020 Turkish Society of Cardiology



portant microbiological diagnostic tests are not performed in most centers and several antimicrobials that are recommended as the first option for the treatment particularly antistaphylococcal penicillins, are unavailable in Turkey. These problems necessitate reviewing the epidemiological, laboratory, and clinical characteristics of IE in our country, as well as the current information about its diagnosis, treatment, and prevention together with local data. The diagnosis and treatment processes of IE should be standardized at every stage so that the management can be conducted in a setting in which physicians of various specialties are involved and is consistent with the current recommendations. The Study Group for Infective Endocarditis and Other Cardiovascular Infections of the Turkish Society of Clinical Microbiology and Infectious Diseases called for the collaboration of the relevant specialist organizations to establish a consensus report on the diagnosis, treatment, and prevention of IE in the context of current information and local data in Turkey.

Although infective endocarditis (IE) is rare, it is still important as an infectious disease because of the resulting morbidity and substantial mortality. Epidemiological studies in developed countries have shown that the incidence of IE has been approximately 6/100,000 in recent years and it is ranked fourth among the most life-threatening infectious diseases after sepsis, pneumonia, and intraabdominal infections. Although IE is not a reportable disease in Turkey, and an incidence study has not been performed, the incidence may be expected to be higher than in developed countries due to both the more frequent presence of predisposing cardiac conditions and higher rates of nosocomial bacteremia, which may lead to IE in risk groups. Additionally, while IE generally affects elderly people in developed countries, it develops in young people in Turkey. In order to reduce mortality and morbidity, it is critical to diagnose IE, to determine the causative agent, and to start treatment rapidly. However, most patients cannot be diagnosed at the first visit, about half can be diagnosed after 3 months, and the disease often goes unnoticed. In patients diagnosed with IE, the rate of identification of causative organisms is more than 90% in developed countries, while it is around 60% in Turkey. Some important microbiological diagnostic tests are not performed in most centers. Some antimicrobials that are recommended as the first option for treatment of IE, particularly antistaphylococcal penicillins, are unavailable in Turkey.^[1-18] These problems

oranı gelişmiş ülkelere göre Türkiye'de çok daha düşüktür. İE'li hastaların tanısının konulmasında kullanılabilecek bazı önemli mikrobiyolojik testler bu hastaları izleyen merkezlerin çoğunda yapılamamaktadır. Tedavide ilk seçenek olarak önerilen, başta antistafilokoksik penisilinler olmak üzere önemli bazı antimikrobik ajanlar ülkemizde piyasada yoktur. Bu sorunlar, ülkemizde hem İE'nin epidemiyolojik, laboratuvar ve klinik özelliklerini, hem de tanısı, tedavisi ve önlenmesiyle ilgili güncel bilgileri, yerel verileri de içerecek şekilde gözden geçirmeyi zorunlu kılmaktadır. İE'li hastalar birçok uzmanlık dalından hekim tarafından izlenebilir. Birçok daldan hekimin rol aldığı İE'li hastaların yönetiminin daima güncel önerilere uygun olarak yapılabilmesi için, İE'nin tanı ve tedavi süreçlerinin her aşamada standardize edilmesi gerekir. Bu bakış açısıyla, Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Derneği İnfektif Endokardit ve Diğer Kardiyovasküler İnfeksiyonlar Çalışma Grubu, ülkemizde güncel bilgilerin ve yerel verilerin ışığında İE'nin tanısı, tedavisi ve önlenmesine yönelik bir uzlaşma raporu oluşturabilmek amacıyla ilgili ulusal uzmanlık kuruluşlarına bir işbirliği çağrısında bulunmuştur.

necessitate reviewing the epidemiological, laboratory, and clinical characteristics of IE in our country, as well as the current information about its diagnosis, treatment, and prevention alongside local data. Patients with IE may be patients of physicians in many specialties. Diagnosis and treatment processes for IE should be

Abbreviations:

18F-FDG	18F-fluorodeoxyglucose
AHA	American Heart Association
ANA	Anti-nuclear antibody
ANCA	Antineutrophil cytoplasmic antibodies
ARA	Acute rheumatic fever
CIED	Cardiac implantable electronic devices
CRP	C-reactive protein
CT	Computed tomography
cTnI	Cardiac troponin I
ESC	European Society of Cardiology
ESR	Erythrocyte sedimentation rate
HACEK	Haemophilus parainfluenzae, Aggregatibacter spp. Cardiobacterium spp. Eikenella corrodens and Kingella spp.
IFA	Immunofluorescence assay
IVDU	Intravenous drug use
IE	Infective endocarditis
IM	Intramuscularly
IV	Intravenously
MDCTA	Electrocardiogram-gated multidetector computed tomography angiography
MIC	Minimum inhibitory concentration
MRI	Magnetic resonance imaging
MRSA	Methicillin-resistant Staphylococcus aureus
MSSA	Methicillin-sensitive Staphylococcus aureus
NBTE	Non-bacterial thrombotic endocarditis
NT-pro-BNP	N-terminal pro b-type natriuretic peptide
NYHA	New York Heart Association
PCR	Polymerase chain reaction
PET	Positron emission tomography
RF	Rheumatoid factor
SPECT	Single-photon emission computed tomography
TEE	Transesophageal echocardiogram
TTE	Transthoracic echocardiogram

standardized at every stage so that management of IE can always be in line with current recommendations and should be conducted in a setting in which several physicians are involved. With this in mind, the Study Group for Infective Endocarditis and Other Cardiovascular Infections of the Turkish Society of Clinical Microbiology and Infectious Diseases called for the collaboration of relevant specialist organizations to create a consensus report on the diagnosis, treatment, and prevention of IE in the context of current information and local data in Turkey. In periodic meetings of the assigned representatives of all of the parties, various questions were identified and consensus answers were developed based upon a review of the related literature and international guidelines.

1. Why was this consensus report written?

IE generally affects elderly people in developed countries, but it still also affects young people in Turkey. It is one of the most life-threatening infectious diseases and frequently leads to mortality. Compared with European countries and the United

States, patients in Turkey with IE are younger, the predisposing factors are different, identification rate of IE pathogens is lower, access to some important diagnostic tests is not possible or hardly possible, and some of the antimicrobials recommended for treatment are not available in our country. Therefore, European and American diagnostic and treatment guidelines do not completely meet our requirements and these conditions led to the preparation of a national consensus report for IE.^[1–18]

Epidemiology of Infective Endocarditis in Turkey and Globally

2. What is the incidence of infective endocarditis in our country and globally?

The incidence of IE is approximately 6/100,000 glob-

Table 1. Comparison of epidemiological and clinical features of patients with infective endocarditis in Turkey and USA/Europe

Feature	Turkey	USA/Europe
Age, years (mean)	47	61
Male (%)	60	65
Predisposing conditions (%)		
Acute rheumatic fever	37	1.85
Prosthetic valve	28	10–30
Intravenous drug use	2	24
Cardiac implantable electronic device	7	15
Chronic hemodialysis	9	13
Causative microorganisms (%)		
<i>Staphylococcus aureus</i>	21	32
<i>Viridans streptococci</i>	19	18
Coagulase-negative Staphylococci	10	11
<i>Enterococcus</i> spp.	9	11
<i>Brucella</i> spp.	7	–
Blood culture-negative (%)	37	8
Nosocomial endocarditis (%)	25	25
Mortality (%)	24	19

Table 2. The incidence of infective endocarditis among risk groups

Predisposing condition	Incidence (per 100,000 population)
General population	
Mean	6
>70 years old	12
>75 years old	19
Structural heart valve diseases	
Rheumatic and degenerative heart valve diseases	348
Mitral valve prolapsus (regurgitating)	48
Congenital heart diseases	
Ventricular septal defect (small)	480
Bicuspid aortic valve	66
Intracardiac foreign body	
Prosthetic valve	>1000 (2800)
Transcatheter aortic valve implantation	>1000
Permanent pacemaker/intracardiac defibrillator	1000
Previous infective endocarditis	7300
Patient with renal failure	
End-stage chronic renal failure	627
Hemodialysis	1092
Intravenous drug use	1125
Solid organ transplant	1350

ally. There are no data about the incidence of IE in Turkey, though it is predicted to be higher in our country due to higher incidences of both valvular diseases and nosocomial bacteremia.^[19–51] A comparison of epidemiological features of IE cases in Turkey and the USA and Europe is shown in Table 1.

3. Which patient populations have a greater risk of developing infective endocarditis in our country and globally?

IE is more frequently seen in patients with a previous episode of IE, valvular heart disease, congenital heart disease, any intracardiac prosthetic material, intravenous drug use (IVDU), chronic hemodialysis treatment, and solid organ or hematopoietic stem cell transplantation compared with the normal population. The incidence of IE among risk groups is shown in Table 2.^[2,4,5,23,27–31,45,50,52–84]

4. Which microorganisms are most frequently identified as the cause of infective endocarditis in our country and globally?

The most frequent causative microorganisms are, in order, *Staphylococcus aureus*, streptococci, coagulase-negative staphylococci, and enterococci, both in Turkey and globally. *Brucella* spp. are the fifth most common causative agent of IE in Turkey (Table 1). *Coxiella burnetii*, which is one of the main causes of blood culture-negative IE globally, has been identified in some case reports from our country and so it must be included in the differential diagnosis. Although *Bartonella* spp. and *Tropheryma whippelii* are frequently the causes of blood culture-negative IE globally, there are no available data about these causative agents in Turkey and research concerning these agents should be performed. Gram-negative bacilli and fungi are generally causative agents of healthcare-associated IE. *Mycobacterium chimaera* should be kept in mind as a possible pathogen for blood culture-negative IE in patients who underwent implantation of an intracardiac prosthetic device, such as a prosthetic heart valve, in the last decade.^[4,82,85–127]

Pathogenesis of Infective Endocarditis

5. What is the pathogenesis of infective endocarditis?

Mechanical injury on the endocardial surface leads to the formation of non-bacterial thrombotic endocardi-

tis and bacterial adhesion on the surface occurs during transient bacteremia. The vegetation enlarges and becomes mature through bacterial proliferation, deposition of fibrinogen, and platelet aggregation. *S. aureus* may bind directly to an inflamed but structurally intact endocardial surface and instead being ingested by endothelial cells, causing cellular tissue lysis and damage. These damaged cells induce the release of tissue factor and cytokines, causing blood clotting and promoting the extension of inflammation and vegetation formation.^[21,27,86,128–136]

Diagnosis of Infective Endocarditis

6. What are the clinical features in patients with infective endocarditis and which clinical signs should lead to the suspicion of infective endocarditis?

Acute IE must be in the differential diagnosis in patients admitted to the emergency room with a fever who have predisposing factors for IE (valvular heart diseases; intracardiac prosthetic devices, such as a prosthetic valve; IVDU; or chronic hemodialysis, etc.), and in patients who have sepsis of an unknown source, peripheral embolism, multiple infectious foci of sepsis, or a new-onset murmur.

Both subacute and chronic IE must be kept in mind in the differential diagnosis of patients with unexplained fever, fatigue, weight loss, and elevated acute phase reactants; unexplained arterial emboli, including the central nervous system and the pulmonary system; unexplained heart or valvular failure; and unexplained blood culture positivity, especially if there is a predisposing condition for IE.^[4,14,23,137–143]

7. What are the laboratory findings of infective endocarditis?

Continuous bacteremia in patients with IE causes continuous intravascular stimulation, which consequently leads to acute phase responses to the causative agent and excessive production of both antibodies and immune complexes. Some laboratory test results may be either lower or higher than the normal range due to either sepsis or organ failure caused by the disease itself.^[144–172]

8. Which echocardiographic methods should be used in the diagnosis of infective endocarditis and what is the appropriate timing?

Transthoracic echocardiography (TTE) must be per-

formed for all patients with suspected IE as soon as possible. Transesophageal echocardiography (TEE) must be performed in case of a negative TTE result when there is a high index of suspicion for IE, particularly when the TTE is of suboptimal quality. TEE should also be performed for patients with a prosthetic valve or other intracardiac prosthetic device.^[3,65,66,141,173–183]

9. What are the echocardiographic findings leading to a diagnosis of infective endocarditis?

Vegetation, abscess, pseudoaneurysm or intracardiac fistula, valvular aneurysm or perforation, new partial dehiscence of a prosthetic valve, and new or worsening valvular regurgitation are echocardiographic findings and images that raise the suspicion of IE.^[3,65,66,141]

10. What are the sensitivities and specificities of echocardiographic examinations for diagnosis of infective endocarditis?

The sensitivity of TTE and TEE for the detection of vegetation in IE patients is 70% and 96%, respectively, in native valves, and 50% and 92%, respectively, in prosthetic valves. Both modalities have a specificity of 90% for the detection of vegetation.^[173]

11. What is the role of echocardiography in the determination of response to treatment and during follow-up of infective endocarditis?

While the size and mobility of the vegetation is expected to decrease with effective antimicrobial treatment, an increase in vegetation size should be taken into account as a risk factor for a new embolic event. It is difficult to interpret persisting and unchanging vegetation size. In this situation, the patient should be evaluated carefully with other clinical and laboratory findings. A well-timed echocardiogram is of vital importance to identify patients with the symptoms and signs (shortness of breath, rhythm-conduction disorders, etc.) of a local cardiac complication (abscess, heart failure, etc.) requiring emergent surgery.^[3,173–186]

12. When should cardiac computed tomography be performed in patients with suspected infective endocarditis and what are the advantages and disadvantages?

Although cardiac computed tomography (CT) has the advantage of providing more information about cardiac anatomy (anatomy of pseudoaneurysm, abscess, fistula, and perivalvular extension), it is inferior to TEE in the detection of vegetation. Cardiac CT should

be performed in the event of high suspicion of either native or prosthetic valve endocarditis following a negative TEE.^[65,175,187,188]

13. When should magnetic resonance imaging be performed in patients with suspected infective endocarditis and what are the advantages and disadvantages?

The experience using cardiac magnetic resonance imaging (MRI) to define cardiac pathologies in patients with IE is limited. Existing proof suggests that cardiac MRI can be a good option to evaluate the cardiac anatomy, like cardiac CT. Further studies are needed. Currently, MRI is generally used to visualize intracranial complications in patients with neurological symptoms. A cranial MRI should be the diagnostic choice for IE patients with neurological symptoms, as its sensitivity is greater than that of a cranial CT in the detection of cranial lesions.^[65,189,190]

14. When should 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging be performed in patients with suspected infective endocarditis and what are the advantages and disadvantages?

Imaging with 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/CT can be used to confirm the diagnosis by identifying both valvular and paravalvular lesions in patients with the suspicion of prosthetic valve endocarditis 3 months after the surgery when the TEE result was negative. 18F-FDG PET/CT can also be used to define septic foci outside the heart in both native and prosthetic valve endocarditis. The most important advantages of this modality are the ability to define infectious foci both inside and outside the heart, to establish functional data, and to monitor response to treatment. False-positivity, especially within the first 3 months after surgery in early prosthetic valve endocarditis and the lower sensitivity to diagnose intracardiac pathologies in native valve endocarditis are disadvantages of 18F-FDG PET/CT.^[175,191–197]

15. When should radiolabeled leukocyte scintigraphy with single photon emission computed tomography be performed in patients with suspected infective endocarditis and what are the advantages and disadvantages?

Radiolabeled leukocyte scintigraphy with single-photon emission computed tomography (SPECT)/CT can

be used as an imaging modality for the diagnosis of prosthetic valve endocarditis within the first 3 months of prosthesis implantation. Although scintigraphy has a higher specificity, the most important disadvantage is a lower sensitivity.^[65,198,199]

16. What should the algorithm be for imaging modalities in the diagnosis of infective endocarditis?

Echocardiography is the first imaging modality of choice to define cardiac lesions in patients with suspected IE. Both TTE and TEE are necessary in almost all patients. TTE and TEE are inconclusive in approximately 15% of all IE cases, whereas the percentage is up to 30% in patients with intracardiac prosthetic devices, such as a prosthetic valve or a cardiac implantable electronic device (CIED). In these patients, cardiac CT should be the imaging technique in patients with native valve endocarditis, while cardiac CT or SPECT/CT should be applied for patients who have prosthetic valve endocarditis within the first 1–3 months of valve surgery, and cardiac CT and PET/CT should be selected for patients with prosthetic valve endocarditis 3 months after

valve surgery.^[65,66,173–176] A flowchart for the diagnostic imaging work-up of patients suspected of IE is presented in Figure 1.^[175]

17. How should blood culture sampling be performed in patients with suspected infective endocarditis?

In patients with suspected IE, 3 sets of blood cultures (3 pairs of aerobic and anaerobic bottles, 6 bottles in total) should be drawn at 30-minute intervals without waiting for a febrile period. Each blood culture set, comprising 1 aerobic and 1 anaerobic bottle, should be inoculated with 18–20 mL of blood (9–10 mL blood per bottle). A total of 60 mL of blood should be drawn from a patient with suspected IE. In patients who had cardiac surgery in the previous decade and there is a suspicion of prosthetic valve endocarditis, 3 additional blood culture bottles specified for mycobacterial growth should be inoculated, unless there is microbial growth in the initial blood culture bottles. Two sets of control blood cultures should be repeated every 48 hours after the initiation of therapy until the blood cultures are sterile.^[3,65,86,119,200–207]




Figure 1. Flowchart for the diagnostic imaging work-up of patients suspected of infective endocarditis.^[175] Yellow circles indicate the end of a diagnostic pathway when efforts to diagnose (extracardiac complications of) infective endocarditis can be ceased. *Allocation specifically for the detection of extracardiac foci. FDG PET: Fluorodeoxyglucose positron emission tomography; MDCTA: Electrocardiogram-gated multidetector computed tomography angiography; TEE: Transesophageal echocardiogram; TTE: Transthoracic echocardiogram.

18. How should valvular tissue or embolic specimens resected during surgery be cultured for the diagnosis of infective endocarditis?

Excised valvular tissue from patients with suspected IE should be evaluated both microbiologically (stains, culture, molecular techniques) and histopathologically.^[208–210]

19. Which serological tests should be performed for the diagnosis of infective endocarditis and when?

In patients with negative blood cultures, a Wright

agglutination test (with Coomb's serum) and a *Coxiella* phase 1 immunoglobulin G (IgG) test with the reference immunofluorescence assay (IFA) should be performed first. If the results of these 2 tests are negative, IgG antibodies for *Bartonella* spp., *Legionella* spp., *Chlamydia* spp., and *Mycoplasma* spp. should be tested, preferably using an IFA.^[4,111,112,210–216]

20. What molecular tests can be used in either blood or tissue samples of patients with suspected infective endocarditis and when should they be considered?




Figure 2. Diagnostic testing algorithm for the identification of the microbiological etiology of infective endocarditis. ¹Blood cultures: Three sets of blood cultures (a total of 6 bottles each inoculated with 10 mL of blood) collected from different venipuncture sites with at least 1 hour between the first and last draw. ²In patients who are suspected of having prosthetic valve endocarditis, 3 additional blood culture bottles specified for mycobacterial growth (BD BACTEC Myco/F Lytic [Becton, Dickinson and Company, Franklin Lakes, NJ, USA], etc.) should be inoculated, unless there is microbial growth in the usual blood culture bottles. ³PCR assays: Multiplex PCR tests targeting streptococci and staphylococci (LightCycler, SeptiFast, [F. Hoffmann-La Roche Ltd., Basel, Switzerland], etc.) or broad-range bacterial (16S rRNA) or fungal (18S rRNA) PCR followed by sequencing (SepsiTest; Molzym, Bremen, Germany, etc.) should be done for patients with blood culture-negative endocarditis who had taken antibiotics before admission. For patients with positive serological test results, organism-specific PCR should be conducted. ⁴Serologic testing: Wright agglutination test with Coombs serum or Brucellacapt test (Viracell S.L., Granada, Spain), *Coxiella burnetii* phase I IgG, *Bartonella quintana* IgG, and *Bartonella henselae* IgG should be ordered first. If those test results are negative, then *Legionella* spp. IgG, *Mycoplasma* spp. IgG, *Chlamydia pneumoniae* IgG and galactomannan antigen for *Aspergillus* spp. should be investigated in the serum. Interpretation of serological test results: *Coxiella burnetii* phase I IgG antibodies >1/800, *Bartonella* spp. IgG antibodies >1/800, *Chlamydia pneumoniae* IgG antibodies >1/512, *Legionella* spp. IgG antibodies >1/256, Wright agglutination test >1/160 Brucellacapt IgG antibodies >1/320, and a galactomannan optic density index of ≥ 0.5 should be considered positive. ANA: antinuclear antibody; EDTA: Ethylenediaminetetraacetic acid; HACEK: *Haemophilus parainfluenzae*, *Aggregatibacter* spp., *Cardiobacterium* spp., *Eikenella corrodens*, and *Kingella* spp.; IFA: Indirect immunofluorescence assay; IgG: Immunoglobulin G; MALDI-TOF: Matrix-assisted laser desorption ionization-time of flight; MIC: Minimum inhibitory concentration; PCR: Polymerase chain reaction.

Multiplex polymerase chain reaction (PCR) tests, such as SeptiFast (F. Hoffmann-La Roche Ltd., Basel, Switzerland) and SeptiTest (Molzym, Bremen, Germany), etc. should be used to identify the pathogen in a whole blood specimen of patients with suspected IE whose blood cultures are negative and the patient previously received antibiotic therapy. If the blood cultures are negative in a patient who has not received antibiotic therapy, then 16S rRNA gene and *Tropheryma whippelii* PCR testing should be performed on the resected heart valve obtained during surgery.^[140,217–225]

21. What is the contribution of a histopathological examination of valvular tissue excised from patients with suspected infective endocarditis?

Histopathological examination of resected valvular tissue provides valuable information about the activation and degree of the inflammation in patients with blood culture-positive IE, whereas in blood culture-negative IE patients, it provides a means to identify pathogens, particularly intracellular pathogens, such as *Coxiella burnetii*, *Bartonella* spp. and *Tropheryma whippelii* with proper staining and immunohistochem-

ical examinations. Figure 2 and Figure 3 are diagnostic testing algorithms for the identification of the microbiological etiology of IE.^[119,138,225–232]

22. What is the sensitivity and specificity of the modified Duke criteria in the diagnosis of infective endocarditis?

The modified Duke criteria have a sensitivity of 80% in native valve endocarditis and are insufficient in patients with prosthetic heart valves, intracardiac prosthetic devices, or blood culture-negative endocarditis. Additional imaging techniques and serological-molecular tests should be added the diagnostic work-up of these patients.^[65,141,233] The modified Duke criteria are presented in Table 3 and the modified European Society of Cardiology criteria are provided in Table 4.^[3,65]

23. How is non-bacterial thrombotic endocarditis differentiated from infective endocarditis?

Non-bacterial thrombotic endocarditis (NBTE) can be seen with numerous clinical entities such as malignancy, connective tissue and autoimmune disorders, and hypercoagulable states. NBTE can be documented in approximately 1% of patients with




Figure 3. Microbiological and histopathological evaluation of heart valves removed from patient with endocarditis. *PAS-positive staining reaction is seen in macrophages infected with *Tropheryma whippelii*. **For example, *Mycoplasma hominis*, *Legionella* spp., *Chlamydia* spp., *Cutibacterium* (formerly *Propionibacterium*), *acne*, etc. PAS: Periodic-acid Schiff; PCR: Polymerase chain reaction.

Table 3. Definition of infective endocarditis according to the modified Duke criteria^[3,65]

Definite IE
Pathological criteria
<ul style="list-style-type: none"> • Microorganisms: demonstrated by culture or histology in a vegetation, or in a vegetation that has embolized, or in an intracardiac abscess specimen, or • Pathological lesions: vegetation or intracardiac abscess confirmed by histology showing active endocarditis
Clinical criteria
<ul style="list-style-type: none"> • 2 major criteria, or • 1 major criterion and 3 minor criteria, or • 5 minor criteria
Possible IE
<ul style="list-style-type: none"> • 1 major criterion and 1 minor criterion, or • 3 minor criteria
Rejected IE
<ul style="list-style-type: none"> • Firm alternate diagnosis, or • Resolution of symptoms suggesting IE with antibiotic therapy for ≤ 4 days, or • No pathological evidence of IE at surgery or autopsy, with antibiotic therapy for ≤ 4 days, or • Does not meet criteria for possible IE above
IE: Infective endocarditis.

malignancy, most frequently with pancreatic adenocarcinoma (10%). The primary clinical presentation of NBTE is a thromboembolism. It is essential to differentiate NBTE from IE. The same diagnostic work-up that is recommended for IE should be completed. The diagnosis of NBTE is challenging. NBTE can be diagnosed in a patient with the presence of a disease process known to be associated with NBTE with high suspicion in the presence of multiple systemic emboli, unchanged vegetation size despite antibiotic therapy, or a new heart murmur. In patients with underlying comorbidities that predispose to NBTE, the presence of a heart murmur, persistence of vegetation despite appropriate antibiotic therapy, or multiple systemic emboli should lead to suspicion of NBTE. Although the vegetations in NBTE are generally small, their roots are wide and irregular in shape. The vegetations in NBTE show minimal inflammation where they are attached.^[131,234–236]

Table 4. Definitions used in the European Society of Cardiology 2015 Modified Criteria for the Diagnosis of Infective Endocarditis^[3,65]

Major criteria
1. Blood cultures positive for IE
<ul style="list-style-type: none"> a. Typical microorganisms consistent with IE from 2 separate blood cultures: <ul style="list-style-type: none"> • Viridans streptococci, <i>Streptococcus gallolyticus</i> (<i>Streptococcus bovis</i>), HACEK group, <i>Staphylococcus aureus</i>; or • Community-acquired enterococci, in the absence of a primary focus; or b. Microorganisms consistent with IE from persistently positive blood cultures: <ul style="list-style-type: none"> • ≥ 2 positive blood cultures of blood samples drawn >12 h apart; or • All of 3 or a majority of ≥ 4 separate cultures of blood (with first and last samples drawn ≥ 1 h apart); or c. Single positive blood culture for <i>Coxiella burnetii</i> or phase I IgG antibody titre $>1:800$.
2. Imaging positive for IE
<ul style="list-style-type: none"> a. Echocardiogram positive for IE;* <ul style="list-style-type: none"> • Vegetation; • Abscess, pseudoaneurysm, intracardiac fistula; • Valvular perforation or aneurysm; • New partial dehiscence of prosthetic valve. b. Abnormal activity around the site of prosthetic valve implantation detected with ^{18}F-FDG PET/CT (only if the prosthesis was implanted >3 months prior) or leukocyte SPECT/CT. c. Definite paravalvular lesions observed with cardiac CT.
Minor criteria
1. Predisposition, such as predisposing heart condition, or injection drug use.
2. Fever, defined as a temperature $>38^\circ\text{C}$.
3. Vascular phenomena (including those detected by imaging only): major arterial emboli, septic pulmonary infarcts, infectious (mycotic) aneurysm, intracranial hemorrhage, conjunctival hemorrhages, and Janeway's lesions.
4. Immunological phenomena: glomerulonephritis, Osler's nodes, Roth's spots, and rheumatoid factor.
5. Microbiological evidence: positive blood culture, but does not meet a major criterion as noted above or serological evidence of active infection with organism consistent with IE.

*Although it was not included in the ESC 2015 modified Duke criteria, "new valvular regurgitation (worsening or changing or pre-existing murmur not sufficient)" was included as a major echocardiographic criterion in the original Duke criteria.^[9] ^{18}F -FDG PET/CT: ^{18}F -fluorodeoxyglucose positron emission tomography/computed tomography; HACEK: *Haemophilus parainfluenzae*, *Aggregatibacter* spp., *Cardiobacterium* spp., *Eikenella corrodens* and *Kingella* spp.; IE: Infective endocarditis; IgG: Immunoglobulin G; SPECT/CT: Single-photon emission computed tomography.

Table 5. Simplified risk score calculation for 6-month mortality in infective endocarditis^[237]

Prognostic variable	Weight
Age (years)	
≤45	0
46–60	+2
61–70	+3
>70	+4
History of dialysis	+3
Nosocomial IE	+2
Prosthetic valve IE	+1
Symptoms >1 month before admission	-1
<i>Staphylococcus aureus</i> as causative agent	+1
Viridans group streptococci as causative agent	-2
Aortic vegetation	+1
Mitral vegetation	+1
NYHA class III or IV heart failure caused by IE	+3
Stroke	+2
Paravalvular complications	+2
Persistent bacteremia	+2
Surgical treatment for IE	-2
Probability of 6-month mortality = 2.4169 x score + 0.1099 score ² –4.849.	
IE: Infective endocarditis; NYHA: New York Heart Association.	

Table 6. Probability of 6-month mortality in patients with infective endocarditis according to simplified risk score^[240]

Total risk score	Probability of 6-month mortality (%)
0–6	8–12
7–8	16–20
9–10	30–34
11–16	42–50
17–22	>60

Prognostic Assessment of Patients with Infective Endocarditis At Admission and During Follow-Up

24. When should a prognostic assessment be performed in patients with infective endocarditis and what is the benefit of this assessment?

A prognostic risk assessment should be performed in patients with suspected IE using the simplified risk score calculation during the first evaluation (Table

5 and Table 6). Patients with a higher mortality risk (risk score >8) should be carefully evaluated in a timely manner for urgent surgery and for the possibility of transfer to a reference center and intensive care unit. Prognostic assessment of a patient with IE should be performed 3 times: at admission, within the first week of the start of antibiotic therapy, and before discharge. Making a prediction of the prognosis of IE can help clinicians to prevent probable complications and to be prepared to overcome complications if they occur.^[65,66,237–240]

Infective Endocarditis Team in the Management of Patients with Infective Endocarditis

25. What is an infective endocarditis team and why is such a team necessary?

An IE team is a multidisciplinary team including representatives of relevant specialties who manage the diagnosis and treatment of all IE patients at the institution, decide collaboratively on all aspects of the disease, especially on antimicrobial and surgical treatment, and meet once a week, or more frequently when needed, to regularly follow-up and evaluate patients. IE patients may be treated by physicians from several specialties because the disease has a wide range of clinical presentations. Since it is a rare disease, it is unlikely that every physician has sufficient experience. These features drive delayed diagnosis and treatment of the disease, and consequently, increased morbidity and mortality. Therefore, IE teams should be established at institutions in order to promptly diagnose IE, provide standardized therapy following the current guidelines, increase practitioners' knowledge and experience, and provide comprehensive follow-up to patients with IE.

At a minimum, there should be a cardiologist, a cardiovascular surgeon, and an infectious diseases and clinical microbiology specialist on the IE team. When needed, a neurologist, a radiologist, a nuclear medicine specialist, a pathologist, and a neurosurgeon should join the team at reference centers. It has been shown that a multidisciplinary approach leads to a decrease in morbidity and mortality of IE patients. IE cases complicated with heart failure, abscess, neurological complications, etc. should be followed up at reference centers where there are neurosurgery and cardiac surgery facilities. Uncomplicated cases can be followed up at non-reference centers, provided that

Table 7. Department of hospitalization for patients with infective endocarditis

Patient's condition	Department of hospitalization
Patients with unstable hemodynamic condition, or severe valve dysfunction, or within the first days of <i>Staphylococcus aureus</i> endocarditis	Intensive care unit or coronary intensive care unit
Patients with stable hemodynamic status and good valve function	Cardiology Infectious disease and clinical microbiology
Patients with indication for emergent surgery	Cardiovascular surgery
Patients with an indication for urgent/elective surgery	Cardiology Infectious disease and clinical microbiology
Patients without any surgical indications	Cardiology Infectious disease and clinical microbiology

there is close communication with a reference center and the patient is regularly evaluated by the IE team and referred to a reference center when necessary (Table 7 and Table 8).^[65,241–245]

Antimicrobial Treatment of Infective Endocarditis

26. What is the general principle of antimicrobial treatment of infective endocarditis and how should the duration of treatment be determined?

The general principle of antimicrobial treatment of IE is prolonged, parenteral administration of bactericidal agents. The duration of antimicrobial treatment is determined according to the pathogen, the presence of prosthetic material, and the duration of symptoms. The therapy duration is generally 4–6 weeks for native valve endocarditis and >6 weeks for prosthetic valve endocarditis.^[3,86,140,246,247]

27. Is oral antibiotic therapy feasible in the treatment of left-sided endocarditis?

Since there are questions about the feasibility and efficacy of oral antimicrobial treatment of left-sided endocarditis, and since left-sided endocarditis is associated with substantially higher mortality, the parenteral route should be preferred for the complete duration of antimicrobial treatment of left-sided endocarditis in our country. In the event that IV access is unavailable or outpatient parenteral antibiotic therapy is unavailable, oral therapy may be feasible to complete the treatment in stable patients with uncomplicated native valve endocarditis due to drug-susceptible viridans group streptococci when there is a high probability of compliance and confidence in follow-up, provided that the initial 2 weeks of antibiotic therapy

were completed parenterally, the patient is informed about all of the possible risks and provides informed consent. Switching to oral therapy should be a joint decision of the IE team.^[248–251]

28. Is empirical treatment necessary for infective endocarditis?

Antibiotic therapy should be initiated without delay, as it reduces not only the risk of an embolic event in patients with either acute or subacute IE, but also decreases the mortality associated with sepsis in patients with acute IE. Therefore, treatment with empirical antibiotics should be initiated promptly once blood cultures have been performed.^[3,65,140,205,246,252]

29. What are the empirical drugs of choice for native, early, and late prosthetic valve infective endocarditis in adults in our country?

Ampicillin/sulbactam±gentamicin can be initiated empirically in the treatment of community-acquired cases with either a subacute or a chronic course of native or late prosthetic valve endocarditis, while vancomycin+ampicillin/sulbactam or ceftriaxone±gentamicin may be the choice for an acute course. A vancomycin+cefepime±gentamicin combination can be initiated empirically in the treatment of nosocomial native, early, and late prosthetic valve endocarditis. Gentamicin should be avoided in patients with initial impaired renal function. Rifampin can also be added to empirical treatment of early prosthetic valve endocarditis. Daptomycin alone is not a drug of choice for initial empirical treatment of IE because of its suboptimal efficacy for streptococci and enterococci and the probability of the easy development of resistance in these strains during therapy (Table 9).^[3,65,137,205,253–258]

Table 8. Approach to a patient with suspected endocarditis

Recommendations	Timing
Determination of patient's hemodynamic status and appropriate decision for hospitalization placement	Immediately
Prediction of prognosis according to simplified risk score and referral of patients with a score of ≥ 8 to a reference center	In the first 24 hours or following results of blood cultures and then weekly
TTE	Immediately
TEE	
When TTE is of suboptimal quality or complications are suspected	Immediately
Other conditions	In the first 48 hours
Whole blood count, serum CRP, ESR, procalcitonin, BUN, creatinine, urine analysis, ALT, AST, glucose, NT-pro-BNP and cTnI levels	Immediately
Three sets of blood cultures	Within the first hour (at 0, 30 th , and 60 th minutes)
Collection of blood samples in 3 plain tubes and 1 EDTA tube	
• Send the 1st plain tube of blood to the laboratory for RF, ANA, and Wright agglutination testing	In the first 24 hours
• Send the 2 nd plain tube of blood to the laboratory for <i>Coxiella burnetii</i> phase I IgG testing	In the case of negative blood cultures
• Send the 3 rd plain tube and 1st EDTA tube of blood to the laboratory for multiplex and specific PCR testing and other serological antibody testing	In the case of negative blood cultures
ECG	Immediately
Repeat blood cultures in patients with a history of antibiotic usage in the previous 10 days and stable general condition	72 hours after discontinuation of antibiotics
Fundoscopy examination	In the first 48 hours
Classification of the diagnosis according to modified Duke criteria	In the first 5 days
Abdominal ultrasound	In the case of persistent fever and examination for a minor Duke criterion In the first 7 days
Cardiac CT, MRI, 18F-FDG PET/CT, SPECT/CT with scintigraphy with labeled leukocytes	In patients with inconclusive echocardiographic results and suspected IE In the first 7 days

¹⁸F-FDG PET/CT: ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography; ALT: Alanine aminotransferase; ANA: Antinuclear antibody; AST: Aspartate aminotransferase; BUN: Blood urea nitrogen; CRP: C-reactive protein; CT: Computed tomography; cTnI: Cardiac troponin I; ECG: Electrocardiogram; EDTA: Ethylenediaminetetraacetic acid; ESR: Erythrocyte sedimentation rate; IgG: Immunoglobulin G; MRI: Magnetic resonance imaging; NT-pro-BNP: N-terminal pro b-type natriuretic peptide; PCR: Polymerase chain reaction; SPECT/CT: Single-photon emission computed tomography; RF: Rheumatoid factor; TEE: Transesophageal echocardiogram; TTE: Transthoracic echocardiogram.

30. What are the drugs of choice in the treatment of streptococcal native and prosthetic valve endocarditis in our country?

The treatment decision in streptococcal IE is made according to the penicillin G minimum inhibitory concentration (MIC) values of the pathogen. The first treat-

ment of choice is penicillin G in strains that are fully sensitive to penicillin G, penicillin+gentamicin in relatively resistant strains, and vancomycin or teicoplanin in resistant strains. Daptomycin is not recommended in endocarditis caused by streptococci that are sensitive to penicillin and vancomycin due to the possibility of the development of resistance during therapy.^[4,86,205,259-268]

Table 9. Empirical antimicrobial treatment of infective endocarditis^{[3,65,137,205,368]*}

Type of infective endocarditis	Antimicrobial agent	Dosage and route	Duration (weeks)		Comment
			Native	Prosthetic valve	
Native valve and late prosthetic valve (>1 year), community-acquired endocarditis, subacute course	Ampicillin/sulbactam +	12 g/day** i.v. in 4–6 doses	4	6	Gentamicin should be avoided in patients with initial high serum level of creatinine
	Gentamicin	3 mg/kg/day i.v. in 1 dose	2	2	
Native valve and late prosthetic valve (>1 year), community-acquired endocarditis, acute course doses	Vancomycin +	30–60 mg/kg/day i.v. in 2–3	4–6	≥6	Duration of treatment should be 6 weeks in cases of native endocarditis and ≥6 weeks for prosthetic valve endocarditis, especially in the event of complicated IE, such as with metastatic foci, etc.
	Ampicillin/sulbactam, or	12 g/day** i.v. in 4–6 doses	4–6	≥6	
	Ceftriaxone	2 g/day, i.v. in 1 dose	4–6	≥6	
Native valve and late prosthetic valve (>1 year), healthcare-associated endocarditis	Vancomycin +	30–60 mg/kg/day i.v. in 2–3 doses	4	6	
	Cefepime	6 g/day, i.v. in 3 doses	4	6	
Native valve and late prosthetic valve (>1 year) endocarditis, β-lactam allergy	Vancomycin +	30–60 mg/kg/day i.v. in 2–3 doses	4	6	Gentamicin should be avoided in patients with a higher risk of nephrotoxicity
	Gentamicin	3 mg/kg/day i.v. in 1 dose	2	2	
Early prosthetic valve endocarditis (≤1 year)	Vancomycin +	30–60 mg/kg/day i.v. in 2–3 doses		6	
	Gentamicin +	3 mg/kg/day i.v. in 1 dose	2		
	Cefepime +	6 g/day, i.v. in 3 doses	6		
	Rifampin	900 mg/day, i.v. or orally in 3 doses	6		
Cardiac implantable electronic device, lead-related, or valve endocarditis doses	Vancomycin ±	30–60 mg/kg/day i.v. in 2–3	Antimicrobial therapy should be continued for 2-4 weeks and 4-6 weeks for lead-related and valve endocarditis, respectively, after the removal of the device		Addition of either gentamicin, or cefepime, or meropenem to vancomycin should be considered for septic patients with unstable hemodynamic status
	Gentamicin, or	3 mg/kg/day i.v. in 1 dose			
	Cefepime, or	6 g/day, i.v. in 3 doses			
	Meropenem	3 g/day, i.v. in 3 doses			

*Same regimen may be used for patients with negative blood cultures and serological test results. ** As ampicillin.

31. What are the drugs of choice in the treatment of enterococcal endocarditis in our country?

In the treatment of enterococcal endocarditis, if the strain is sensitive to ampicillin (or penicillin G), the recommended regimen is ampicillin+gentamicin or ampicillin+ceftriaxone (if the strain is *Enterococcus faecalis*). The recommended regimen is vancomycin or teicoplanin+gentamicin if the strain is resistant to ampicillin. A daptomycin+ampicillin+gentamicin combination is recommended if it is resistant to ampicillin, vancomycin, and teicoplanin. Gentamicin should be included in the treatment unless there is high-level gentamicin resistance.^[1–4,65,205,269–282]

32. What are the drugs of choice in the treatment of staphylococcal endocarditis in our country?

Cefazolin is the drug of choice in methicillin-sensitive *S. aureus* (MSSA) IE in our country, since anti-staphylococcal penicillins are not available in the domestic market. In patients with central nervous system-septic emboli, vancomycin+cefazolin or cefotaxime should be preferred. Daptomycin should be used in patients who have a hypersensitivity reaction, such as anaphylaxis, to β -lactam agents. Vancomycin in combination with cefazolin may be given to patients who are in risk groups for methicillin-resistant *S. aureus* (MRSA) until antimicrobial susceptibility test results are completed. Following test results indicating MSSA, treatment with cefazolin should be continued. Adding rifampicin and gentamicin is not recommended in native valve IE. In prosthetic valve IE, the cefazolin+ gentamicin and rifampicin combination is recommended.

In MRSA IE, if the MIC is $\leq 2 \mu\text{g/mL}$, vancomycin is recommended. Loading doses of vancomycin should be used, especially for septic patients, followed by daily doses modified according to serum levels, the patient's weight, and renal function. If the vancomycin MIC is $> 2 \mu\text{g/mL}$, daptomycin is recommended in doses of 8–12 mg/kg/day, which is determined according to the MIC values, in combination with cefazolin or trimethoprim/sulfamethoxazole. In patients with MRSA IE, especially if there is persistent bacteremia (> 3 –7 days), a combined vancomycin-cefazolin regimen can be used. In cases of MRSA prosthetic valve IE, if the strain is sensitive, rifampicin and gentamicin should be added to vancomycin. When there is resistance to these agents, ciprofloxacin can be used as an alternative, if there is sensitivity.^[3,4,65,86,104,205,259,269,283–355]

Complications of Infective Endocarditis and Their Management

33. What are the clinical and laboratory signs of heart failure development in patients with infective endocarditis and how it can be managed?

Nearly half of left-sided IE cases, especially those with aortic valve involvement, develop heart failure, which has a higher risk of mortality. Dyspnea, pulmonary edema, hypotension, and other organ dysfunction in patients with IE can be alarms signaling possible heart failure. In IE patients with heart failure, urgent surgery reduces the mortality rate significantly.^[81,169,173,180,356–364]

34. What are the clinical and laboratory signs of uncontrolled infection in infective endocarditis patients and how should they be managed?

Persistent infection in IE patients is characterized by fever and culture positivity, a duration of 5–10 days, or infection spreading around the valve annulus forming an abscess, pseudoaneurysm, fistula, or atrioventricular block etc. despite antibiotic treatment, demonstrating that the infection is not under control. In cases of persistent infection, repeated blood cultures and echocardiographic examination imaging for different foci of infection and changing intravascular catheters should be performed. Patients with continuing fever despite all of these measures, especially continuing blood culture positivity with no other infection source, should be evaluated for early valve surgery. Recent studies have indicated that blood culture positivity lasting > 48 –72 hours increases mortality. Early surgery for these patients may be beneficial.^[3,65,86,110,173,271,365–367]

35. What is the incidence of embolic events in patients with infective endocarditis and what are the risk factors? How should embolic events be managed?

Some 20–50% of patients with IE have embolic complications. The most important risk factor is the size ($> 10 \text{ mm}$) and mobility of the vegetation. The risk declines substantially with the start of antibiotic treatment. The decision to perform early surgery to prevent embolism is always challenging and there should be a unique evaluation for each patient. The factors that influence this decision are the size and mobility of the vegetation, recurrent embolism under treatment, the type of microorganism, and the duration of antibiotic treatment.^[3,65,181,183,368–375]

Surgical Treatment in Infective Endocarditis

36. What are the indications and appropriate timing for valvular surgery in the management of infective endocarditis?

Urgent surgery is recommended in IE patients with

heart failure. Early surgery is recommended in uncontrolled local (abscess, fistula, aneurysm, etc.) or systemic infection (ongoing blood culture positivity or fever with no other source), recurrent emboli, large vegetation, and severe left heart valve regurgitation or stenosis without clinical heart failure. If urgent surgery

Table 10. Class I indications and timing of surgery in left-sided valve infective endocarditis (Recommendations from the European Society of Cardiology 2015 infective endocarditis guidelines)^[65]

Indications	Timing	Class of recommendation	Level of evidence
Heart failure			
Aortic or mitral NVE or PVE with severe acute regurgitation, obstruction, or fistula causing refractory pulmonary edema or cardiogenic shock	Emergency	I	B
Aortic or mitral NVE or PVE with severe regurgitation or obstruction causing symptoms of HF or echocardiographic signs of poor hemodynamic performance	Urgent	I	B
Uncontrolled infection			
Locally uncontrolled infection (abscess, false aneurysm, fistula, enlarging vegetation)	Urgent	I	B
Infection caused by fungi or multiresistant organisms	Urgent/elective	I	C
Prevention of embolism			
Aortic or mitral NVE or PVE with persistent vegetation >10 mm after 1 or more embolic episodes despite appropriate antibiotic therapy	Urgent	I	B

HF: Heart failure; NVE: Native valve endocarditis; PVE: Prosthetic valve endocarditis.

Table 11. Class I indications for surgery in left-sided valve infective endocarditis (Recommendations from the American Association for Thoracic Surgery 2016 consensus guidelines)^[377]

Indications	Class of recommendation	Level of evidence
Surgery during initial hospitalization is indicated in patients with IE who present with valve dysfunction resulting in symptoms of heart failure, independent of the completion of a full therapeutic course of antibiotics.	I	B
Surgery during initial hospitalization is indicated in patients with left-sided IE caused by <i>S. aureus</i> , fungal, or other highly resistant microorganisms, independent of the completion of a full therapeutic course of antibiotics.	I	B
Surgery during initial hospitalization is indicated in patients with IE complicated by heart block, annular or aortic abscess, or destructive penetrating lesions, independent of the completion of a full therapeutic course of antibiotics.	I	B
Surgery during initial hospitalization is indicated in patients with evidence of persistent infection manifested by persistent bacteremia or fever lasting longer than 5–7 days after initiation of appropriate antimicrobial therapy, independent of the completion of a full therapeutic course of antibiotics.	I	B
Once an indication for surgery is established, the patient should be operated on within days.	I	B

is indicated, antimicrobial treatment can be initiated before there is evidence of growth in blood cultures.

A decision to perform heart valve surgery in IE patients should be made by the IE team (or by a cardiologist, cardiovascular surgeon, and infectious diseases and clinical microbiology specialist) after evaluating all aspects of the disease. In patients with neurological complications, a surgical decision should be made by the IE team with the addition of a neurologist and a neurosurgeon, according to the presence/absence of silent emboli/transient ischemic attack, ischemic stroke or hemorrhagic stroke, severity of the neurological situation, and urgency of cardiovascular surgery.^[2,3,27,65,181,376-399] After a silent embolism or transient ischemic attack, if indicated, cardiac surgery is recommended without delay (Table 10 and Table 11).^[65]

Monitoring Treatment Response in Patients with Infective Endocarditis and Follow-Up After Discharge

37. How should treatment response be monitored in patients with infective endocarditis?

In IE patients who have been given the appropriate antibiotic treatment and undergone surgical repair (when needed), fever and serum C-reactive protein (CRP) level should decrease, blood cultures should be negative, valve functions should be stabilized, vegetation size on echocardiography should not be enlarged, but rather reduced, and the foci of an abscess should vanish. Therefore, after starting antimicrobial treatment, 2 sets of blood cultures should be taken every 48 hours until there is clear positivity, serial CRP measurements should be taken, and a gradual decrease in the CRP level during treatment reaching a normal level should be expected by the end of treatment. An echocardiographic examination should also be performed during hospitalization and just prior to discharge.^[65,102,400-404]

38. What recommendations should be made to infective endocarditis patients at discharge?

Since a history of IE is an important risk factor for recurrent endocarditis, patients should be informed about the probability of recurrence of the disease and the signs and symptoms of the condition. They should be informed about avoiding the use of empirical antibiotics before blood cultures are collected in case of fever, chills, and other symptoms of infection. They

should also be informed about prophylaxis for endocarditis, and to avoid procedures (piercing, tattoo, etc.) that may cause bacteremia and endocarditis.^[65]

39. How should operated/non-operated infective endocarditis patients be followed-up in outpatient clinics?

A TTE should be performed on discharge to provide a baseline, and as part of the follow-up, patients should be monitored with additional, periodic TTE examinations in the first year to detect possible secondary heart failure. Periodic follow-up visits should be scheduled at 1, 3, 6, and 12 months after hospital discharge. Patients should be evaluated for late side effects of the antibiotics, especially aminoglycosides used for the endocarditis treatment. A clinical examination should be accompanied by measurements of leukocyte count, CRP, and erythrocyte sedimentation rate in addition to the TTE.^[65]

Specific Conditions

40. What are important concerns in the management of patients with prosthetic valve endocarditis?

It is more difficult to diagnose prosthetic valve endocarditis than native valve endocarditis because both blood culture and echocardiographic examination results are frequently negative. The sensitivity of TTE and TEE in diagnosis of prosthetic valve endocarditis is 30% and 80%, respectively. IE should be carefully investigated using newer imaging modalities like multidetector computed tomographic angiography (MDCTA) and PET/CT in patients with suspected prosthetic valve endocarditis with a normal echocardiogram. Surgery is frequently required in addition to antibiotic treatment in patients who have heart failure or a paravalvular abscess or endocarditis caused by *S. aureus* or fungi.^[4,65,187,405-411]

41. What are important concerns in the management of infective endocarditis associated with cardiac implantable electronic devices?

CIED-associated IE represents almost 10% of all episodes of IE and the percentage is expected to increase with the growing number of devices implanted. IE should be kept in the differential diagnosis when there is 1 or more of any of the clinical presentations (fever of unknown origin, pocket infection, bacteremia with unknown source, complications of multiple pul-

monary embolisms) in patients with a CIED. Blood cultures should be performed promptly and any findings of IE should be investigated with TTE and TEE. Radiolabeled leukocyte scintigraphy or PET/CT modalities can be additive to a diagnosis of CIED-associated endocarditis in the case of a normal echocardiographic examination. The exact treatment of CIED-associated endocarditis should be the combination of antimicrobials covering the most prominent staphylococci and complete hardware removal. Percutaneous removal of hardware must be preferred in all cases, and especially in patients with vegetation <20 mm in diameter. The duration of antimicrobial therapy should be 2–4 weeks in patients with a vegetation diagnosed at the extracted lead tip after complete hardware removal, while 4–6 weeks of treatment is necessary in patients with endocardial lesions. Blood cultures should be negative for at least 14 days before implanting a new device in patients with valvular endocarditis who have an indication for CIED. In other cases, blood cultures should be negative for at least 72 hours before the placement

of a new device. To prevent CIED-related infections, a single dose of prophylaxis cefazolin just before the implantation of a CIED is recommended; additional doses are not required.^[69,70,412–432] The management of suspected CIED infection, bacteremia without evidence of CIED infection, and management of suspected pocket infection is detailed in Figures 4, 5, and 6, respectively.

42. What are important concerns in the management of patients with non-CIED-related right-sided endocarditis (IVDU, etc.)?

In cases of IVDU, right-sided endocarditis is most common. The incidence of IE related to IVDU is likely to increase with the increasing prevalence of IVDU in Turkey and globally. It is not necessary to use TEE, as the tricuspid valve anatomy and its pathology can easily be visualized with TTE. *S. aureus* is the most common pathogen. The most prominent symptoms of IE in cases of IVDU are fever and pulmonary symptoms mimicking respiratory tract infections. It is not possible to use a short term (2-week





Figure 4. Management of suspected CIED infection. Antimicrobial therapy should be maintained for at least 4–6 weeks for endocarditis (4 weeks for native valve, 6 weeks for prosthetic valve or staphylococcal valvular endocarditis). If lead vegetation is present in the absence of valve vegetation, 4 weeks of antibiotics for *Staphylococcus aureus* and 2 weeks for other pathogens is recommended. *Usually the contralateral side; a subcutaneous implantable cardioverter-defibrillator may also be considered. **2010 American Heart Association CIED Infection Update distinguishes between pocket infection and erosion.^[70,415] CIED: Cardiovascular implantable electronic device; TEE: Transesophageal echocardiography.



duration) treatment modality to treat right-sided endocarditis with IVUDU due to MSSA, as anti-staphylococcal penicillins are not currently available in our country. Instead, these patients must be treated with cefazolin for a duration of 4-6 weeks. Oral combination therapy with ciprofloxacin and rifampin can be used to treat uncomplicated right-side endocarditis with IVUDU caused by strains susceptible to both drugs, but this approach should be reserved for special situations in which conventional intravenous antibiotic therapy is not possible or is undesirable because of problems during the hospital stay, and there should be a requirement of regular post-discharge follow-up. The increasing resistance to quinolones among *S. aureus* strains may limit the use of this approach.^[65,138,433–443]

43. What are important concerns in the management of healthcare-associated infective endocarditis?

Currently, at least a quarter of IE cases are healthcare-associated endocarditis. It is classified as nosocomial endocarditis if development arises during a hospital stay or within 6 months of discharge. It is considered non-nosocomial healthcare-associated endocarditis when the patient was exposed to healthcare interventions (hemodialysis, chemotherapy, etc.) outside the hospital within 30 days prior to the onset of signs or


symptoms consistent with IE. The classification of community-acquired, nosocomial, or non-nosocomial healthcare-associated IE at admission is important because the choice of empirical therapy is completely different for healthcare-associated IE and community-acquired IE.^[4,22,83,84,444–449]

44. What are important concerns in the management of infective endocarditis in HIV-infected patients?

IE among HIV-infected patients is common, especially among cases of IVUDU with HIV infection. The risk for developing IE is not increased in an HIV-infected patient without IVUDU. The incidence of IE is higher among HIV-positive IVUDU individuals than HIV-negative IVUDU individuals. The development of IE is easier and the mortality rate is higher in patients with a low CD4+ T lymphocyte count. The morbidity and mortality rate of cardiovascular surgery is similar in IE in HIV-positive and HIV-negative IVUDU. The decision to perform a valvular replacement must be individualized according to the risk of recurrence of IE in patients who continue IVUDU.^[74,450–464]

45. What are important concerns related to infective endocarditis in elderly patients?

IE is seen with increasing frequency in elderly patients. The clinical presentation is more silent in



these patients, with smaller vegetations, and fewer embolic events. Healthcare-associated endocarditis is more common among older patients, in part because the group has more prosthetic materials. The causative pathogens are typically either staphylococci acquired through healthcare or *Streptococcus gallolyticus* (*Streptococcus bovis* biotype I) or *Enterococci* related to an intestinal or urinary source. IE in the elderly has greater mortality. The best explanation for the mortality rate among older patients is the reduced likelihood of surgery when needed. In addition, the antimicrobial treatment is unique in older patients, with the increased risk of severe side effects and drug-drug interactions. A team involving a geriatrist, a cardiologist, a cardiovascular surgeon, and an infectious disease specialist is essential to decide on the appropriate diagnostic and therapeutic strategy in older patients with IE in order to overcome these difficulties.^[4,24,30,143,465–473]

46. What are important concerns related to infective endocarditis in solid organ transplant recipients?

The risk for IE is greater in solid organ transplant recipients than in the normal population and IE is often

overlooked. Gram-negative bacilli and fungi may be causative pathogens in addition to classic pathogens, such as staphylococci. If the source of any bacteremia or fungemia is not known or a new embolic event occurs in solid organ recipients, IE should be kept in mind in the differential diagnosis.^[4,5,7,8,79,80,474–485]

47. What are important concerns in the management of infective endocarditis in patients with chronic renal failure and patients receiving chronic hemodialysis?

Although all patients with chronic renal failure are at increased risk of IE, the risk is greatest among hemodialysis patients. The 2 most important factors to explain this are the increased prevalence of bacteremia and cardiac valvular calcifications in hemodialysis patients. Currently, chronic hemodialysis patients comprise 10–20% of patients with IE and IE occurs in 1–3% of patients with chronic hemodialysis. Left-sided endocarditis with the involvement of mitral valve is common in patients with chronic renal failure. The most common pathogen is *S. aureus*. The risk of surgery and risk of developing complications, such as an embolization,

is higher. However, valvular surgery can be both feasible and beneficial in appropriately selected patients for whom general guideline recommendations can be applied. There was no significant difference in the survival rate of biological valve and prosthetic valve replacement patients. A bioprosthetic valve is thought to be a more rational choice because of the increased tendency to hemorrhage and difficulty in long-term anticoagulation among older patients with a short life expectancy.^[77,78,486–498]

48. What are important concerns in the management of a patient with infective endocarditis in the intensive care unit?

Conditions predisposing to IE should be investigated in patients with an intensive care unit admission with acute heart failure, sepsis, and cranial or peripheral embolic events. IE should be in the differential diagnosis in susceptible patients when a heart murmur is heard during the physical examination and appropriate empirical treatment should be initiated promptly, if necessary. An echocardiographic examination should be performed to rule out the diagnosis of IE in intensive care unit patients with persistent fever and continued blood culture positivity despite appropriate antimicrobial treatment.^[65,499–524]

49. What are important concerns in the management of infective endocarditis in pregnant women?

The IE risk is not greater in pregnant women. However, if IE develops in a pregnant woman with a predisposing condition, the timing of both cardiovascular surgery and delivery should be decided by a multidisciplinary team composed of a cardiologist, a cardiovascular surgeon, an obstetrician, and a neonatologist. Cardiovascular surgery is not recommended in the first 2 trimesters. Cardiovascular surgery following an elective caesarean section is preferred after 28 gestational weeks. Emergent surgery has to be planned in the case of IE leading to acute heart failure, despite a higher risk of fetal mortality. The principles of antimicrobial therapy for severe infections in pregnant women are also valid for pregnant women with IE.^[104,525–530]

50. Should cancer screening be performed in patients with infective endocarditis?

As the risk of the presence of colon cancer has been found to be greater in patients with *Streptococcus gallolyticus* (*Streptococcus bovis* biotype I) endocarditis,

a colonoscopy is recommended for these patients. A colonoscopy should also be considered in patients with enterococcal endocarditis if the source of infection has not been identified. Cancer patients are in a higher risk group for the acquisition of healthcare-associated endocarditis as they are more exposed to invasive procedures and they need more healthcare. The probability of IE should be kept in mind and a diagnostic work-up should be performed when cancer patients have a fever of unknown origin or a persistent blood culture positivity.^[531–536]

Antithrombotic therapy in Infective Endocarditis

51. Which antithrombotic agents should be used and for which indications in patients with infective endocarditis and how?

All antithrombotic therapy should be ceased in the case of a severe intracranial hemorrhage in patients with IE who are already on oral anticoagulants for a prosthetic valve. However, it is recommended to initiate parenteral anticoagulation as soon as possible for these patients. Ongoing oral anticoagulants have to be shifted to a parenteral route in the case of an ischemic neurological event without hemorrhage in patients with IE. It is very important to make all decisions following a multidisciplinary discussion.^[181,537,538]

Prevention of Infective Endocarditis

52. How and in what situations should antimicrobial prophylaxis be administered in patients with infective endocarditis?

Antimicrobial prophylaxis is only recommended before invasive dental procedures in patients at the highest risk for the acquisition of IE (previous IE, presence of prosthetic heart valve or ring annuloplasty, cyanotic congenital heart disease, cardiac allograft valvulopathy). A single dose of 2 g amoxicillin or 600 mg clindamycin given orally 1 hour before the procedure is recommended as prophylaxis. Patients with IE should be examined by a dentist to determine any dental source of infection and eliminate it as necessary. An additional dose of prophylactic antimicrobial agent, preferably selecting a different class of antibiotic to cover all probable pathogens, should be administered 1 hour before the procedure to patients who have already been receiving appropriate antimicrobials for IE.^[3,17,25,58,61,65,66,269,376,539–567]

53. What is recommended for patients at high risk for infective endocarditis about their oral and dental hygiene?

Patients at high risk to develop IE should obtain professional dental care twice a year, whereas a yearly exam is recommended for intermediate-risk patients.^[65]

54. What are other measures for the prevention of infective endocarditis?

A central venous catheter should not be placed in patients at risk of developing IE unless required. If catheterization is necessary, then the catheter should be inserted using an aseptic technique and maximal sterile barrier precautions, including the use of a cap, mask, sterile gown, sterile gloves, and a sterile full body drape. Antistaphylococcal therapy for 5–7 days is recommended for patients with a predisposing condition for the acquisition of IE if *S. aureus* is isolated from the removed intra-venous catheter's tip culture. There is no vaccine available in clinical use to prevent IE. Procedures breaching the skin integrity, such as tattoos and body piercing, should be avoided. The potential for nasal carriage of *S. aureus* through habits such as rhinitis should also be avoided. Stöckert 3T heater-cooler system devices (LivaNova PLC, London, England) manufactured between 2006 and 2014 were found to have been contaminated with *Mycobacterium chimaera* and should not be used in cardiovascular surgery centers, particularly if either a prosthetic valve or a vascular graft will be replaced.^[65,102,121,568–585]

Peer-review: Externally peer-reviewed.

Conflict-of-interest: None.

REFERENCES

- Bin Abdulhak AA, Baddour LM, Erwin PJ, Hoen B, Chu VH, Mensah GA, et al. Global and regional burden of infective endocarditis, 1990–2010: a systematic review of the literature. *Glob Heart* 2014;9:131–43.
- Cahill TJ, Prendergast BD. Infective endocarditis. *Lancet* 2016;387:882–93.
- Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Tleyjeh IM, Rybak MJ, et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. *Circulation* 2015;132:1435–86.
- Şimşek–Yavuz S, Şensoy A, Kaşıkçıoğlu H, Çeken S, Deniz D, Yavuz A, et al. Infective endocarditis in Turkey: aetiology, clinical features, and analysis of risk factors for mortality in 325 cases. *Int J Infect Dis* 2015;30:106–14.
- Hoen B, Duval X. Clinical practice. Infective endocarditis. *N Engl J Med* 2013;368:1425–33.
- Seckeler MD, Hoke TR. The worldwide epidemiology of acute rheumatic fever and rheumatic heart disease. *Clin Epidemiol* 2011;3:67–84.
- Tibazarwa KB, Volmink JA, Mayosi BM. Incidence of acute rheumatic fever in the world: a systematic review of population-based studies. *Heart* 2008;94:1534–40.
- Allegranzi B, Bagheri Nejad S, Combescure C, Graafmans W, Attar H, Donaldson L, et al. Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. *Lancet* 2011;377:228–41.
- Köse MR. Sağlık İstatistikleri Yıllığı 2015. Ankara: Sağlık Bakanlığı Sağlık Araştırmaları Genel Müdürlüğü; 2016.
- Türkiye Halk Sağlığı Kurumu. Faaliyet Raporu 2015. Ankara: Sağlık Bakanlığı; 2016.
- Gümüşlü F, Özkan S, Baykal F, Güllü Ü. Türkiye’de Verem Savaşı, 2007 Raporu. Ankara: Sağlık Bakanlığı Verem Savaşı Dairesi Başkanlığı; 2007.
- Kandemir Ö. Bruselloz. *Türkiye Klinikleri J Inf Dis–Special Topics* 2015;8:1–9.
- Kaura A, Dworakowska D, Dworakowski R. Infective endocarditis – Cinderella in cardiology. *Kardiol Pol* 2017;75:965–74.
- Naderi HR, Sheybani F, Erfani SS. Errors in diagnosis of infective endocarditis. *Epidemiol Infect* 2018;146:394–400.
- Başaran S, Şimşek–Yavuz S, Alp E, Keskin Ç, Çağatay A, Öncül O, et al. İnfektif endokarditin tanınamaması, tanısının gecikmesi ve sonuçları. In: Tekin S, editor. XX. Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Kongresi (13–16 Mart 2019, Antalya) Kitabı. İstanbul: Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Derneği; 2019. p. 266–7.
- Aydın M, Azap Ö, Şimşek–Yavuz S. İnfektif endokardit tanısı ve tedavi olanaklarının belirlenmesi: neyi, ne kadar yapıyoruz. In: Tekin S, editor. Klinik 2016: 30. Yıl Kurultayı (9–12 Mart 2016, Antalya) Özet Kitabı. İstanbul: Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Derneği; 2016. p. 450–1.
- Yılmaz–Karadağ F, Şimşek–Yavuz S, Karadeniz A, Aydın Ö, Ergen P, Tükenmez–Tigen E et al. Diş hekimlerinin infektif endokardit profilaksisi hakkında bilgi düzeylerinin değerlendirilmesi: ön çalışma verileri. In: Tekin S, editor. Klinik 2016: 30. Yıl Kurultayı (9–12 Mart 2016, Antalya) Özet Kitabı. İstanbul: Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Derneği; 2016. p. 292–3.
- Tissot–Dupont H, Casalta JP, Gouriet F, Hubert S, Salaun E, Habib G, et al. International experts’ practice in the antibiotic therapy of infective endocarditis is not following the guidelines. *Clin Microbiol Infect* 2017;23:736–9.
- Cresti A, Chiavarelli M, Scalese M, Nencioni C, Valentini S, Guerrini F, et al. Epidemiological and mortality trends in infective endocarditis, a 17-year population-based prospective study. *Cardiovasc Diagn Ther* 2017;7:27–35.
- Slipczuk L, Codolosa JN, Davila CD, Romero–Corral A, Yun J, Pressman GS, et al. Infective endocarditis epidemiology over five decades: a systematic review. *PLoS One* 2013;8:e82665.
- Holland TL, Baddour LM, Bayer AS, Hoen B, Miro JM, Fowler VG Jr. Infective endocarditis. *Nat Rev Dis Primers* 2016;2:16059.

22. Toyoda N, Chikwe J, Itagaki S, Gelijns AC, Adams DH, Egorova NN. Trends in Infective Endocarditis in California and New York State, 1998–2013. *JAMA* 2017;317:1652–60.
23. Murdoch DR, Corey GR, Hoen B, Miró JM, Fowler VG Jr, Bayer AS, et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis–Prospective Cohort Study. *Arch Intern Med* 2009;169:463–73.
24. Selton-Suty C, Célard M, Le Moing V, Doco-Lecompte T, Chirouze C, Iung B, et al. Preeminence of *Staphylococcus aureus* in infective endocarditis: a 1-year population-based survey. *Clin Infect Dis* 2012;54:1230–9.
25. Duval X, Delahaye F, Alla F, Tattevin P, Obadia JF, Le Moing V, et al. Temporal trends in infective endocarditis in the context of prophylaxis guideline modifications: three successive population-based surveys. *J Am Coll Cardiol* 2012;59:1968–76.
26. Hoen B, Alla F, Selton-Suty C, Béguinot I, Bouvet A, Briancçon S, et al. Changing profile of infective endocarditis: results of a 1-year survey in France. *JAMA* 2002;288:75–81.
27. Cahill TJ, Baddour LM, Habib G, Hoen B, Salaun E, Petersson GB, et al. Challenges in Infective Endocarditis. *J Am Coll Cardiol* 2017;69:325–44.
28. Fatima S, Dao B, Jameel A, Sharma K, Strogatz D, Scribani M, et al. Epidemiology of Infective Endocarditis in Rural Upstate New York, 2011 – 2016. *J Clin Med Res* 2017;9:754–8.
29. Cetinkaya Y, Akova M, Akalin HE, Aşçıoğlu S, Hayran M, Uzuns O, et al. A retrospective review of 228 episodes of infective endocarditis where rheumatic valvular disease is still common. *Int J Antimicrob Agents* 2001;18:1–7.
30. Leblebicioglu H, Yilmaz H, Tasova Y, Alp E, Saba R, Caylan R, et al. Characteristics and analysis of risk factors for mortality in infective endocarditis. *Eur J Epidemiol* 2006;21:25–31.
31. Elbey MA, Akdağ S, Kalkan ME, Kaya MG, Sayın MR, Karapınar H, et al. A multicenter study on experience of 13 tertiary hospitals in Turkey in patients with infective endocarditis. *Anadolu Kardiyol Derg* 2013;13:523–7.
32. Cancan Gursul N, Vardar I, Demirdal T, Gursul E, Ural S, Yesil M. Clinical and microbiological findings of infective endocarditis. *J Infect Dev Ctries* 2016;10:478–87.
33. Zencir C, Akpek M, Senol S, Selvi M, Onay S, Cetin M, et al. Association between hematologic parameters and in-hospital mortality in patients with infective endocarditis. *Kaohsiung J Med Sci* 2015;31:632–8.
34. Tuğcu A, Yıldırımtekin O, Baytaroglu C, Kurtoglu H, Köse O, Sener M, et al. Clinical spectrum, presentation, and risk factors for mortality in infective endocarditis: a review of 68 cases at a tertiary care center in Turkey. *Türk Kardiyol Dern Ars* 2009;37:9–18.
35. Sucu M, Davutoğlu V, Ozer O, Aksoy M. Epidemiological, clinical and microbiological profile of infective endocarditis in a tertiary hospital in the South–East Anatolia Region. *Türk Kardiyol Dern Ars* 2010;38:107–11.
36. Heper G, Yorukoglu Y. Clinical, bacteriologic and echocardiographic evaluation of infective endocarditis in Ankara, Turkey. *Angiology* 2002;53:191–7.
37. Agca FV, Demircan N, Peker T, Ari H, Karaagac K, Ozluk OA, et al. Infective endocarditis: a tertiary referral centre experience from Turkey. *Int J Clin Exp Med* 2015;8:13962–8.
38. Işıkgöz–Taşbakan M, Guliyeva G, Kayıkçioğlu M, Yamazhan T, Özdemir S, Pullukcu H, et al. Enfektif endokardit: 100 hastanın değerlendirilmesi. 32. Ankem Akılcı Antibiyotik Kullanımı Kongresi (10–14 Mayıs 2017, Antalya) Kitabı. İstanbul: Antibiyotik ve Kemoterapi Derneği; 2017. p. 104.
39. Erbay AR, Erbay A, Canga A, Keskin G, Sen N, Atak R, et al. Risk factors for in-hospital mortality in infective endocarditis: five years' experience at a tertiary care hospital in Turkey. *J Heart Valve Dis* 2010;19:216–24.
40. Akil MA, Acet H, Elbey MA, Aydın M, Bilik Z, Yıldız A, et al. Prognostic factors and in-hospital outcome of native valve endocarditis in Turkey. A multicenter study. *Acta Medica Mediterranea* 2014;30:1035–9.
41. Adademir T, Tuncer EY, Tas S, Donmez AA, Polat EB, Tuncer A. Surgical treatment of aortic valve endocarditis: a 26-year experience. *Rev Bras Cir Cardiovasc* 2014;29:16–24.
42. Cay S, Gürel OM, Korkmaz S. Clinical and epidemiological characteristics of infective endocarditis. *Türk Kardiyol Dern Ars* 2009;37:182–6.
43. Turak O, Canpolat U, Ozcan F, Yayla C, Mendi MA, Oksüz F, et al. D-dimer level predicts in-hospital mortality in patients with infective endocarditis: a prospective single-center study. *Thromb Res* 2014;134:587–92.
44. Ozveren O, Oztürk MA, Sengül C, Bakal RB, Akgün T, Izgi C, et al. Infective endocarditis and complications; a single center experience. *Türk Kardiyol Dern Ars*. 2014;42:629–34.
45. Kocabaş U, Kaya E, Özerkan–Çakan F. Microbiological profile, echocardiographic characteristics and early results of infective endocarditis: a review of 194 cases at a tertiary care center in Turkey. *J Am Coll Cardiol* 2013;62:81.
46. Kucukates E, Gultekin N, Bagdatli Y. Cases of active infective endocarditis in a university hospital during a 10-year period. *J Pak Med Assoc* 2013;63:1163–7.
47. Kaya Z, Yıldız A, Biçer–Yeşilay A, Kocaaslan A, Aydın MS, Sezen Y, et al. Merkezimizde takip edilen her üç enfektif endokardit olgusundan birisi *Brusella* endokarditidir. *Gaziantep Tıp Derg* 2013;19:103–7.
48. Çaylan R, Aydın K, Kaygusuz S, Köksal İ, Örem C. Otuziki enfektif endokardit atağının değerlendirilmesi. *Flora* 2001;6:267–73.
49. İnanc MT, Kaya MG, Gündüz Kaya E, Doğan A, Ardic İ, Doğru O. Enfektif endokardit: retrospektif olarak 27 hastanın değerlendirilmesi. *Tıp Araştırmaları Derg* 2007;5:91–9.
50. Şimşek–Yavuz S, Berzeg–Deniz D, Tükenmez–Tigen E, et al. In: Tekin S, Şimşek F, editors. KLİMİK İEÇG Türkiye enfektif endokardit kohortu: 2015–2016 verileri. XVIII. Türk Klinik Mikrobiyoloji ve Enfeksiyon Hastalıkları Kongresi (22–26 Mart 2017, Antalya) Özet Kitabı. İstanbul: Türk Klinik Mikrobiyoloji ve Enfeksiyon Hastalıkları Derneği; 2017. p. 133.
51. Frontera JA, Gradon JD. Right-side endocarditis in injection drug users: review of proposed mechanisms of pathogenesis. *Clin Infect Dis* 2000;30:374–9.
52. Örtün UA, Ceylan O, Bilici M, Karademir S, Ocal B, Senocak F, et al. Acute rheumatic fever in the Central Anatolia Region of Turkey: a 30-year experience in a single center. *Eur J Pediatr* 2012;171:361–8.
53. Onat A, Keleş İ, Çetinkaya A, Başar Ö, Yıldırım B, Erer B, et al. Prevalence of Coronary Mortality and Morbidity in the Turkish Adult Risk Factor Study: 10-year Follow-up Suggests Coronary “Epidemic”. *Türk Kardiyol Dern Ars* 2001;29:8–19.
54. Onat A, fiurdumavcı G, fiencak M, Örnek E, Gözükara E,

- Karaaslan Y, et al. Survey on Prevalence of Cardiac Disease and its Risk Factors in Adults in Turkey: 3. Prevalence of Heart Diseases. *Turk Kardiyol Dern Ars* 1991;19:2–33.
55. Demirbağ R, Sade LE, Aydın M, Bozkurt A, Acartürk E. The Turkish registry of heart valve disease. *Turk Kardiyol Dern Ars* 2013;41:1–10.
 56. Watkins DA, Johnson CO, Colquhoun SM, Karthikeyan G, Beaton A, Bukhman G, et al. Global, Regional, and National Burden of Rheumatic Heart Disease, 1990–2015. *N Engl J Med* 2017;377:713–22.
 57. Marijon E, Mirabel M, Celermajer DS, Jouven X. Rheumatic heart disease. *Lancet* 2012;379:953–64.
 58. Baskerville CA, Hanrahan BB, Burke AJ, Holwell AJ, Rémond MG, Maguire GP. Infective endocarditis and rheumatic heart disease in the north of Australia. *Heart Lung Circ* 2012;21:36–41.
 59. Katan O, Michelena HI, Avierinos JF, Mahoney DW, DeSimone DC, Baddour LM, et al. Incidence and predictors of infective endocarditis in mitral valve prolapse: A population-based study. *Mayo Clin Proc* 2016;91:336–42.
 60. Zegri-Reiriz I, de Alarcón A, Muñoz P, Martínez Sellés M, González-Ramallo V, Miro JM, et al. Infective endocarditis in patients with bicuspid aortic valve or mitral valve prolapse. *J Am Coll Cardiol* 2018;71:2731–40.
 61. Baumgartner H. Infective endocarditis in adults with congenital heart disease: is it time to change our approach to prophylaxis based on new insights into risk prediction? *Eur Heart J* 2011;32:1835–7.
 62. Mylotte D, Rushani D, Therrien J, Guo L, Liu A, Guo K, et al. Incidence, Predictors, and Mortality of Infective Endocarditis in Adults With Congenital Heart Disease Without Prosthetic Valves. *Am J Cardiol* 2017;120:2278–83.
 63. Li Y, Wei X, Zhao Z, Liao Y, He J, Xiong T, et al. Prevalence and complications of bicuspid aortic valve in chinese according to echocardiographic database. *Am J Cardiol* 2017;120:287–91.
 64. Regueiro A, Linke A, Latib A, Ihlemann N, Urena M, Walther T, et al. Association between transcatheter aortic valve replacement and subsequent infective endocarditis and in-hospital death. *JAMA* 2016;316:1083–92.
 65. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). *Eur Heart J* 2015;36:3075–128.
 66. SEC Working Group for the ESC 2015 Guidelines on the Management of Infective Endocarditis; Expert Reviewers for the ESC 2015 Guidelines on the Management of Infective Endocarditis; SEC Guidelines Committee. Comments on the ESC 2015 Guidelines for the Management of Infective Endocarditis. *Rev Esp Cardiol (Engl Ed)* 2016;69:7–10.
 67. Amat-Santos IJ, Ribeiro HB, Urena M, Allende R, Houde C, Bédard E, et al. Prosthetic valve endocarditis after transcatheter valve replacement: a systematic review. *JACC Cardiovasc Interv* 2015;8:334–46.
 68. Sandoe JA, Barlow G, Chambers JB, Gammage M, Guleri A, Howard P, et al. Guidelines for the diagnosis, prevention and management of implantable cardiac electronic device infection. Report of a joint Working Party project on behalf of the British Society for Antimicrobial Chemotherapy (BSAC, host organization), British Heart Rhythm Society (BHRS), British Cardiovascular Society (BCS), British Heart Valve Society (BHVS) and British Society for Echocardiography (BSE). *J Antimicrob Chemother* 2015;70:325–59.
 69. Johansen JB, Jørgensen OD, Møller M, Arnsbo P, Mortensen PT, Nielsen JC. Infection after pacemaker implantation: infection rates and risk factors associated with infection in a population-based cohort study of 46299 consecutive patients. *Eur Heart J* 2011;32:991–8.
 70. Baddour LM, Epstein AE, Erickson CC, Knight BP, Levi-son ME, Lockhart PB, et al. Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. *Circulation* 2010;121:458–77.
 71. Aydın M, Yildiz A, Kaya Z, Kaya Z, Basarir AO, Cakmak N, et al. Clinical Characteristics and Outcome of Cardiovascular Implantable Electronic Device Infections in Turkey. *Clin Appl Thromb Hemost* 2016;22:459–64.
 72. Hannan MM, Husain S, Mattner F, Danziger-Isakov L, Drew RJ, Corey GR, et al. Working formulation for the standardization of definitions of infections in patients using ventricular assist devices. *J Heart Lung Transplant* 2011;30:375–84.
 73. Kusne S, Staley L, Arabia F. Prevention and Infection Management in Mechanical Circulatory Support Device Recipients. *Clin Infect Dis* 2017;64:222–8.
 74. Wilson LE, Thomas DL, Astemborski J, Freedman TL, Vlahov D. Prospective study of infective endocarditis among injection drug users. *J Infect Dis* 2002;185:1761–6.
 75. Keeshin SW, Feinberg J. Endocarditis as a Marker for New Epidemics of Injection Drug Use. *Am J Med Sci* 2016;352:609–14.
 76. Wurcel AG, Anderson JE, Chui KK, Skinner S, Knox TA, Snyderman DR, et al. Increasing Infectious Endocarditis Admissions Among Young People Who Inject Drugs. *Open Forum Infect Dis* 2016;3:ofw157.
 77. Díaz-García HR, Contreras-de la Torre NA, Alemán-Villalobos A, et al. Infective endocarditis in end-stage renal disease patients in developing countries: what is the real problem? In: Firstenberg MS, editor. *Contemporary Challenges in Endocarditis*. London: IntechOpen; 2016. p. 121–42.
 78. Chaudry MS, Carlson N, Gislason GH, Kamper AL, Rix M, Fowler VG Jr, et al. Risk of infective endocarditis in patients with end stage renal disease. *Clin J Am Soc Nephrol* 2017;12:1814–22.
 79. Ruttman E, Bonatti H, Legit C, Ulmer H, Stelzmueller I, Antretter H, et al. Severe endocarditis in transplant recipients—an epidemiologic study. *Transpl Int* 2005;18:690–6.
 80. Paterson DL, Dominguez EA, Chang FY, Snyderman DR, Singh N. Infective endocarditis in solid organ transplant recipients. *Clin Infect Dis* 1998;26:689–94.
 81. Olmos C, Vilacosta I, Fernández C, Sarriá C, López J, Del Trigo M, et al. Comparison of clinical features of left-sided infective endocarditis involving previously normal versus previously abnormal valves. *Am J Cardiol* 2014;114:278–83.
 82. Fowler VG Jr, Miro JM, Hoen B, Cabell CH, Abrutyn E, Rubinstein E, et al. *Staphylococcus aureus* endocarditis: a consequence of medical progress. *JAMA* 2005;293:3012–21.
 83. Lomas JM, Martínez-Marcos FJ, Plata A, Ivanova R, Gálvez J, Ruiz J, et al. Healthcare-associated infective endocarditis:

- an undesirable effect of healthcare universalization. *Clin Microbiol Infect* 2010;16:1683–90.
84. Fernández-Hidalgo N, Almirante B, Tornos P, Pigrau C, Sambola A, Igual A, et al. Contemporary epidemiology and prognosis of health care-associated infective endocarditis. *Clin Infect Dis* 2008;47:1287–97.
 85. Ambrosioni J, Hernandez-Meneses M, Téllez A, Pericàs J, Falces C, Tolosana JM, et al. The changing epidemiology of infective endocarditis in the twenty-first century. *Curr Infect Dis Rep* 2017;19:21.
 86. Fowler VG, Scheld WM, Bayer AS. Endocarditis and intravascular infections. In: Bennett JE, Dolin R, Blaser MJ, editors. *Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases*. 8th ed. Philadelphia: Elsevier Saunders; 2015. p. 990–1028.
 87. Sabe MA, Shrestha NK, Gordon S, Menon V. *Staphylococcus lugdunensis*: a rare but destructive cause of coagulase-negative staphylococcus infective endocarditis. *Eur Heart J Acute Cardiovasc Care* 2014;3:275–80.
 88. Şimşek-Yavuz S, Başaran S, Aliyev V, Midilli K, Çağatay A, Özsüt H, et al. Diphtheroids in blood cultures could be streptococcus mutans: A case of infective endocarditis diagnosed after 16 months. *Klimik Dergisi* 2015;28:122–5.
 89. Şimşek Yavuz S, Eren M, Yavuz A, Biçer Y, Koçak F, Bilgen F, et al. İnfektif endokardit: 58 olgunun değerlendirilmesi. *Klimik Derg* 2003;16:55–62.
 90. Schlegel L, Grimont F, Ageron E, Grimont PA, Bouvet A. Reappraisal of the taxonomy of the *Streptococcus bovis*/*Streptococcus equinus* complex and related species: description of *Streptococcus gallolyticus* subsp. *gallolyticus* subsp. nov., *S. gallolyticus* subsp. *macedonicus* subsp. nov. and *S. gallolyticus* subsp. *pasteurianus* subsp. nov. *Int J Syst Evol Microbiol* 2003;53:631–45.
 91. Boleij A, Muyltjens CM, Bukhari SI, Cayet N, Glaser P, Hermans PW, et al. Novel clues on the specific association of *Streptococcus gallolyticus* subsp. *gallolyticus* with colorectal cancer. *J Infect Dis* 2011;203:1101–9.
 92. Boleij A, van Gelder MM, Swinkels DW, Tjalsma H. Clinical Importance of *Streptococcus gallolyticus* infection among colorectal cancer patients: systematic review and meta-analysis. *Clin Infect Dis* 2011;53:870–8.
 93. Corredoira-Sánchez J, García-Garrote F, Rabuñal R, López-Roses L, García-País MJ, Castro E, et al. Association between bacteremia due to *Streptococcus gallolyticus* subsp. *gallolyticus* (*Streptococcus bovis* I) and colorectal neoplasia: a case-control study. *Clin Infect Dis* 2012;55:491–6.
 94. Kumar R, Herold JL, Taylor J, Xu J, Xu Y. Variations among *Streptococcus gallolyticus* subsp. *gallolyticus* strains in connection with colorectal cancer. *Sci Rep* 2018;8:1514.
 95. Kumar R, Herold JL, Schady D, Davis J, Kopetz S, Martinez-Moczygemba M, et al. *Streptococcus gallolyticus* subsp. *gallolyticus* promotes colorectal tumor development. *PLoS Pathog* 2017;13:e1006440.
 96. Dahl A, Lauridsen TK, Arpi M, Sørensen LL, Østergaard C, Sogaard P, et al. Risk factors of endocarditis in patients with enterococcus faecalis bacteremia: External validation of the NOVA score. *Clin Infect Dis* 2016;63:771–5.
 97. Bouza E, Kestler M, Beca T, Mariscal G, Rodríguez-Créixems M, Bermejo J, et al. The NOVA score: a proposal to reduce the need for transesophageal echocardiography in patients with enterococcal bacteremia. *Clin Infect Dis* 2015;60:528–35.
 98. Berge A, Krantz A, Östlund H, Naclér P, Rasmussen M. The DENOVA score efficiently identifies patients with monomicrobial *Enterococcus faecalis* bacteremia where echocardiography is not necessary. *Infection* 2019;47:45–50.
 99. Chirouze C, Athan E, Alla F, Chu VH, Ralph Corey G, Selton-Suty C, et al. Enterococcal endocarditis in the beginning of the 21st century: analysis from the International Collaboration on Endocarditis–Prospective Cohort Study. *Clin Microbiol Infect* 2013;19:1140–7.
 100. Komiyama EY, Lepesqueur LS, Yassuda CG, Samaranayake LP, Parahitiyawa NB, Balducci I, et al. Enterococcus species in the oral cavity: Prevalence, virulence factors and antimicrobial susceptibility. *PLoS One* 2016;11:e0163001.
 101. Pericàs JM, Corredoira J, Moreno A, García-País MJ, Falces C, Rabuñal R, et al. Relationship between enterococcus faecalis infective endocarditis and colorectal neoplasm: Preliminary results from a cohort of 154 patients. *Rev Esp Cardiol (Engl Ed)* 2017;70:451–8.
 102. Şimşek-Yavuz S. İnfektif endokardit: Güncel bilgiler. *Klimik Derg* 2015;28:46–67.
 103. Koruk ST, Erdem H, Koruk I, Erbay A, Tezer-Tekce Y, Erbay AR, et al. Management of *Brucella* endocarditis: results of the Gulhane study. *Int J Antimicrob Agents* 2012;40:145–50.
 104. Gilbert DN, Chambers HF, Eliopoulos GM, Saag MS, Pavia AT, editors. *The Sanford Guide to Antimicrobial Therapy* 2019. 49th ed. Sperryville, VA: Antimicrobial Therapy, Inc.; 2019.
 105. Chambers ST, Murdoch D, Morris A, Holland D, Pappas P, Almela M, et al. HACEK infective endocarditis: characteristics and outcomes from a large, multi-national cohort. *PLoS One* 2013;8:e63181.
 106. Lützen L, Olesen B, Voldstedlund M, Christensen JJ, Moser C, Knudsen JD, et al. Incidence of HACEK bacteraemia in Denmark: A 6-year population-based study. *Int J Infect Dis* 2018;68:83–7.
 107. Revest M, Egmann G, Cattoir V, Tattevin P. HACEK endocarditis: state-of-the-art. *Expert Rev Anti Infect Ther* 2016;14:523–30.
 108. Morpeth S, Murdoch D, Cabell CH, Karchmer AW, Pappas P, Levine D, et al. Non-HACEK gram-negative bacillus endocarditis. *Ann Intern Med* 2007;147:829–35.
 109. Falcone M, Tiseo G, Durante-Mangoni E, Ravasio V, Barbaro F, Ursi MP, et al. Risk Factors and Outcomes of Endocarditis Due to Non-HACEK Gram-Negative Bacilli: Data from the Prospective Multicenter Italian Endocarditis Study Cohort. *Antimicrob Agents Chemother* 2018;62:pii:e02208–17.
 110. San Román JA, Vilacosta I, López J, Sarriá C. Critical questions about left-sided infective endocarditis. *J Am Coll Cardiol* 2015;66:1068–76.
 111. Fournier PE, Thuny F, Richet H, Lepidi H, Casalta JP, Arzouni JP, et al. Comprehensive diagnostic strategy for blood culture-negative endocarditis: a prospective study of 819 new cases. *Clin Infect Dis* 2010;51:131–40.
 112. Houpikian P, Raoult D. Blood culture-negative endocarditis in a reference center: etiologic diagnosis of 348 cases. *Medicine (Baltimore)* 2005;84:162–73.
 113. Geissdörfer W, Moos V, Moter A, Loddenkemper C, Jansen A, Tandler R, et al. High frequency of tropheryma whipplei in culture-negative endocarditis. *J Clin Microbiol* 2012;50:216–22.

114. Million M, Thuny F, Richet H, Raoult D. Long-term outcome of Q fever endocarditis: a 26-year personal survey. *Lancet Infect Dis* 2010;10:527–35.
115. Şimşek Yavuz S, Özbek E, Başaran S, Çelebi B, Yılmaz E, Başaran M, et al. The first case of chronic Q fever endocarditis and aortitis from Turkey: A 5-year infection before diagnosis with drain in sternum. *Anatol J Cardiol* 2016;16:814–6.
116. Şimşek-Yavuz S, Başaran S, Yılmaz E, Keskin Ç, Alp E, Kılıç S et al. İnfektif endokardit tanısına serolojik incelemelerin ve PET/BT'nin katkıları. In: Tekin S, editor. XX. Türk Klinik Mikrobiyoloji ve Enfeksiyon Hastalıkları Kongresi (13–16 Mart 2019, Antalya) Kitabı. İstanbul: Türk Klinik Mikrobiyoloji ve Enfeksiyon Hastalıkları Derneği; 2019. p. 224–5.
117. Özdemir S. Nadir Rastlanan Enfektif Endokardit Etkenlerinin Araştırılması: HACEK Grubu Mikroorganizmalar, Chlamydia pneumoniae, Coxiella burnetii ve Bartonella türleri [Doktora Tezi]. İstanbul: İstanbul Üniversitesi Sağlık Bilimleri Enstitüsü; 2012.
118. Karaman İN, Azizy A, Yılmaz fi, Tükenmez-Tigen E, Odabaşı Z, Söyletir G et al. Bir kültür negatif doğal kapak endokarditi etkeni olarak Bartonella quintana. In: Tekin S, editor. XX. Türk Klinik Mikrobiyoloji ve Enfeksiyon Hastalıkları Kongresi (13–16 Mart 2019, Antalya) Kitabı. İstanbul: Türk Klinik Mikrobiyoloji ve Enfeksiyon Hastalıkları Derneği; 2019. p. 321–2.
119. Liesman RM, Pritt BS, Maleszewski JJ, Patel R. Laboratory diagnosis of infective endocarditis. *J Clin Microbiol* 2017;55:2599–608.
120. Bruschi JL. Legionnaire's disease: Cardiac manifestations. *Infect Dis Clin North Am* 2017;31:69–80.
121. Marra AR, Diekema DJ, Edmond MB. Mycobacterium chimaera Infections Associated With Contaminated Heater-Cooler Devices for Cardiac Surgery: Outbreak Management. *Clin Infect Dis* 2017;65:669–74.
122. Şimşek-Yavuz S. Açık kalp cerrahisi uygulanmış hastalarda kontamine ısıtıcı-soğutucu cihazlarla ilişkili mycobacterium chimaera enfeksiyonları: Küresel bir salgın. *Klinik Dergisi* 2017;30:49–58.
123. Pasha AK, Lee JZ, Low SW, Desai H, Lee KS, Al Mohajer M. Fungal endocarditis: update on diagnosis and management. *Am J Med* 2016;129:1037–43.
124. Yuan SM. Fungal Endocarditis. *Braz J Cardiovasc Surg* 2016;31:252–5.
125. Meshaal MS, Labib D, Said K, Hosny M, Hassan M, Abd Al Aziz S, et al. Aspergillus endocarditis: Diagnostic criteria and predictors of outcome, A retrospective cohort study. *PLoS One* 2018;13:e0201459.
126. Işık S, Tavazar S, Ünal N, Heybeli I, Ergüney E, Pişkinpaşa ME, et al. İnfektif endokarditte klinik ve patolojik bulguların korelasyonu. *İstanbul Tıp Dergisi* 2001;4:13–7.
127. Gouriet F, Chaudet H, Gautret P, Pellegrin L, de Santi VP, Savini H, et al. Endocarditis in the Mediterranean Basin. *New Microbes New Infect* 2018;26:S43–S51.
128. Galley HF, Webster NR. Physiology of the endothelium. *Br J Anaesth*. 2004;93:105–13.
129. Forner L, Larsen T, Kilian M, Holmstrup P. Incidence of bacteremia after chewing, tooth brushing and scaling in individuals with periodontal inflammation. *J Clin Periodontol* 2006;33:401–7.
130. Werdan K, Dietz S, Löffler B, Niemann S, Bushnaq H, Silber RE, et al. Mechanisms of infective endocarditis: pathogen-host interaction and risk states. *Nat Rev Cardiol* 2014;11:35–50.
131. Liu J, Frishman WH. Nonbacterial thrombotic endocarditis: pathogenesis, diagnosis, and management. *Cardiol Rev* 2016;24:244–7.
132. Veloso TR, Chaouch A, Roger T, Giddey M, Vouillamoz J, Majcherczyk P, et al. Use of a human-like low-grade bacteremia model of experimental endocarditis to study the role of Staphylococcus aureus adhesins and platelet aggregation in early endocarditis. *Infect Immun* 2013;81:697–703.
133. Moser C, Pedersen HT, Lerche CJ, Kolpen M, Line L, Thomsen K, et al. Biofilms and host response – helpful or harmful. *APMIS* 2017;125:320–38.
134. Steyers CM 3rd, Miller FJ Jr. Endothelial dysfunction in chronic inflammatory diseases. *Int J Mol Sci* 2014;15:11324–49.
135. Elgharably H, Hussain ST, Shrestha NK, Blackstone EH, Pettersson GB. Current hypotheses in cardiac surgery: biofilm in infective endocarditis. *Semin Thorac Cardiovasc Surg*. Spring 2016;28:56–9.
136. Piper C, Körfer R, Horstkotte D. Prosthetic valve endocarditis. *Heart* 2001;85:590–3.
137. Yang E, Frazee BW. Infective Endocarditis. *Emerg Med Clin North Am* 2018;36:645–63.
138. Fernández Guerrero ML, Álvarez B, Manzarbeitia F, Renedo G. Infective endocarditis at autopsy: a review of pathologic manifestations and clinical correlates. *Medicine (Baltimore)* 2012;91:152–64.
139. Wang A, Gaca JG, Chu VH. Management considerations in infective endocarditis: A review. *JAMA* 2018;320:72–83.
140. Thuny F, Grisoli D, Collart F, Habib G, Raoult D. Management of infective endocarditis: challenges and perspectives. *Lancet* 2012;379:965–75.
141. Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG Jr, Ryan T, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. *Clin Infect Dis* 2000;30:633–8.
142. Dhawan VK. Infective endocarditis in elderly patients. *Curr Infect Dis Rep* 2003;5:285–92.
143. Chirillo F. It is not how old you are, it is how you are old: need for changes in the management of infective endocarditis in the elderly. *Heart* 2017;103:1562–4.
144. Cornelissen CG, Frechen DA, Schreiner K, Marx N, Krüger S. Inflammatory parameters and prediction of prognosis in infective endocarditis. *BMC Infect Dis* 2013;13:272.
145. Vollmer T, Piper C, Kleesiek K, Dreier J. Lipopolysaccharide-binding protein: a new biomarker for infectious endocarditis? *Clin Chem* 2009;55:295–304.
146. Messias-Reason IJ, Hayashi SY, Nishihara RM, Kirschfink M. Complement activation in infective endocarditis: correlation with extracardiac manifestations and prognosis. *Clin Exp Immunol* 2002;127:310–5.
147. Barrier J, Roblot P, Ramassamy A, Becq-Giraudon B. Immunologic studies in the differential diagnosis of infectious endocarditis and septicemia without endocardial lesion. *Rev Med Interne* 1996;17:21–4.
148. Cabane J, Godeau P, Herremans G, Acar J, Digeon M, Bach JF. Fate of circulating immune complexes in infective endocarditis. *Am J Med* 1979;66:277–82.
149. Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic antibodies. *Lancet* 2006;368:404–18.

150. Konstantinov KN, Ulf-Møller CJ, Tzamaloukas AH. Infections and antineutrophil cytoplasmic antibodies: triggering mechanisms. *Autoimmun Rev* 2015;14:201–3.
151. Husmann CA, Holle JU, Moosig F, Mueller S, Wilde B, Cohen Tervaert JW, et al. Genetics of toll like receptor 9 in ANCA associated vasculitides. *Ann Rheum Dis* 2014;73:890–6.
152. Jennette JC, Falk RJ. Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. *Nat Rev Rheumatol* 2014;10:463–73.
153. Kain R, Rees AJ. What is the evidence for antibodies to LAMP-2 in the pathogenesis of ANCA associated small vessel vasculitis? *Curr Opin Rheumatol* 2013;25:26–34.
154. Yipp BG, Petri B, Salina D, Jenne CN, Scott BN, Zbytniuk LD, et al. Infection-induced NETosis is a dynamic process involving neutrophil multitasking in vivo. *Nat Med* 2012;18:1386–93.
155. Gagliardi JP, Nettles RE, McCarty DE, Sanders LL, Corey GR, Sexton DJ. Native valve infective endocarditis in elderly and younger adult patients: comparison of clinical features and outcomes with use of the Duke criteria and the Duke Endocarditis Database. *Clin Infect Dis* 1998;26:1165–8.
156. Mahr A, Batteux F, Tubiana S, Goulvestre C, Wolff M, Papo T, et al. Brief report: prevalence of antineutrophil cytoplasmic antibodies in infective endocarditis. *Arthritis Rheumatol* 2014;66:1672–7.
157. Konstantinov KN, Emil SN, Barry M, Kellie S, Tzamaloukas AH. Glomerular disease in patients with infectious processes developing antineutrophil cytoplasmic antibodies. *ISRN Nephrol* 2013;2013:324315.
158. Langlois V, Lesourd A, Girszyn N, Ménard JF, Levesque H, Caron F, et al. Antineutrophil Cytoplasmic Antibodies Associated With Infective Endocarditis. *Medicine (Baltimore)* 2016;95:e2564.
159. Zaratzian C, Gouriet F, Tissot-Dupont H, Casalta JP, Million M, Bardin N, et al. Antiphospholipid antibodies proposed in the diagnosis of infective endocarditis. *Eur J Clin Microbiol Infect Dis* 2017;36:1159–62.
160. Brouqui P, Dupont HT, Drancourt M, Berland Y, Etienne J, Leport C, et al. Chronic Q fever. Ninety-two cases from France, including 27 cases without endocarditis. *Arch Intern Med* 1993;153:642–8.
161. Gouriet F, Bothelo-Nevers E, Coulibaly B, Raoult D, Casalta JP. Evaluation of sedimentation rate, rheumatoid factor, C-reactive protein, and tumor necrosis factor for the diagnosis of infective endocarditis. *Clin Vaccine Immunol* 2006;13:301.
162. Durack DT, Lukes AS, Bright DK. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service. *Am J Med* 1994;96:200–9.
163. Capo C, Zugun F, Stein A, Tardei G, Lepidi H, Raoult D, et al. Upregulation of tumor necrosis factor alpha and interleukin-1 beta in Q fever endocarditis. *Infect Immun* 1996;64:1638–42.
164. Lamas CC, Eykyn SJ. Suggested modifications to the Duke criteria for the clinical diagnosis of native valve and prosthetic valve endocarditis: analysis of 118 pathologically proven cases. *Clin Infect Dis* 1997;25:713–9.
165. Deck C, Guarda E, Bianchi C, Ortega C, Grisanti M, Vega P, et al. Circulating immune complexes in infective endocarditis. *Rev Med Chil* 1988;116:1101–4.
166. Kauffmann RH, Thompson J, Valentijn RM, Daha MR, Van Es LA. The clinical implications and the pathogenetic significance of circulating immune complexes in infective endocarditis. *Am J Med* 1981;71:17–25.
167. Bayer AS, Theofilopoulos AN, Eisenberg R, Dixon FJ, Guze LB. Circulating immune complexes in infective endocarditis. *N Engl J Med* 1976;295:1500–5.
168. Thoker ZA, Khan KA, Rashid I, Zafar. Correlation of cardiac troponin I levels with infective endocarditis & its adverse clinical outcomes. *Int J Cardiol* 2016;222:661–4.
169. Kahveci G, Bayrak F, Mutlu B, Bitigen A, Karaahmet T, Sonmez K, et al. Prognostic value of N-terminal pro-B-type natriuretic peptide in patients with active infective endocarditis. *Am J Cardiol* 2007;99:1429–33.
170. Gunebakmaz O, Kaya MG, Kaya EG, Ardic I, Yarlioglues M, Dogdu O, et al. Mean platelet volume predicts embolic complications and prognosis in infective endocarditis. *Int J Infect Dis* 2010;14:e982–5.
171. Ponasenko AV, Kutikhin AG, Khutornaya MV, Rutkovskaya NV, Kondyukova NV, Odarenko YN, et al. Inherited Variation in Cytokine, Acute Phase Response, and Calcium Metabolism Genes Affects Susceptibility to Infective Endocarditis. *Mediators Inflamm* 2017;2017:7962546.
172. Shevchenko IuL, Danil'chenko VV, Zhiburt EB, Serebrianaia NB, Khubulava GG, Katkova IV. The immunogenetic status of patients with infectious endocarditis. *Vestn Khir Im I I Grek* 1995;154:58–63.
173. Habib G, Badano L, Tribouilloy C, Vilacosta I, Zamorano JL, Galderisi M, et al. Recommendations for the practice of echocardiography in infective endocarditis. *Eur J Echocardiogr* 2010;11:202–19.
174. Wong D, Rubinshtein R, Keynan Y. Alternative cardiac imaging modalities to echocardiography for the diagnosis of infective endocarditis. *Am J Cardiol* 2016;118:1410–8.
175. Gomes A, Glaudemans AJWM, Touw DJ, van Melle JP, Willems TP, Maass AH, et al. Diagnostic value of imaging in infective endocarditis: a systematic review. *Lancet Infect Dis* 2017;17:e1–e14.
176. Gomes A, van Geel PP, Santing M, Prakken NHJ, Ruis ML, van Assen S, et al. Imaging infective endocarditis: Adherence to a diagnostic flowchart and direct comparison of imaging techniques. *J Nucl Cardiol* 2018 Jul 31. [Epub ahead of print]
177. Young WJ, Jeffery DA, Hua A, Primus C, Serafino Wani R, Das S, et al. Echocardiography in patients with infective endocarditis and the impact of diagnostic delays on clinical outcomes. *Am J Cardiol* 2018;122:650–5.
178. Harding D, Prendergast B. Advanced imaging improves the diagnosis of infective endocarditis. *F1000Res* 2018;7. pii: F1000.
179. Thuny F, Di Salvo G, Belliard O, Avierinos JF, Pergola V, Rosenberg V, et al. Risk of embolism and death in infective endocarditis: prognostic value of echocardiography: a prospective multicenter study. *Circulation* 2005;112:69–75.
180. Mügge A, Daniel WG, Frank G, Lichtlen PR. Echocardiography in infective endocarditis: reassessment of prognostic implications of vegetation size determined by the transthoracic and the transesophageal approach. *J Am Coll Cardiol* 1989;14:631–8.
181. García-Cabrera E, Fernández-Hidalgo N, Almirante B, Ivanova-Georgieva R, Noureddine M, Plata A, et al. Neuro-

- logical complications of infective endocarditis: risk factors, outcome, and impact of cardiac surgery: a multicenter observational study. *Circulation* 2013;127:2272–84.
182. Yang A, Tan C, Daneman N, Hansen MS, Habib G, Salaun E, et al. Clinical and echocardiographic predictors of embolism in infective endocarditis: systematic review and meta-analysis. *Clin Microbiol Infect* 2019;25:178–87.
 183. Mohananey D, Mohadjer A, Pettersson G, Navia J, Gordon S, Shrestha N, et al. Association of vegetation size with embolic risk in patients with infective endocarditis: A systematic review and meta-analysis. *JAMA Intern Med* 2018;178:502–10.
 184. Rohmann S, Erhel R, Darius H, Makowski T, Meyer J. Effect of antibiotic treatment on vegetation size and complication rate in infective endocarditis. *Clin Cardiol* 1997;20:132–40.
 185. Manzano C, Vilacosta I, Fernández C, San Román JA, Sarriá C, Pozo E, López J, et al. Evolution of vegetation size in left-sided endocarditis. Is it a prognostic factor during hospitalization? *Rev Esp Cardiol* 2011;64:714–7.
 186. Manzano MC, Vilacosta I, San Román JA, Aragoncillo P, Sarriá C, López D, et al. Acute coronary syndrome in infective endocarditis. *Rev Esp Cardiol* 2007;60:24–31.
 187. Parra JA, Hernández L, Muñoz P, Blanco G, Rodríguez-Álvarez R, Vilar DR, et al. Detection of spleen, kidney and liver infarcts by abdominal computed tomography does not affect the outcome in patients with left-side infective endocarditis. *Medicine (Baltimore)* 2018;97:e11952.
 188. Madoff LC. Splenic abscess. In: Bennett JE, Dolin R, Blaser MJ, editors. *Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases*. 8th ed. Philadelphia: Elsevier Saunders; 2015. p. 979–81.
 189. Dursun M, Yılmaz S, Yılmaz E, Yılmaz R, Onur İ, Oflaz H, et al. The utility of cardiac MRI in diagnosis of infective endocarditis: preliminary results. *Diagn Interv Radiol* 2015;21:28–33.
 190. Duval X, Iung B, Klein I, Brochet E, Thabut G, Arnoult F, et al. Effect of early cerebral magnetic resonance imaging on clinical decisions in infective endocarditis: a prospective study. *Ann Intern Med* 2010;152:497–504.
 191. Kouijzer IJ, Bleeker-Rovers CP, Oyen WJ. 18F-FDG PET/CT for the detection of septic embolisms in patients with infectious endocarditis. *J Nucl Med* 2014;55:1045–6.
 192. Bonfiglioli R, Nanni C, Morigi JJ, Graziosi M, Trapani F, Bartoletti M, et al. 18F-FDG PET/CT diagnosis of unexpected extracardiac septic embolisms in patients with suspected cardiac endocarditis. *Eur J Nucl Med Mol Imaging* 2013;40:1190–6.
 193. Bertagna F, Bisleri G, Motta F, Merli G, Cossalter E, Lucchini S, et al. Possible role of F18-FDG-PET/CT in the diagnosis of endocarditis: preliminary evidence from a review of the literature. *Int J Cardiovasc Imaging* 2012;28:1417–25.
 194. Coulden R, Chung P, Sonnex E, Ibrahim Q, Maguire C, Abele J. Suppression of myocardial 18F-FDG uptake with a preparatory “Atkins-style” low-carbohydrate diet. *Eur Radiol* 2012;22:2221–8.
 195. Caldarella C, Leccisotti L, Treglia G, Giordano A. Which is the optimal acquisition time for FDG PET/CT imaging in patients with infective endocarditis? *J Nucl Cardiol* 2013;20:307–9.
 196. Chen W, Kim J, Molchanova-Cook OP, Dilsizian V. The potential of FDG PET/CT for early diagnosis of cardiac device and prosthetic valve infection before morphologic damages ensue. *Curr Cardiol Rep* 2014;16:459.
 197. Pizzi MN, Roque A, Cuéllar-Calabria H, Fernández-Hidalgo N, Ferreira-González I, González-Alujas MT, et al. 18F-FDG-PET/CTA of Prosthetic cardiac valves and valve-tube grafts: infective versus inflammatory patterns. *JACC Cardiovasc Imaging* 2016;9:1224–7.
 198. Roca M, de Vries EF, Jamar F, Israel O, Signore A. Guidelines for the labelling of leucocytes with (111)In-oxine. Inflammation/Infection Taskgroup of the European Association of Nuclear Medicine. *Eur J Nucl Med Mol Imaging* 2010;37:835–41.
 199. de Vries EF, Roca M, Jamar F, Israel O, Signore A. Guidelines for the labelling of leucocytes with (99m)Tc-HMPAO. Inflammation/Infection Taskgroup of the European Association of Nuclear Medicine. *Eur J Nucl Med Mol Imaging* 2010;37:842–8.
 200. Díez-Villanueva P, Muñoz P, Marín M, Bermejo J, de Alarcón González A, Fariñas MC, et al. Infective endocarditis: Absence of microbiological diagnosis is an independent predictor of inhospital mortality. *Int J Cardiol* 2016;220:162–5.
 201. Pazin GJ, Saul S, Thompson ME. Blood culture positivity: suppression by outpatient antibiotic therapy in patients with bacterial endocarditis. *Arch Intern Med* 1982;142:263–8.
 202. Hall KK, Lyman JA. Updated review of blood culture contamination. *Clin Microbiol Rev* 2006;19:788–802.
 203. Lamy B, Dargère S, Arendrup MC, Parienti JJ, Tattevin P. How to optimize the use of blood cultures for the diagnosis of bloodstream infections? A State-of-the Art. *Front Microbiol* 2016;7:697.
 204. Bouza E, Sousa D, Rodríguez-Créixems M, Lechuz JG, Muñoz P. Is the volume of blood cultured still a significant factor in the diagnosis of bloodstream infections? *J Clin Microbiol* 2007;45:2765–9.
 205. Gould FK, Denning DW, Elliott TS, Foweraker J, Perry JD, Prendergast BD, et al. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. *J Antimicrob Chemother* 2012;67:269–89.
 206. Klinik Mikrobiyoloji Uzmanlık Derneği. Tıbbi Mikrobiyoloji Uzmanları İçin Klinik Örnekten Sonuç Raporuna Uygulama Rehberi: Kan Dolaşımı Örnekleri. Ankara: Klinik Mikrobiyoloji Uzmanlık Derneği; 2017.
 207. Towns ML, Jarvis WR, Hsueh PR. Guidelines on blood cultures. *J Microbiol Immunol Infect* 2010;43:347–9.
 208. Muñoz P, Bouza E, Marín M, Alcalá L, Rodríguez Créixems M, Valerio M, et al. Heart valves should not be routinely cultured. *J Clin Microbiol* 2008;46:2897–901.
 209. García-Granja PE, López J, Vilacosta I, Sarriá C, Ladrón R, Olmos C, et al. Impact of valve culture in the prognosis of active left-sided infective endocarditis. *Clin Infect Dis* 2019;68:1017–23.
 210. Morris AJ, Drinkovic D, Pottumarthy S, Strickett MG, MacCulloch D, Lambie N, et al. Gram stain, culture, and histopathological examination findings for heart valves removed because of infective endocarditis. *Clin Infect Dis* 2003;36:697–704.
 211. Subedi S, Jennings Z, Chen SC. Laboratory approach to the diagnosis of culture-negative infective endocarditis. *Heart Lung Circ* 2017;26:763–71.
 212. Nawrot U, Kowalska-Krochmal B, Sulik-Tyska B, Kozak

- M, Swietek K, Pajaczkowska M, et al. Evaluation of blood culture media for the detection of fungi. *Eur J Clin Microbiol Infect Dis* 2015;34:161–7.
213. Benslimani A, Fenollar F, Lepidi H, Raoult D. Bacterial zoonoses and infective endocarditis, Algeria. *Emerg Infect Dis* 2005;11:216–24.
 214. Fournier PE, Mainardi JL, Raoult D. Value of microimmunofluorescence for diagnosis and follow-up of Bartonella endocarditis. *Clin Diagn Lab Immunol* 2002;9:795–801.
 215. Dowell SF, Peeling RW, Boman J, Carlone GM, Fields BS, Guarner J, et al. Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). *Clin Infect Dis* 2001;33:492–503.
 216. Gdoura R, Pereyre S, Frikha I, Hammami N, Clerc M, Sahnoun Y, et al. Culture-negative endocarditis due to Chlamydia pneumoniae. *J Clin Microbiol* 2002;40:718–20.
 217. Moter A, Musci M, Schmiedel D. Molecular methods for diagnosis of infective endocarditis. *Curr Infect Dis Rep* 2010;12:244–52.
 218. Fenollar F, Raoult D. Molecular diagnosis of bloodstream infections caused by non-cultivable bacteria. *Int J Antimicrob Agents* 2007;30 Suppl 1:S7–15.
 219. Fenollar F, Raoult D. Molecular genetic methods for the diagnosis of fastidious microorganisms. *APMIS* 2004;112:785–807.
 220. Breitkopf C, Hammel D, Scheld HH, Peters G, Becker K. Impact of a molecular approach to improve the microbiological diagnosis of infective heart valve endocarditis. *Circulation* 2005;111:1415–21.
 221. Miller RJ, Chow B, Pillai D, Church D. Development and evaluation of a novel fast broad-range 16S ribosomal DNA PCR and sequencing assay for diagnosis of bacterial infective endocarditis: multi-year experience in a large Canadian healthcare zone and a literature review. *BMC Infect Dis* 2016;16:146.
 222. Kühn C, Disqué C, Mühl H, Orszag P, Stiesch M, Haverich A. Evaluation of commercial universal rRNA gene PCR plus sequencing tests for identification of bacteria and fungi associated with infectious endocarditis. *J Clin Microbiol* 2011;49:2919–23.
 223. Brenner SA, Rooney JA, Manzwetsch P, Regnery RL. Isolation of Bartonella (Rochalimaea) henselae: effects of methods of blood collection and handling. *J Clin Microbiol* 1997;35:544–7.
 224. Raoult D, Casalta JP, Richet H, Khan M, Bernit E, Rovey C, et al. Contribution of systematic serological testing in diagnosis of infective endocarditis. *J Clin Microbiol* 2005;43:5238–42.
 225. Brandão TJ, Januario-da-Silva CA, Correia MG, Zappa M, Abrantes JA, Dantas AM, et al. Histopathology of valves in infective endocarditis, diagnostic criteria and treatment considerations. *Infection* 2017;45:199–207.
 226. Burke A, Tavora F, editors. *Practical Cardiovascular Pathology*. Philadelphia: Wolters Kluwer; 2011.
 227. Miller DV, Revelo MP, editors. *Diagnostic Pathology: Cardiovascular*. 2nd ed. Philadelphia: Elsevier; 2018.
 228. Lepidi H, Durack DT, Raoult D. Diagnostic methods current best practices and guidelines for histologic evaluation in infective endocarditis. *Infect Dis Clin North Am* 2002;16:339–61.
 229. Siciliano RF, Strabelli TM, Zeigler R, Rodrigues C, Castelli JB, Grinberg M, et al. Infective endocarditis due to Bartonella spp. and Coxiella burnetii: experience at a cardiology hospital in Sao Paulo, Brazil. *Ann N Y Acad Sci* 2006;1078:215–22.
 230. Lepidi H, Houpikian P, Liang Z, Raoult D. Cardiac valves in patients with Q fever endocarditis: microbiological, molecular, and histologic studies. *J Infect Dis* 2003;187:1097–106.
 231. Eiken PW, Edwards WD, Tazelaar HD, McBane RD, Zehr KJ. Surgical pathology of nonbacterial thrombotic endocarditis in 30 patients, 1985–2000. *Mayo Clin Proc* 2001;76:1204–12.
 232. Lepidi H, Coulibaly B, Casalta JP, Raoult D. Autoimmunohistochemistry: a new method for the histologic diagnosis of infective endocarditis. *J Infect Dis* 2006;193:1711–7.
 233. Granados U, Fuster D, Pericas JM, Llopis JL, Ninot S, Quintana E, et al. Diagnostic Accuracy of 18F-FDG PET/CT in Infective Endocarditis and Implantable Cardiac Electronic Device Infection: A Cross-Sectional Study. *J Nucl Med* 2016;57:1726–32.
 234. Pinede L, Duhaut P, Loire R. Clinical presentation of left atrial cardiac myxoma. A series of 112 consecutive cases. *Medicine (Baltimore)* 2001;80:159–72.
 235. Roldan CA, Tolstrup K, Macias L, Qualls CR, Maynard D, Charlton G, et al. Libman-Sacks Endocarditis: Detection, Characterization, and Clinical Correlates by Three-Dimensional Transesophageal Echocardiography. *J Am Soc Echocardiogr* 2015;28:770–9.
 236. el-Shami K, Griffiths E, Streiff M. Nonbacterial thrombotic endocarditis in cancer patients: pathogenesis, diagnosis, and treatment. *Oncologist* 2007;12:518–23.
 237. Park LP, Chu VH, Peterson G, Skoutelis A, Lejko-Zupa T, Bouza E, et al. Validated risk score for predicting 6-month mortality in infective endocarditis. *J Am Heart Assoc* 2016;5:e003016.
 238. Mestres CA, Paré JC, Miró JM; Working Group on Infective Endocarditis of the Hospital Clínic de Barcelona. Organization and Functioning of a Multidisciplinary Team for the Diagnosis and Treatment of Infective Endocarditis: A 30-year Perspective (1985–2014). *Rev Esp Cardiol (Engl Ed)* 2015;68:363–8.
 239. Shiue AB, Stancoven AB, Purcell JB, Pinkston K, Wang A, Khara A, et al. Relation of level of B-type natriuretic peptide with outcomes in patients with infective endocarditis. *Am J Cardiol* 2010;106:1011–5.
 240. Benoit M, Thuny F, Le Priol Y, Lepidi H, Bastonero S, Casalta JP, et al. The transcriptional programme of human heart valves reveals the natural history of infective endocarditis. *PLoS One* 2010;5:e8939.
 241. Erwin JP, Otto CM. Infective endocarditis: old problem, new guidelines and still much to learn. *Heart* 2014;100:996–8.
 242. González De Molina M, Fernández-Guerrero JC, Azpitarte J. Infectious endocarditis: degree of discordance between clinical guidelines recommendations and clinical practice. *Rev Esp Cardiol* 2002;55:793–800.
 243. Delahaye F, Rial MO, de Gevigney G, Ecohard R, Delaye J. A critical appraisal of the quality of the management of infective endocarditis. *J Am Coll Cardiol* 1999;33:788–93.
 244. Botelho-Nevers E, Thuny F, Casalta JP, Richet H, Gouriet F, Collart F, et al. Dramatic reduction in infective endocarditis-related mortality with a management-based approach. *Arch Intern Med* 2009;169:1290–8.

245. Chirillo F, Scotton P, Rocco F, Rigoli R, Borsatto F, Pedrocco A, et al. Impact of a multidisciplinary management strategy on the outcome of patients with native valve infective endocarditis. *Am J Cardiol* 2013;112:1171–6.
246. Fernández-Hidalgo N, Almirante B, Tornos P, González-Alujas MT, Planes AM, Larrosa MN, et al. Prognosis of left-sided infective endocarditis in patients transferred to a tertiary-care hospital—prospective analysis of referral bias and influence of inadequate antimicrobial treatment. *Clin Microbiol Infect* 2011;17:769–75.
247. Leibovici L. Aminoglycoside-containing antibiotic combinations for the treatment of bacterial endocarditis: an evidence-based approach. *Int J Antimicrob Agents* 2010;36:S46–9.
248. Davido B, Dinh A, Nemo EM, Makhloufi S, Leplay C, Salomon J. Efficacy of the switch to oral antibiotics in the treatment of non-Staphylococcus aureus infective endocarditis in non-severely ill patients. *Clin Microbiol Infect* 2017;23:124–5.
249. Mzabi A, Kernéis S, Richaud C, Podglajen I, Fernandez-Gerlinger MP, Mainardi JL. Switch to oral antibiotics in the treatment of infective endocarditis is not associated with increased risk of mortality in non-severely ill patients. *Clin Microbiol Infect* 2016;22:607–12.
250. Iversen K, Ihlemann N, Gill SU, Madsen T, Elming H, Jensen KT, et al. Partial oral versus intravenous antibiotic treatment of endocarditis. *N Engl J Med* 2019;380:415–24.
251. Boucher HW. Partial oral therapy for osteomyelitis and endocarditis – Is It Time? *N Engl J Med* 2019;380:487–9.
252. Dickerman SA, Abrutyn E, Barsic B, Bouza E, Cecchi E, Moreno A, et al. The relationship between the initiation of antimicrobial therapy and the incidence of stroke in infective endocarditis: an analysis from the ICE Prospective Cohort Study (ICE-PCS). *Am Heart J* 2007;154:1086–94.
253. Pefanis A, Thauvin-Eliopoulos C, Eliopoulos GM, Moellering RC Jr. Activity of ampicillin-sulbactam and oxacillin in experimental endocarditis caused by beta-lactamase-hyper-producing Staphylococcus aureus. *Antimicrob Agents Chemother* 1993;37:507–11.
254. Backo M, Gaenger E, Burkart A, Chai YL, Bayer AS. Treatment of experimental staphylococcal endocarditis due to a strain with reduced susceptibility in vitro to vancomycin: efficacy of ampicillin-sulbactam. *Antimicrob Agents Chemother* 1999;43:2565–8.
255. Ramos MC, Ing M, Kim E, Witt MD, Bayer AS. Ampicillin-sulbactam is effective in prevention and therapy of experimental endocarditis caused by beta-lactamase-producing coagulase-negative staphylococci. *Antimicrob Agents Chemother* 1996;40:97–101.
256. Lavoie SR, Wong ES, Coudron PE, Williams DS, Markowitz SM. Comparison of ampicillin-sulbactam with vancomycin for treatment of experimental endocarditis due to a beta-lactamase-producing, highly gentamicin-resistant isolate of Enterococcus faecalis. *Antimicrob Agents Chemother* 1993;37:1447–51.
257. Paul M, Zemer-Wassercug N, Talker O, Lishtzinsky Y, Lev B, Samra Z, et al. Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia? *Clin Microbiol Infect* 2011;17:1581–6.
258. García-de-la-Mària C, Pericas JM, Del Río A, Castañeda X, Vila-Farrés X, Armero Y, et al. Early in vitro and in vivo development of high-level daptomycin resistance is common in mitis group Streptococci after exposure to daptomycin. *Antimicrob Agents Chemother* 2013;57:2319–25.
259. Bashore TM, Cabell C, Fowler V Jr. Update on infective endocarditis. *Curr Probl Cardiol* 2006;31:274–352.
260. Sinner SW, Tunkel A. Viridans streptococci, nutritionally variant streptococci, groups C and G streptococci, and other related organisms. In: Bennett JE, Dolin R, Blaser MJ, editors. *Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases*. 8th ed. Philadelphia: Elsevier Saunders; 2015. p. 2349–61.
261. Knoll B, Tleyjeh IM, Steckelberg JM, Wilson WR, Baddour LM. Infective endocarditis due to penicillin-resistant viridans group streptococci. *Clin Infect Dis* 2007;44:1585–92.
262. Fujitani S, Rowlinson MC, George WL. Penicillin G-resistant viridans group streptococcal endocarditis and interpretation of the American Heart Association's Guidelines for the Treatment of Infective Endocarditis. *Clin Infect Dis* 2008;46:1064–6.
263. Prabhu RM, Piper KE, Baddour LM, Steckelberg JM, Wilson WR, Patel R. Antimicrobial susceptibility patterns among viridans group streptococcal isolates from infective endocarditis patients from 1971 to 1986 and 1994 to 2002. *Antimicrob Agents Chemother* 2004;48:4463–5.
264. Berzeg-Deniz D, Şimşek-Yavuz S, Öcalmaz Mfi, Eren-Şensoy A, Ertürk A, Çeken S. Penisilin G: Unutmak için çok mu erken?. In: Şimşek-Yavuz S, Timurkaynak F, editors. XVII. Türk Klinik Mikrobiyoloji ve Enfeksiyon Hastalıkları Kongresi (25–29 Mart 2015, Antalya) Kitabı. İstanbul: Türk Klinik Mikrobiyoloji ve Enfeksiyon Hastalıkları Derneği; 2015. s. 121.
265. Versporten A, Bolokhovets G, Ghazaryan L, Abilova V, Pyshnik G, Spasojevic T, et al. Antibiotic use in eastern Europe: a cross-national database study in coordination with the WHO Regional Office for Europe. *Lancet Infect Dis* 2014;14:381–7.
266. Sütük S, Kaşkatepe B, Çetin M. Antimicrobial susceptibility against penicillin, ampicillin and vancomycin of viridans group Streptococcus in oral microbiota of patients at risk of infective endocarditis. *Infez Med* 2016;24:190–3.
267. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 8.1, valid from 2018-05-15 [Internet]. Basel, Switzerland: EUCAST. Available at: http://www.eu-cast.org/clinical_breakpoints/. Accessed Feb 10, 2020.
268. Finch RG, Eliopoulos GM. Safety and efficacy of glycopeptide antibiotics. *J Antimicrob Chemother* 2005;55 Suppl 2:ii5–13.
269. Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Bolger AF, Levison ME, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. *Circulation* 2005;111:e394–434.
270. Arias CA, Murray BE. Enterococcus species, Streptococcus gallolyticus group, and Leuconostoc species. In: Bennett JE, Dolin R, Blaser MJ, editors. *Mandell, Douglas, and Ben-*

- nett's Principles and Practice of Infectious Diseases. 8th ed. Philadelphia: Elsevier Saunders; 2015:2328–39.
271. Miro JM, Pericas JM, del Rio A; Hospital Clinic Endocarditis Study Group. A new era for treating *Enterococcus faecalis* endocarditis: ampicillin plus short-course gentamicin or ampicillin plus ceftriaxone: that is the question! *Circulation* 2013;127:1763–6.
 272. Nigo M, Munita JM, Arias CA, Murray BE. What's new in the treatment of enterococcal endocarditis? *Curr Infect Dis Rep* 2014;16:431.
 273. Gavalda J, Torres C, Tenorio C, López P, Zaragoza M, Capdevila JA, et al. Efficacy of ampicillin plus ceftriaxone in treatment of experimental endocarditis due to *Enterococcus faecalis* strains highly resistant to aminoglycosides. *Antimicrob Agents Chemother* 1999;43:639–46.
 274. Gavalda J, Len O, Miró JM, Muñoz P, Montejo M, Alarcón A, et al. Brief communication: treatment of *Enterococcus faecalis* endocarditis with ampicillin plus ceftriaxone. *Ann Intern Med* 2007;146:574–9.
 275. Fernández-Hidalgo N, Almirante B, Gavalda J, Gurgui M, Peña C, de Alarcón A, et al. Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating *enterococcus faecalis* infective endocarditis. *Clin Infect Dis* 2013;56:1261–8.
 276. Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. *Clin Infect Dis* 2003;36:159–68.
 277. Falagas ME, Manta KG, Ntziora F, Vardakas KZ. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. *J Antimicrob Chemother* 2006;58:273–80.
 278. Miller WR, Murray BE, Rice LB, Arias CA. Vancomycin-Resistant Enterococci: Therapeutic Challenges in the 21st Century. *Infect Dis Clin North Am* 2016;30:415–39.
 279. Balli EP, Venetis CA, Miyakis S. Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia. *Antimicrob Agents Chemother* 2014;58:734–9.
 280. Britt NS, Potter EM, Patel N, Steed ME. Comparison of the effectiveness and safety of linezolid and daptomycin in vancomycin-resistant enterococcal bloodstream infection: a national cohort study of veterans affairs patients. *Clin Infect Dis* 2015;61:871–8.
 281. Chuang YC, Lin HY, Chen PY, Lin CY, Wang JT, Chang SC. Daptomycin versus linezolid for the treatment of vancomycin-resistant enterococcal bacteraemia: implications of daptomycin dose. *Clin Microbiol Infect* 2016;22:890.e1–890.e7.
 282. Chuang YC, Lin HY, Chen PY, Lin CY, Wang JT, Chen YC, et al. Effect of daptomycin dose on the outcome of vancomycin-resistant, daptomycin-susceptible enterococcus faecium bacteremia. *Clin Infect Dis* 2017;64:1026–34.
 283. Leenstra T, Woudt S, van Heereveld J, et al. Central Asian and Eastern European Surveillance of Antimicrobial Resistance, Annual Report 2017 [Internet]. Geneva: World Health Organization. Available at: http://www.euro.who.int/__data/assets/pdf_file/0005/354434/WHO_CAESAR_AnnualReport_2017.pdf?ua=1. Accessed Feb 10, 2020.
 284. Chang FY, Peacock JE Jr, Musher DM, Triplett P, MacDonaldd BB, Mylotte JM, et al. *Staphylococcus aureus* bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. *Medicine (Baltimore)* 2003;82:333–9.
 285. Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. *Am J Health Syst Pharm* 2009;66:82–98.
 286. Elyasi S, Khalili H, Dashti-Khavidaki S, Mohammadpour A. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. *Eur J Clin Pharmacol* 2012;68:1243–55.
 287. Kim SH, Kim KH, Kim HB, Kim NJ, Kim EC, Oh MD, et al. Outcome of vancomycin treatment in patients with methicillin-susceptible *Staphylococcus aureus* bacteremia. *Antimicrob Agents Chemother* 2008;52:192–7.
 288. Small PM, Chambers HF. Vancomycin for *Staphylococcus aureus* endocarditis in intravenous drug users. *Antimicrob Agents Chemother* 1990;34:1227–31.
 289. McConeghy KW, Bleasdale SC, Rodvold KA. The empirical combination of vancomycin and a β -lactam for *Staphylococcal* bacteremia. *Clin Infect Dis* 2013;57:1760–5.
 290. Park GE, Ko JH, Cho SY, Ha YE, Lee NY, Kang CI, et al. Empirical combination of a β -lactam to vancomycin may not improve outcomes of methicillin-susceptible *Staphylococcus aureus* bacteremia, compared to vancomycin monotherapy. *Eur J Clin Microbiol Infect Dis* 2017;36:1091–6.
 291. Lee S, Choe PG, Song KH, Park SW, Kim HB, Kim NJ, et al. Is cefazolin inferior to nafcillin for treatment of methicillin-susceptible *Staphylococcus aureus* bacteremia? *Antimicrob Agents Chemother* 2011;55:5122–6.
 292. Flynt LK, Kenney RM, Zervos MJ, Davis SL. The safety and economic impact of cefazolin versus nafcillin for the treatment of methicillin-susceptible *staphylococcus aureus* bloodstream infections. *Infect Dis Ther* 2017;6:225–31.
 293. Li J, Echevarria KL, Traugott KA. β -Lactam Therapy for Methicillin-Susceptible *Staphylococcus aureus* Bacteremia: A Comparative Review of Cefazolin versus Antistaphylococcal Penicillins. *Pharmacotherapy* 2017;37:346–60.
 294. McDanel JS, Roghmann MC, Perencevich EN, Ohl ME, Goto M, Livorsi DJ, et al. Comparative effectiveness of cefazolin versus nafcillin or oxacillin for treatment of methicillin-susceptible *staphylococcus aureus* infections complicated by bacteremia: A Nationwide Cohort Study. *Clin Infect Dis* 2017;65:100–6.
 295. Davis JS, Turnidge J, Tong S. A large retrospective cohort study of cefazolin compared with flucloxacillin for methicillin-susceptible *Staphylococcus aureus* bacteraemia. *Int J Antimicrob Agents* 2018;52:297–300.
 296. Pollett S, Baxi SM, Rutherford GW, Doernberg SB, Bacchetti P, Chambers HF. Cefazolin versus Nafcillin for Methicillin-Sensitive *Staphylococcus aureus* Bloodstream Infection in a California Tertiary Medical Center. *Antimicrob Agents Chemother* 2016;60:4684–9.
 297. Lee S, Song KH, Jung SI, Park WB, Lee SH, Kim YS, et al. Comparative outcomes of cefazolin versus nafcillin for methicillin-susceptible *Staphylococcus aureus* bacteraemia: a prospective multicentre cohort study in Korea. *Clin Microbiol Infect* 2018;24:152–8.
 298. Loubet P, Burdet C, Vindrios W, Grall N, Wolff M, Yazdan-

- panah Y, et al. Cefazolin versus anti-staphylococcal penicillins for treatment of methicillin-susceptible *Staphylococcus aureus* bacteraemia: a narrative review. *Clin Microbiol Infect* 2018;24:125–32.
299. Rao SN, Rhodes NJ, Lee BJ, Scheetz MH, Hanson AP, Segreti J, et al. Treatment outcomes with cefazolin versus oxacillin for deep-seated methicillin-susceptible *Staphylococcus aureus* bloodstream infections. *Antimicrob Agents Chemother* 2015;59:5232–8.
 300. Bai AD, Showler A, Burry L, Steinberg M, Ricciuto DR, Fernandes T, et al. Comparative effectiveness of cefazolin versus cloxacillin as definitive antibiotic therapy for MSSA bacteraemia: results from a large multicentre cohort study. *J Antimicrob Chemother* 2015;70:1539–46.
 301. Li J, Echevarria KL, Hughes DW, Cadena JA, Bowling JE, Lewis JS 2nd. Comparison of cefazolin versus oxacillin for treatment of complicated bacteremia caused by methicillin-susceptible *Staphylococcus aureus*. *Antimicrob Agents Chemother* 2014;58:5117–24.
 302. Nannini EC, Singh KV, Arias CA, Murray BE. In vivo effects of cefazolin, daptomycin, and nafcillin in experimental endocarditis with a methicillin-susceptible *Staphylococcus aureus* strain showing an inoculum effect against cefazolin. *Antimicrob Agents Chemother* 2013;57:4276–81.
 303. Nannini EC, Stryjewski ME, Singh KV, Bourgogne A, Rude TH, Corey GR, et al. Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible *Staphylococcus aureus*: frequency and possible cause of cefazolin treatment failure. *Antimicrob Agents Chemother* 2009;53:3437–41.
 304. Murray RJ. *Staphylococcus aureus* infective endocarditis: diagnosis and management guidelines. *Intern Med J* 2005;35 Suppl 2:S25–44.
 305. Nannini EC, Stryjewski ME, Singh KV, Rude TH, Corey GR, Fowler VG Jr, et al. Determination of an inoculum effect with various cephalosporins among clinical isolates of methicillin-susceptible *Staphylococcus aureus*. *Antimicrob Agents Chemother* 2010;54:2206–8.
 306. Sonnevile R, Mirabel M, Hajage D, Tubach F, Vignon P, Perez P, et al. Neurologic complications and outcomes of infective endocarditis in critically ill patients: the ENDO-cardite en REAnimation prospective multicenter study. *Crit Care Med* 2011;39:1474–81.
 307. Snygg-Martin U, Gustafsson L, Rosengren L, Alsjö A, Ackersholm P, Andersson R, et al. Cerebrovascular complications in patients with left-sided infective endocarditis are common: a prospective study using magnetic resonance imaging and neurochemical brain damage markers. *Clin Infect Dis* 2008;47:23–30.
 308. Dien Bard J, Hindler JA, Gold HS, Limbago B. Rationale for eliminating *Staphylococcus* breakpoints for β -lactam agents other than penicillin, oxacillin or ceftazidime. *Clin Infect Dis* 2014;58:1287–96.
 309. Patel UC, McKissic EL, Kasper D, Lentino JR, Pachucki CT, Lee T, et al. Outcomes of ceftriaxone use compared to standard of therapy in methicillin susceptible staphylococcal aureus (MSSA) bloodstream infections. *Int J Clin Pharm* 2014;36:1282–9.
 310. Lothar SA, Press N. Once-Daily Treatments for methicillin-susceptible *Staphylococcus aureus* Bacteremia: Are They Good Enough? *Curr Infect Dis Rep* 2017;19:43.
 311. Kosowska-Shick K, McGhee PL, Appelbaum PC. Affinity of ceftaroline and other β -lactams for penicillin-binding proteins from *Staphylococcus aureus* and *Streptococcus pneumoniae*. *Antimicrob Agents Chemother* 2010;54:1670–7.
 312. Palmer SM, Kang SL, Cappelletty DM, Rybak MJ. Bactericidal killing activities of cefepime, ceftazidime, cefotaxime, and ceftriaxone against *Staphylococcus aureus* and β -lactamase-producing strains of *Enterobacter aerogenes* and *Klebsiella pneumoniae* in an in vitro infection model. *Antimicrob Agents Chemother* 1995;39:1764–71.
 313. Thwaites GE, Edgeworth JD, Gkrania-Klotsas E, Kirby A, Tilley R, Török ME, et al. Clinical management of *Staphylococcus aureus* bacteraemia. *Lancet Infect Dis* 2011;11:208–22.
 314. Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by *Staphylococcus aureus*. *N Engl J Med* 2006;355:653–65.
 315. Carugati M, Bayer AS, Miró JM, Park LP, Guimarães AC, Skoutelis A, et al. High-dose daptomycin therapy for left-sided infective endocarditis: a prospective study from the international collaboration on endocarditis. *Antimicrob Agents Chemother* 2013;57:6213–22.
 316. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in *Staphylococcus aureus* infections: a systematic review and meta-analysis. *Clin Infect Dis* 2012;54:755–71.
 317. Moore CL, Osaki-Kiyan P, Haque NZ, Perri MB, Donabedian S, Zervos MJ. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant *Staphylococcus aureus* with a high vancomycin minimum inhibitory concentration: a case-control study. *Clin Infect Dis* 2012;54:51–8.
 318. Kalil AC, Van Schooneveld TC, Fey PD, Rupp ME. Association between vancomycin minimum inhibitory concentration and mortality among patients with *Staphylococcus aureus* bloodstream infections: a systematic review and meta-analysis. *JAMA* 2014;312:1552–64.
 319. Pericàs JM, Messina JA, García-de-la-Mària C, Park L, Sharma-Kuinkel BK, Marco F, et al. Influence of vancomycin minimum inhibitory concentration on the outcome of methicillin-susceptible *Staphylococcus aureus* left-sided infective endocarditis treated with antistaphylococcal β -lactam antibiotics: a prospective cohort study by the International Collaboration on Endocarditis. *Clin Microbiol Infect* 2017;23:544–9.
 320. Cervera C, Castañeda X, de la María CG, del Río A, Moreno A, Soy D, et al. Effect of vancomycin minimal inhibitory concentration on the outcome of methicillin-susceptible *Staphylococcus aureus* endocarditis. *Clin Infect Dis* 2014;58:1668–75.
 321. Kalimuddin S, Chan YFZ, Phillips R, Ong SP, Archuleta S, Lye DC, et al. A randomized phase 2B trial of vancomycin versus daptomycin for the treatment of methicillin-resistant *Staphylococcus aureus* bacteremia due to isolates with high vancomycin minimum inhibitory concentrations – results of a prematurely terminated study. *Trials* 2018;19:305.
 322. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children: executive summary. *Clin Infect Dis* 2011;52:285–92.
 323. Brown J, Brown K, Forrest A. Vancomycin AUC₂₄/MIC ratio in patients with complicated bacteremia and infective en-

- docarditis due to methicillin-resistant *Staphylococcus aureus* and its association with attributable mortality during hospitalization. *Antimicrob Agents Chemother* 2012;56:634–8.
324. Neely MN, Youn G, Jones B, Jelliffe RW, Drusano GL, Rodvold KA, et al. Are vancomycin trough concentrations adequate for optimal dosing? *Antimicrob Agents Chemother*. 2014;58:309–16.
 325. Neely MN, Kato L, Youn G, Kraler L, Bayard D, van Guilder M, et al. Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing. *Antimicrob Agents Chemother* 2018;62. Pii: e02042–17.
 326. Badwal J. Vanquish thy troughs: targeting AUC/MIC for vancomycin dosing [Internet]. Austin, TX: The University of Texas at Austin. Available at: http://sites.utexas.edu/pharmacotherapy-rounds/files/2018/03/BadwalRR_FinalHandout-without-pic-March-2018.pdf. Accessed Feb 10, 2020.
 327. Chavada R, Ghosh N, Sandaradura I, Maley M, Van Hal SJ. Establishment of an AUC_{0–24} threshold for nephrotoxicity is a step towards individualized vancomycin dosing for methicillin-resistant *Staphylococcus aureus* bacteremia. *Antimicrob Agents Chemother*. 2017;61. pii: e02535–16.
 328. Castañeda X, García-de-la-Mària C, Gasch O, Pericas JM, Armero Y, Soy D, et al. AUC/MIC Pharmacodynamic Target Is Not a Good Predictor of Vancomycin Efficacy in Methicillin-Resistant *Staphylococcus aureus* Experimental Endocarditis. *Antimicrob Agents Chemother* 2017;61. pii: e02486–16.
 329. Drew RH, Sakoulas G. Vancomycin: parenteral dosing, monitoring, and adverse effects in adults [Internet]. Waltham, MA: UpToDate Inc. Available at: <https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults>. Accessed Feb 10, 2020.
 330. Chambers HF, Sande MA. Teicoplanin versus nafcillin and vancomycin in the treatment of experimental endocarditis caused by methicillin-susceptible or -resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother* 1984;26:61–4.
 331. de Górgolas M, Avilés P, Verdejo C, Fernández Guerrero ML. Treatment of experimental endocarditis due to methicillin-susceptible or methicillin-resistant *Staphylococcus aureus* with trimethoprim-sulfamethoxazole and antibiotics that inhibit cell wall synthesis. *Antimicrob Agents Chemother* 1995;39:953–7.
 332. Kaatz GW, Seo SM, Reddy VN, Bailey EM, Rybak MJ. Daptomycin compared with teicoplanin and vancomycin for therapy of experimental *Staphylococcus aureus* endocarditis. *Antimicrob Agents Chemother* 1990;34:2081–5.
 333. Gilbert DN, Wood CA, Kimbrough RC. Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with *Staphylococcus aureus* intravascular infection. The Infectious Diseases Consortium of Oregon. *Antimicrob Agents Chemother* 1991;35:79–87.
 334. Ueda T, Takesue Y, Nakajima K, Ichki K, Wada Y, Komatsu M, et al. High-dose regimen to achieve novel target trough concentration in teicoplanin. *J Infect Chemother* 2014;20:43–7.
 335. Lee CH, Tsai CY, Li CC, Chien CC, Liu JW. Teicoplanin therapy for MRSA bacteremia: a retrospective study emphasizing the importance of maintenance dosing in improving clinical outcomes. *J Antimicrob Chemother* 2015;70:257–63.
 336. Svetitsky S, Leibovici L, Paul M. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. *Antimicrob Agents Chemother* 2009;53:4069–79.
 337. Dohmen PM, Guleri A, Capone A, Utili R, Seaton RA, González-Ramallo VJ, et al. Daptomycin for the treatment of infective endocarditis: results from a European registry. *J Antimicrob Chemother* 2013;68:936–42.
 338. Gasch O, Camoez M, Domínguez MA, Padilla B, Pintado V, Almirante B, et al. Emergence of resistance to daptomycin in a cohort of patients with methicillin-resistant *Staphylococcus aureus* persistent bacteraemia treated with daptomycin. *J Antimicrob Chemother* 2014;69:568–71.
 339. Holubar M, Meng L, Deresinski S. Bacteremia due to methicillin-resistant *Staphylococcus aureus*: New therapeutic approaches. *Infect Dis Clin North Am* 2016;30:491–507.
 340. Senneville E, Caillon J, Calvet B, Jehl F. Towards a definition of daptomycin optimal dose: Lessons learned from experimental and clinical data. *Int J Antimicrob Agents* 2016;47:12–9.
 341. García-de-la-Mària C, Gasch O, García-Gonzalez J, Soy D, Shaw E, Ambrosioni J, et al. The combination of daptomycin and fosfomycin has synergistic, potent, and rapid bactericidal activity against methicillin-resistant *Staphylococcus aureus* in a rabbit model of experimental endocarditis. *Antimicrob Agents Chemother* 2018;62. pii: e02633–17.
 342. Claeys KC, Smith JR, Casapao AM, Mynatt RP, Avery L, Shroff A, et al. Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant *Staphylococcus aureus* infections. *Antimicrob Agents Chemother* 2015;59:1969–76.
 343. Miró JM, Entenza JM, Del Río A, Velasco M, Castañeda X, Garcia de la Mària C, et al. High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant *Staphylococcus aureus* endocarditis. *Antimicrob Agents Chemother* 2012;56:4511–5.
 344. Smith JR, Yim J, Rice S, Stamper K, Kebriaei R, Rybak MJ. Combination of tedizolid and daptomycin against methicillin-resistant *Staphylococcus aureus* in an in vitro model of simulated endocardial vegetations. *Antimicrob Agents Chemother* 2018;62. pii: e00101–18.
 345. Zainah H, Zervos M, Stephane W, Chamas Alhelo S, Alkhoury G, Weinmann A. Daptomycin failure for treatment of pulmonary septic emboli in native tricuspid and mitral valve methicillin-resistant *Staphylococcus aureus* endocarditis. *Case Rep Infect Dis* 2013;2013:653582.
 346. ClinicalTrials.gov. Database. A phase 3 telavancin *Staphylococcus aureus* (S. aureus) bacteremia trial [Internet]. Bethesda, MD: National Institutes of Health. Available at: <https://clinicaltrials.gov/ct2/show/NCT02208063>. Accessed Feb 10, 2020.
 347. Dilworth TJ, Ibrahim O, Hall P, Sliwinski J, Walraven C, Mercier RC. β -Lactams enhance vancomycin activity against methicillin-resistant *Staphylococcus aureus* bacteremia compared to vancomycin alone. *Antimicrob Agents Chemother* 2014;58:102–9.
 348. Davis JS, Sud A, O’Sullivan MVN, Robinson JO, Ferguson PE, Foo H, et al. Combination of vancomycin and β -lactam therapy for methicillin-resistant *Staphylococcus aureus* bacteremia: a pilot multicenter randomized controlled trial. *Clin Infect Dis* 2016;62:173–80.
 349. Jang HC, Kim SH, Kim KH, Kim CJ, Lee S, Song KH, et

- al. Salvage treatment for persistent methicillin-resistant *Staphylococcus aureus* bacteremia: efficacy of linezolid with or without carbapenem. *Clin Infect Dis* 2009;49:395–401.
350. Seah J, Lye DC, Ng TM, Krishnan P, Choudhury S, Teng CB. Vancomycin monotherapy vs. combination therapy for the treatment of persistent methicillin-resistant *Staphylococcus aureus* bacteremia. *Virulence* 2013;4:734–9.
 351. Kullar R, Casapao AM, Davis SL, Levine DP, Zhao JJ, Crank CW, et al. A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis. *J Antimicrob Chemother* 2013;68:2921–6.
 352. Cosgrove SE, Vigliani GA, Fowler VG Jr, Abrutyn E, Corey GR, Levine DP, et al. Initial low-dose gentamicin for *Staphylococcus aureus* bacteremia and endocarditis is nephrotoxic. *Clin Infect Dis* 2009;48:713–21.
 353. Riedel DJ, Weekes E, Forrest GN. Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by *Staphylococcus aureus*. *Antimicrob Agents Chemother* 2008;52:2463–7.
 354. Rieg S, Joost I, Weiß V, Peyerl-Hoffmann G, Schneider C, Hellmich M, et al. Combination antimicrobial therapy in patients with *Staphylococcus aureus* bacteraemia—a post hoc analysis in 964 prospectively evaluated patients. *Clin Microbiol Infect* 2017;23:406.e1–406.e8.
 355. Casalta JP, Zaratzian C, Hubert S, Thuny F, Gouriet F, Habib G, et al. Treatment of *Staphylococcus aureus* endocarditis with high doses of trimethoprim/sulfamethoxazole and clindamycin—Preliminary report. *Int J Antimicrob Agents* 2013;42:190–1.
 356. Klompas M, Kalil AC. Colouring outside the guidelines. *Clin Microbiol Infect* 2017;23:691–2.
 357. Tornos P, Iung B, Permanyer-Miralda G, Baron G, Delahaye F, Gohlke-Bärwolf Ch, et al. Infective endocarditis in Europe: lessons from the Euro heart survey. *Heart* 2005;91:571–5.
 358. Hasbun R, Vikram HR, Barakat LA, Buenconsejo J, Quagliarello VJ. Complicated left-sided native valve endocarditis in adults: risk classification for mortality. *JAMA* 2003;289:1933–40.
 359. Nadji G, Rusinaru D, Réyadi JP, Jeu A, Sorel C, Tribouilloy C. Heart failure in left-sided native valve infective endocarditis: characteristics, prognosis, and results of surgical treatment. *Eur J Heart Fail* 2009;11:668–75.
 360. López J, Sevilla T, Vilacosta I, García H, Sarriá C, Pozo E, et al. Clinical significance of congestive heart failure in prosthetic valve endocarditis. A multicenter study with 257 patients. *Rev Esp Cardiol (Engl Ed)* 2013;66:384–90.
 361. Anguera I, Miro JM, Vilacosta I, Almirante B, Anguita M, Muñoz P, et al. Aorto-cavitary fistulous tract formation in infective endocarditis: clinical and echocardiographic features of 76 cases and risk factors for mortality. *Eur Heart J* 2005;26:288–97.
 362. Piper C, Hetzer R, Körfer R, Bergemann R, Horstkotte D. The importance of secondary mitral valve involvement in primary aortic valve endocarditis: the mitral kissing vegetation. *Eur Heart J* 2002;23:79–86.
 363. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail* 2016;18:891–975.
 364. Kiefer T, Park L, Tribouilloy C, Cortes C, Casillo R, Chu V, et al. Association between valvular surgery and mortality among patients with infective endocarditis complicated by heart failure. *JAMA* 2011;306:2239–47.
 365. Habib G, Tribouilloy C, Thuny F, Giorgi R, Brahim A, Amazouz M, et al. Prosthetic valve endocarditis: who needs surgery? A multicentre study of 104 cases. *Heart* 2005;91:954–9.
 366. Chambers J, Sandoe J, Ray S, Prendergast B, Taggart D, Westaby S, et al. The infective endocarditis team: recommendations from an international working group. *Heart* 2014;100:524–7.
 367. López J, Sevilla T, Vilacosta I, Sarriá C, Revilla A, Ortiz C, et al. Prognostic role of persistent positive blood cultures after initiation of antibiotic therapy in left-sided infective endocarditis. *Eur Heart J* 2013;34:1749–54.
 368. Habib G, Hoen B, Tornos P, Thuny F, Prendergast B, Vilacosta I, et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. *Eur Heart J* 2009;30:2369–413.
 369. Vilacosta I, Graupner C, San Román JA, Sarriá C, Ronderos R, Fernández C, et al. Risk of embolization after institution of antibiotic therapy for infective endocarditis. *J Am Coll Cardiol* 2002;39:1489–95.
 370. Selton-Suty C, Maigrat CH, Devignes J, Goehring F, Erpelding ML, Alla F, et al. Possible relationship between antiphospholipid antibodies and embolic events in infective endocarditis. *Heart* 2018;104:509–16.
 371. Hubert S, Thuny F, Resseguier N, Giorgi R, Tribouilloy C, Le Dolley Y, et al. Prediction of symptomatic embolism in infective endocarditis: construction and validation of a risk calculator in a multicenter cohort. *J Am Coll Cardiol* 2013;62:1384–92.
 372. Takahashi Y, Izumi C, Miyake M, Imanaka M, Kuroda M, Nishimura S, et al. Diagnostic accuracy of the Embolic Risk French Calculator for symptomatic embolism with infective endocarditis among Japanese population. *J Cardiol* 2017;70:607–14.
 373. Hess A, Klein I, Iung B, Lavallée P, Ilic-Habensuss E, Dornic Q, et al. Brain MRI findings in neurologically asymptomatic patients with infective endocarditis. *AJNR Am J Neuroradiol* 2013;34:1579–84.
 374. Goulenok T, Klein I, Mazighi M, Messika-Zeitoun D, Alexandra JF, Mourvillier B, et al. Infective endocarditis with symptomatic cerebral complications: contribution of cerebral magnetic resonance imaging. *Cerebrovasc Dis* 2013;35:327–36.
 375. Merkler AE, Chu SY, Lerario MP, Navi BB, Kamel H. Temporal relationship between infective endocarditis and stroke. *Neurology* 2015;85:512–6.
 376. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Fleisher LA, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the Ameri-

- can College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol* 2017;70:252–89.
377. Pettersson GB, Coselli JS; Writing Committee, Pettersson GB, Coselli JS, Hussain ST, et al. 2016 The American Association for Thoracic Surgery (AATS) consensus guidelines: Surgical treatment of infective endocarditis: Executive summary. *J Thorac Cardiovasc Surg* 2017;153:1241–58.
 378. Ferrera C, Vilacosta I, Fernández C, López J, Sarriá C, Olmos C, et al. Early surgery for acute-onset infective endocarditis. *Eur J Cardiothorac Surg* 2018;54:1060–6.
 379. Tornos P, Gonzalez-Alujas T, Thuny F, Habib G. Infective endocarditis: the European viewpoint. *Curr Probl Cardiol* 2011;36:175–222.
 380. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J* 2017;38:2739–91.
 381. Kang DH, Lee S, Kim YJ, Kim SH, Kim DH, Yun SC, et al. Long-term results of early surgery versus conventional treatment for infective endocarditis trial. *Korean Circ J* 2016;46:846–850.
 382. Tattevin P, Mainardi JL. Analysis of the 2015 American and European guidelines for the management of infective endocarditis. *Med Mal Infect* 2016;46:406–10.
 383. Jia L, Wang Z, Fu Q, Bu H, Wei M. Could early surgery get beneficial in adult patients with active native infective endocarditis? A meta-analysis. *Biomed Res Int* 2017;2017:3459468.
 384. Oliver L, Lepeule R, Moussafeur A, Fiore A, Lim P, Ternacle J. Early surgery in infective endocarditis: Why should we wait? *Arch Cardiovasc Dis* 2016;109:651–4.
 385. Wilbring M, Irmischer L, Alexiou K, Matschke K, Tugtekin SM. The impact of preoperative neurological events in patients suffering from native infective valve endocarditis. *Interact Cardiovasc Thorac Surg* 2014;18:740–7.
 386. Tam DY, Yanagawa B, Verma S, Ruel M, Fremes SE, Mazine A, et al. Early vs late surgery for patients with endocarditis and neurological injury: a systematic review and meta-analysis. *Can J Cardiol* 2018;34:1185–99.
 387. Hodges KE, Hussain ST, Stewart WJ, Pettersson GB. Surgical management of infective endocarditis complicated by ischemic stroke. *J Card Surg* 2017;32:9–13.
 388. Byrne JG, Rezai K, Sanchez JA, Bernstein RA, Okum E, Leacche M, et al. Surgical management of endocarditis: the society of thoracic surgeons clinical practice guideline. *Ann Thorac Surg* 2011;91:2012–9.
 389. Misfeld M, Gírrbach F, Etz CD, Binner C, Aspern KV, Dohmen PM, et al. Surgery for infective endocarditis complicated by cerebral embolism: a consecutive series of 375 patients. *J Thorac Cardiovasc Surg* 2014;147:1837–44.
 390. Yanagawa B, Pettersson GB, Habib G, Ruel M, Saposnik G, Latter DA, et al. Surgical management of infective endocarditis complicated by embolic stroke: practical recommendations for clinicians. *Circulation* 2016;134:1280–92.
 391. Delahaye F. Is early surgery beneficial in infective endocarditis? A systematic review. *Arch Cardiovasc Dis* 2011;104:35–44.
 392. Thanavaro KL, Nixon JV. Endocarditis 2014: an update. *Heart Lung* 2014;43:334–7.
 393. Weber C, Gassa A, Rokohl A, Sabashnikov A, Deppe AC, Eghbalzadeh K, et al. Severity of presentation, not sex, increases risk of surgery for infective endocarditis. *Ann Thorac Surg* 2019;107:1111–7.
 394. De Feo M, Cotrufo M, Carozza A, De Santo LS, Amendolara F, Giordano S, et al. The need for a specific risk prediction system in native valve infective endocarditis surgery. *ScientificWorldJournal* 2012;2012:307571.
 395. Olmos C, Vilacosta I, Habib G, Maroto L, Fernández C, López J, et al. Risk score for cardiac surgery in active left-sided infective endocarditis. *Heart* 2017;103:1435–42.
 396. Gatti G, Perrotti A, Obadia JF, Duval X, Iung B, Alla F, et al. Simple scoring system to predict in-hospital mortality after surgery for infective endocarditis. *J Am Heart Assoc* 2017;6 pii: e004806.
 397. Mistiaen WP. What are the main predictors of in-hospital mortality in patients with infective endocarditis: a review. *Scand Cardiovasc J* 2018;52:58–68.
 398. Tao E, Wan L, Wang W, Luo Y, Zeng J, Wu X. The prognosis of infective endocarditis treated with biological valves versus mechanical valves: A meta-analysis. *PLoS One* 2017;12:e0174519.
 399. García-Granja PE, López J, Vilacosta I, Sarriá C, Ladrón R, Olmos C, et al. Surgery changes prognosis in infective endocarditis: The importance of post-surgical clinical evolution. *Eur J Intern Med* 2018;55:52–6.
 400. Alagna L, Park LP, Nicholson BP, Keiger AJ, Strahilevitz J, Morris A, et al. Repeat endocarditis: analysis of risk factors based on the International Collaboration on Endocarditis – Prospective Cohort Study. *Clin Microbiol Infect* 2014;20:566–75.
 401. Thuny F, Giorgi R, Habachi R, Ansaldi S, Le Dolley Y, Casalta JP, et al. Excess mortality and morbidity in patients surviving infective endocarditis. *Am Heart J* 2012;164:94–101.
 402. Kervan Ü, Koç O, Özatik MA, Bayraktar G, fiener E, Çağlı K, et al. Distribution and service quality of the cardiovascular surgery clinics in Turkey. *Turkish J Thorac Cardiovasc Surg* 2011;19:483–9.
 403. Østergaard L, Valeur N, Ihlemann N, Bundgaard H, Gislason G, Torp-Pedersen C, et al. Incidence of infective endocarditis among patients considered at high risk. *Eur Heart J* 2018;39:623–9.
 404. Østergaard L, Valeur N, Ihlemann N, Smerup MH, Bundgaard H, Gislason G, et al. Incidence and factors associated with infective endocarditis in patients undergoing left-sided heart valve replacement. *Eur Heart J* 2018;39:2668–75.
 405. Ivanovic B, Trifunovic D, Matic S, Petrovic J, Sacic D, Tadic M. Prosthetic valve endocarditis – A trouble or a challenge? *J Cardiol* 2019;73:126–33.
 406. Wang A, Athan E, Pappas PA, Fowler VG Jr, Olaison L, Paré C, et al. Contemporary clinical profile and outcome of prosthetic valve endocarditis. *JAMA* 2007;297:1354–61.
 407. Kolte D, Goldsweig A, Kennedy KF, Abbott JD, Gordon PC, Sellke FW, et al. Comparison of incidence, predictors, and outcomes of early infective endocarditis after transcatheter aortic valve implantation versus surgical aortic valve replacement in the United States. *Am J Cardiol* 2018;122:2112–9.
 408. Evangelista A, Gonzalez-Alujas MT. Echocardiography in infective endocarditis. *Heart* 2004;90:614–7.
 409. Swart LE, Gomes A, Scholtens AM, Sinha B, Tanis W, Lam MGEH, et al. Improving the diagnostic performance of 18f-fluorodeoxyglucose positron-emission tomography/computed tomography in prosthetic heart valve endocarditis.

- Circulation 2018;138:1412–27.
410. Bittencourt MS, Blankstein R. More evidence supporting fluorodeoxyglucose positron emission tomography for diagnosing prosthetic valve infective endocarditis. *Circulation* 2018;138:1428–30.
 411. Saby L, Laas O, Habib G, Cammilleri S, Mancini J, Tesonnier L, et al. Positron emission tomography/computed tomography for diagnosis of prosthetic valve endocarditis: increased valvular 18F-fluorodeoxyglucose uptake as a novel major criterion. *J Am Coll Cardiol* 2013;61:2374–82.
 412. Hindricks G, Camm J, Merkely B, Raatikainen P, Arnar DO. The EHRA White Book 2017. The Current Status of Cardiac Electrophysiology in ESC Member Countries [Internet]. Sophia Antipolis, France: European Heart Rhythm Association. Available at: https://www.escardio.org/static_file/Es-cardio/Subspecialty/EHRA/Publications/Documents/2017/ehra-white-book-2017.pdf. Accessed Feb 10, 2020.
 413. Sohail RM, Wilson W, Baddour LM. Infections of nonvalvular cardiovascular devices. In: Bennett JE, Dolin R, Blaser MJ, editors. *Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases*. 8th ed. Philadelphia: Elsevier Saunders; 2015. p. 1041–56.
 414. Osmonov D, Ozcan KS, Erdinler I, Altay S, Yildirim E, Turkkan C, et al. Cardiac device-related endocarditis: 31-Years' experience. *J Cardiol* 2013;61:175–80.
 415. Kusumoto FM, Schoenfeld MH, Wilkoff BL, Berul CI, Birgersdotter-Green UM, Carrillo R, et al. 2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extraction. *Heart Rhythm* 2017;14:e503–e51.
 416. Tarakji KG, Ellis CR, Defaye P, Kennergren C. Cardiac implantable electronic device infection in patients at risk. *Arrhythm Electrophysiol Rev* 2016;5:65–71.
 417. Bongiorni MG, Tascini C, Tagliaferri E, Di Cori A, Soldati E, Leonildi A, et al. Microbiology of cardiac implantable electronic device infections. *Europace* 2012;14:1334–9.
 418. Sohail MR, Uslan DZ, Khan AH, Friedman PA, Hayes DL, Wilson WR, et al. Risk factor analysis of permanent pacemaker infection. *Clin Infect Dis* 2007;45:166–73.
 419. Sohail MR, Uslan DZ, Khan AH, Friedman PA, Hayes DL, Wilson WR, et al. Infective endocarditis complicating permanent pacemaker and implantable cardioverter-defibrillator infection. *Mayo Clin Proc* 2008;83:46–53.
 420. Narducci ML, Pelargonio G, Russo E, Marinaccio L, Di Monaco A, Perna F, et al. Usefulness of intracardiac echocardiography for the diagnosis of cardiovascular implantable electronic device-related endocarditis. *J Am Coll Cardiol* 2013;61:1398–405.
 421. Erba PA, Sollini M, Conti U, Bandera F, Tascini C, De Tommasi SM, et al. Radiolabeled WBC scintigraphy in the diagnostic workup of patients with suspected device-related infections. *JACC Cardiovasc Imaging* 2013;6:1075–86.
 422. Grammes JA, Schulze CM, Al-Bataineh M, Yesenosky GA, Saari CS, Vrabel MJ, et al. Percutaneous pacemaker and implantable cardioverter-defibrillator lead extraction in 100 patients with intracardiac vegetations defined by transesophageal echocardiogram. *J Am Coll Cardiol* 2010;55:886–94.
 423. Ruttman E, Hangler HB, Kilo J, Höfer D, Müller LC, Hintringer F, et al. Transvenous pacemaker lead removal is safe and effective even in large vegetations: an analysis of 53 cases of pacemaker lead endocarditis. *Pacing Clin Electrophysiol* 2006;29:231–6.
 424. Deharo JC, Bongiorni MG, Rozkovec A, Bracke F, Defaye P, Fernandez-Lozano I, et al. Pathways for training and accreditation for transvenous lead extraction: a European Heart Rhythm Association position paper. *Europace* 2012;14:124–34.
 425. Wilkoff BL, Love CJ, Byrd CL, Bongiorni MG, Carrillo RG, Crossley GH 3rd, et al. Transvenous lead extraction: Heart Rhythm Society expert consensus on facilities, training, indications, and patient management: this document was endorsed by the American Heart Association (AHA). *Heart Rhythm* 2009;6:1085–104.
 426. Pichlmaier M, Knigina L, Kutschka I, Bara C, Oswald H, Klein G, et al. Complete removal as a routine treatment for any cardiovascular implantable electronic device-associated infection. *J Thorac Cardiovasc Surg* 2011;142:1482–90.
 427. Durante-Mangoni E, Casillo R, Bernardo M, Caianiello C, Mattucci I, Pinto D, et al. High-dose daptomycin for cardiac implantable electronic device-related infective endocarditis. *Clin Infect Dis* 2012;54:347–54.
 428. Jan E, Camou F, Texier-Maugein J, Whinnett Z, Caubet O, Ploux S, et al. Microbiologic characteristics and in vitro susceptibility to antimicrobials in a large population of patients with cardiovascular implantable electronic device infection. *J Cardiovasc Electrophysiol* 2012;23:375–81.
 429. Tumbarello M, Pelargonio G, Trecarichi EM, Narducci ML, Fiori B, Bellocchi F, et al. High-dose daptomycin for cardiac implantable electronic device-related infective endocarditis caused by staphylococcal small-colony variants. *Clin Infect Dis* 2012;54:1516–7.
 430. Tascini C, Bongiorni MG, Di Cori A, Di Paolo A, Polidori M, Tagliaferri E, et al. Cardiovascular implantable electronic device endocarditis treated with daptomycin with or without transvenous removal. *Heart Lung* 2012;41:e24–30.
 431. Kornberger A, Schmid E, Kalender G, Stock UA, Doernberger V, Khalil M, et al. Bridge to recovery or permanent system implantation: an eight-year single-center experience in transvenous semipermanent pacing. *Pacing Clin Electrophysiol* 2013;36:1096–103.
 432. Krahn AD, Longtin Y, Philippon F, Birnie DH, Manlucu J, Angaran P, et al. Prevention of Arrhythmia Device Infection Trial: The PADIT Trial. *J Am Coll Cardiol* 2018;72:3098–109.
 433. Sexton DJ, Chu VH. Infective endocarditis in people who inject drugs [Internet]. Waltham, MA: UpToDate Inc. Available at: <https://www.uptodate.com/contents/infective-endocarditis-in-people-who-inject-drugs>. Accessed Feb 10, 2020.
 434. Akinosoglou K, Apostolakis E, Marangos M, Pasvol G. Native valve right sided infective endocarditis. *Eur J Intern Med* 2013;24:510–9.
 435. Fleischauer AT, Ruhl L, Rhea S, Barnes E. Hospitalizations for endocarditis and associated health care costs among persons with diagnosed drug dependence – North Carolina, 2010–2015. *MMWR Morb Mortal Wkly Rep* 2017;66:569–73.
 436. Schranz AJ, Fleischauer A, Chu VH, Wu LT, Rosen DL. Trends in drug use-associated infective endocarditis and heart valve surgery, 2007 to 2017: A study of statewide discharge data. *Ann Intern Med* 2019;170:31–40.
 437. Number with a drug use disorders by substances, Turkey [Internet]. Oxford: Our World in Data. Available at: <https://>

- ourworldindata.org/grapher/number-with-drug-disorders-by-substance?country=TUR. Accessed Feb 10. 2020.
438. Millar BC, Moore JE. Antibiotic prophylaxis, body piercing and infective endocarditis. *J Antimicrob Chemother* 2004;53:123–6.
 439. Chahoud J, Sharif Yakan A, Saad H, Kanj SS. Right-sided infective endocarditis and pulmonary infiltrates: An update. *Cardiol Rev* 2016;24:230–7.
 440. Hussain ST, Witten J, Shrestha NK, Blackstone EH, Pettersson GB. Tricuspid valve endocarditis. *Ann Cardiothorac Surg* 2017;6:255–61.
 441. Ortiz-Bautista C, López J, García-Granja PE, Sevilla T, Vilacosta I, Sarriá C, et al. Current profile of infective endocarditis in intravenous drug users: The prognostic relevance of the valves involved. *Int J Cardiol* 2015;187:472–4.
 442. Müller KA, Zürn CS, Patrik H, Heuschmid M, Hetzel J, Henning A, et al. Massive haemoptysis in an intravenous drug user with infective tricuspid valve endocarditis. *BMJ Case Rep* 2010;2010. pii: bcr1020092404.
 443. San Román JA, Vilacosta I, López J, Revilla A, Arnold R, Sevilla T, et al. Role of transthoracic and transesophageal echocardiography in right-sided endocarditis: one echocardiographic modality does not fit all. *J Am Soc Echocardiogr* 2012;25:807–14.
 444. Ben-Ami R, Giladi M, Carmeli Y, Orni-Wasserlauf R, Siegman-Igra Y. Hospital-acquired infective endocarditis: should the definition be broadened? *Clin Infect Dis* 2004;38:843–50.
 445. Benito N, Miró JM, de Lazzari E, Cabell CH, del Río A, Altclas J, et al. Health care-associated native valve endocarditis: importance of non-nosocomial acquisition. *Ann Intern Med* 2009;150:586–94.
 446. Wu KS, Lee SS, Tsai HC, Wann SR, Chen JK, Sy CL, et al. Non-nosocomial healthcare-associated infective endocarditis in Taiwan: an underrecognized disease with poor outcome. *BMC Infect Dis* 2011;11:221.
 447. Yang F, Zhang B, Yu J, Shao L, Zhou P, Zhu L, et al. Epidemiology and the prognosis of healthcare-associated infective endocarditis in China: the significance of non-nosocomial acquisition. *Emerg Microbes Infect* 2015;4:e38.
 448. Martín-Dávila P, Fortín J, Navas E, Cobo J, Jiménez-Mena M, Moya JL, et al. Nosocomial endocarditis in a tertiary hospital: an increasing trend in native valve cases. *Chest* 2005;128:772–9.
 449. Hwang JW, Park SW, Cho EJ, Lee GY, Kim EK, Chang SA, et al. Risk factors for poor prognosis in nosocomial infective endocarditis. *Korean J Intern Med* 2018;33:102–12.
 450. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV [Internet]. Washington, DC: Department of Health and Human Services. Available at: <https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf>. Accessed Feb 10. 2020.
 451. Freiberg MS, So-Armah K. HIV and cardiovascular disease: We need a mechanism, and we need a plan. *J Am Heart Assoc* 2016;4:e003411.
 452. Sogaard OS, Reekie J, Ristola M, Jevtovic D, Karpov I, Beniowski M, et al. Severe bacterial non-aids infections in HIV-positive persons: incidence rates and risk factors. *J Infect* 2013;66:439–46.
 453. Currie PF, Sutherland GR, Jacob AJ, Bell JE, Brett RP, Boon NA. A review of endocarditis in acquired immunodeficiency syndrome and human immunodeficiency virus infection. *Eur Heart J* 1995;16:15–8.
 454. Miró JM, del Río A, Mestres CA. Infective endocarditis in intravenous drug abusers and HIV-1 infected patients. *Infect Dis Clin North Am* 2002;16:273–95.
 455. Gebo KA, Burke MD, Lucas GM, Moore RD, Wilson LE. Incidence of, risk factors for, clinical presentation, and 1-year outcomes of infective endocarditis in an urban HIV cohort. *J Acquir Immune Defic Syndr* 2006;43:426–32.
 456. Furuno JP, Johnson JK, Schweizer ML, Uche A, Stine OC, Shurland SM, et al. Community-associated methicillin-resistant *Staphylococcus aureus* bacteremia and endocarditis among HIV patients: a cohort study. *BMC Infect Dis* 2011;11:298.
 457. Nahass RG, Weinstein MP, Bartels J, Gocke DJ. Infective endocarditis in intravenous drug users: a comparison of human immunodeficiency virus type 1-negative and -positive patients. *J Infect Dis* 1990;162:967–70.
 458. Pulvirenti JJ, Kerns E, Benson C, Lisowski J, Demarais P, Weinstein RA. Infective endocarditis in injection drug users: importance of human immunodeficiency virus serostatus and degree of immunosuppression. *Clin Infect Dis* 1996;22:40–5.
 459. Taramasso L, Tatarelli P, Di Biagio A. Bloodstream infections in HIV-infected patients. *Virulence* 2016;7:320–8.
 460. Pedro-Botet ML, Mòdol JM, Vallés X, Romeu J, Sopena N, Giménez M, et al. Changes in bloodstream infections in HIV-positive patients in a university hospital in Spain (1995–1997). *Int J Infect Dis* 2002;6:17–22.
 461. Losa JE, Miro JM, Del Río A, Moreno-Camacho A, García F, Claramonte X, et al. Infective endocarditis not related to intravenous drug abuse in HIV-1-infected patients: report of eight cases and review of the literature. *Clin Microbiol Infect* 2003;9:45–54.
 462. Miró JM, del Río A, Mestres CA. Infective endocarditis and cardiac surgery in intravenous drug abusers and HIV-1 infected patients. *Cardiol Clin* 2003;21:167–84.
 463. Chong T, Alejo DE, Greene PS, Redmond JM, Sussman MS, Baumgartner WA, et al. Cardiac valve replacement in human immunodeficiency virus-infected patients. *Ann Thorac Surg* 2003;76:478–80.
 464. Gansera LS, Eszlari E, Deutsch O, Eichinger WB, Gansera B. High-risk cardiac surgery in patients with intravenous drug abuse and/or active hepatitis C or HIV infection: An ethical discussion of six cases. *Thorac Cardiovasc Surg* 2016;64:2–5.
 465. Forestier E, Fraisse T, Roubaud-Baudron C, Selton-Suty C, Pagani L. Managing infective endocarditis in the elderly: new issues for an old disease. *Clin Interv Aging* 2016;11:1199–206.
 466. Oliver L, Lavoute C, Giorgi R, Salaun E, Hubert S, Casalta JP, et al. Infective endocarditis in octogenarians. *Heart* 2017;103:1602–9.
 467. Şimşek Yavuz S. Infective endocarditis in elderly patients. *Turk Kardiyol Dern Ars* 2017;45:56–63.
 468. Pereira L, Machado A, Oliveira J, Almeida P, Bettencourt P. Infective endocarditis presenting as acute renal failure and unusual complications. *Intern Med* 2015;54:1259–63.
 469. Kim B, Huh HJ, Chung DR, Kim WS, Ki CS, Lee NY. The first case of concurrent infective endocarditis and spondylitis caused by *Streptococcus tigurinus*. *Ann Lab Med*

- 2015;35:654–6.
470. Honarbakhsh S, Chowdhury M, Farooqi F, Deaner A. Syncope secondary to left ventricular outflow tract obstruction, an interesting presentation of infective endocarditis. *BMJ Case Rep* 2015;2015. pii: bcr2015211920.
 471. Armiñanzas C, Fariñas-Alvarez C, Zarauza J, Muñoz P, González Ramallo V, Martínez Sellés M, et al. Role of age and comorbidities in mortality of patients with infective endocarditis. *Eur J Intern Med* 2019;64:63–71.
 472. López J, Revilla A, Vilacosta I, Sevilla T, Villacorta E, Sarriá C, et al. Age-dependent profile of left-sided infective endocarditis: a 3-center experience. *Circulation* 2010;121:892–7.
 473. Durante-Mangoni E, Bradley S, Selton-Suty C, Tripodi MF, Barsic B, Bouza E, et al. Current features of infective endocarditis in elderly patients: results of the International Collaboration on Endocarditis Prospective Cohort Study. *Arch Intern Med* 2008;168:2095–103.
 474. Nasim A, Baqi S, Akhtar SF. *Pseudomonas aeruginosa* endocarditis in renal transplant recipients. *Transpl Infect Dis* 2012;14:180–3.
 475. Avery RK, Barnes DS, Teran JC, Wiedemann HP, Hall G, Wacker T, et al. *Listeria monocytogenes* tricuspid valve endocarditis with septic pulmonary emboli in a liver transplant recipient. *Transpl Infect Dis* 1999;1:284–7.
 476. Nelson JK, Giraldeau G, Montoya JG, Deresinski S, Ho DY, Pham M. Donor-derived *coccidioides immitis* endocarditis and disseminated infection in the setting of solid organ transplantation. *Open Forum Infect Dis* 2016;3:ofw086.
 477. George S, Varghese J, Chandrasekhar S, Perumalla R, Reddy MS, Jayanthi V, et al. Gram-negative bacteria causing infective endocarditis: Rare cardiac complication after liver transplantation. *World J Hepatol* 2013;5:296–7.
 478. Sherman-Weber S, Axelrod P, Suh B, Rubin S, Beltramo D, Manacchio J, et al. Infective endocarditis following orthotopic heart transplantation: 10 cases and a review of the literature. *Transpl Infect Dis* 2004;6:165–70.
 479. Regueiro F, Gutiérrez F, Mons R, Riancho G, Revuelta JM. *Aspergillus* endocarditis in lung transplant recipient: successful surgical treatment. *Ann Thorac Surg* 2013;96:321–3.
 480. Morio F, Treilhaud M, Lepelletier D, Le Pape P, Rigal JC, Delile L, et al. *Aspergillus fumigatus* endocarditis of the mitral valve in a heart transplant recipient: a case report. *Diagn Microbiol Infect Dis* 2008;62:453–6.
 481. Unic D, Starcevic B, Sicaja M, Baric D, Rudez I, Biocic S, et al. Aortic valve endocarditis in a transplanted heart after urethral instrumentation. *Ann Thorac Surg* 2013;96:e61–2.
 482. Sayeed R, Drain AJ, Sivasothy PS, Large SR, Wallwork J. Aortic valve replacement for late infective endocarditis after heart–lung transplantation. *Transplant Proc* 2005;37:4537–9.
 483. Goegele H, Ruttman E, Aranda-Michel J, Kafka R, Stelzmueller I, Hausdorfer H, et al. Fatal endocarditis due to extended spectrum betalactamase producing *Klebsiella terrigena* in a liver transplant recipient. *Wien Klin Wochenschr* 2007;119:385–6.
 484. Moreira AL, Haslett PA, Symmans WF. *Propionibacterium acnes* as the cause of endocarditis in a liver transplant recipient. *Clin Infect Dis* 2000;30:224–6.
 485. Szabó PR, Kertész A, Szerafin T, Fehérvári I, Zsom L, Balla J, et al. Infective endocarditis caused by *Chlamydia pneumoniae* after liver transplantation. Case report. *Orv Hetil* 2015;156:896–900. [Abstract]
 486. Bentata Y. Physiopathological approach to infective endocarditis in chronic hemodialysis patients: left heart versus right heart involvement. *Ren Fail* 2017;39:432–9.
 487. Bhatia N, Agrawal S, Garg A, Mohananeey D, Sharma A, Agarwal M, et al. Trends and outcomes of infective endocarditis in patients on dialysis. *Clin Cardiol* 2017;40:423–9.
 488. Labriola L, Jadoul M. Haemodialysis is a major risk factor for infective endocarditis. *Lancet* 2016;388:339–40.
 489. Süleymanlar G, Ateş K, Seyahi N, editörler. Türkiye’de Nefroloji, Diyaliz ve Transplantasyon Registry 2015. T.C. Sağlık Bakanlığı ve Türk Nefroloji Derneği Ortak Raporu. İstanbul: Türk Nefroloji Derneği; 2016.
 490. Lewis SS, Sexton DJ. Metastatic complications of bloodstream infections in hemodialysis patients. *Semin Dial* 2013;26:47–53.
 491. Sexton DJ. Vascular access infections in patients undergoing dialysis with special emphasis on the role and treatment of *Staphylococcus aureus*. *Infect Dis Clin North Am* 2001;15:731–42.
 492. Hsiao CC, Weng CH, Li YJ, Wu HH, Chen YC, Chen YM, et al. Comparison of the clinical features and outcomes of infective endocarditis between hemodialysis and non-hemodialysis patients. *Ther Clin Risk Manag* 2017;13:663–8.
 493. Nucifora G, Badano LP, Viale P, Gianfagna P, Allocca G, Montanaro D, et al. Infective endocarditis in chronic haemodialysis patients: an increasing clinical challenge. *Eur Heart J* 2007;28:2307–12.
 494. Holland TL, Arnold C, Fowler VG Jr. Clinical management of *Staphylococcus aureus* bacteremia: a review. *JAMA* 2014;312:1330–41.
 495. Leither MD, Shroff GR, Ding S, Gilbertson DT, Herzog CA. Long-term survival of dialysis patients with bacterial endocarditis undergoing valvular replacement surgery in the United States. *Circulation* 2013;128:344–51.
 496. Miller LM, Clark E, Dipchand C, Hiremath S, Kappel J, Kiai M, et al. Hemodialysis tunneled catheter-related infections. *Can J Kidney Health Dis* 2016;3:2054358116669129.
 497. Beathard GA. Bacterial colonization of thrombosed dialysis arteriovenous grafts. *Semin Dial* 2015;28:446–9.
 498. Nassar GM, Ayus JC. Clotted arteriovenous grafts: a silent source of infection. *Semin Dial* 2000;13:1–3.
 499. Farag M, Borst T, Sabashnikov A, Zeriuoh M, Schmack B, Arif R, et al. Surgery for Infective Endocarditis: Outcomes and Predictors of Mortality in 360 Consecutive Patients. *Med Sci Monit* 2017;23:3617–26.
 500. Chu VH, Park LP, Athan E, Delahaye F, Freiburger T, Lamas C, et al. Association between surgical indications, operative risk, and clinical outcome in infective endocarditis: a prospective study from the International Collaboration on Endocarditis. *Circulation* 2015;131:131–40.
 501. Sharma V, Candilio L, Hausenloy DJ. Infective endocarditis: An intensive care perspective. *Trends Anaesth Crit Care* 2012;2:36–41.
 502. Karth GD, Koreny M, Binder T, Knapp S. Complicated infective endocarditis necessitating ICU admission: clinical course and prognosis. *Crit Care* 2002;6:149–54.
 503. Keynan Y, Singal R, Kumar K, Arora RC, Rubinstein E. Infective endocarditis in the intensive care unit. *Crit Care Clin* 2013;29:923–51.
 504. Mourvillier B, Trouillet JL, Timsit JF, Baudot J, Chastre J, Rénier B, et al. Infective endocarditis in the intensive care

- unit: clinical spectrum and prognostic factors in 228 consecutive patients. *Intensive Care Med* 2004;30:2046–52.
505. Georges H, Leroy O, Airapetian N, Lamblin N, Zogheib E, Devos P, et al. Outcome and prognostic factors of patients with right-sided infective endocarditis requiring intensive care unit admission. *BMC Infect Dis* 2018;18:85.
 506. Cantier M, Mazighi M, Klein I, Desilles JP, Wolff M, Timsit JF, et al. Neurologic complications of infective endocarditis: Recent findings. *Curr Infect Dis Rep* 2017;19:41.
 507. Miranda-Montero S, Rodríguez-Esteban M, Alvarez-Acosta L, Lubillo-Montenegro S, Pérez-Hernández H, Llorens-León R. Infectious endocarditis in the intensive care unit. *Med Intensiva* 2012;36:460–6. [Abstract]
 508. Leroy O, Georges H, Devos P, Bitton S, De Sa N, Dedrie C, et al. Infective endocarditis requiring ICU admission: epidemiology and prognosis. *Ann Intensive Care* 2015;5:45.
 509. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. *JAMA* 2009;302:2323–9.
 510. Fang G, Keys TF, Gentry LO, Harris AA, Rivera N, Getz K, et al. Prosthetic valve endocarditis resulting from nosocomial bacteremia. A prospective, multicenter study. *Ann Intern Med* 1993;119:560–7.
 511. El-Ahdab F, Benjamin DK Jr, Wang A, Cabell CH, Chu VH, Stryjewski ME, et al. Risk of endocarditis among patients with prosthetic valves and *Staphylococcus aureus* bacteremia. *Am J Med* 2005;118:225–9.
 512. Gouëllou JP, Asfar P, Brenet O, Kouatchet A, Berthelot G, Alquier P. Nosocomial endocarditis in the intensive care unit: an analysis of 22 cases. *Crit Care Med* 2000;28:377–82.
 513. Miranda-Montero S, Rodríguez-Esteban M, Alvarez-Acosta L, Lubillo-Montenegro S, Pérez-Hernández H, Llorens-León R. Infectious endocarditis in the intensive care unit. *Med Intensiva* 2012;36:460–6. [Abstract]
 514. Tabah A, Koulenti D, Laupland K, Misset B, Valles J, Bruzzi de Carvalho F, et al. Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EURO-BACT International Cohort Study. *Intensive Care Med* 2012;38:1930–45.
 515. Masse J, Elkalioubie A, Blazejewski C, Ledoux G, Wallet F, Poissy J, et al. Colonization pressure as a risk factor of ICU-acquired multidrug resistant bacteria: a prospective observational study. *Eur J Clin Microbiol Infect Dis* 2017;36:797–805.
 516. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. *Clin Infect Dis* 2016;62:e1–50.
 517. Arnold CJ, Johnson M, Bayer AS, Bradley S, Giannitsioti E, Miró JM, et al. Candida infective endocarditis: an observational cohort study with a focus on therapy. *Antimicrob Agents Chemother* 2015;59:2365–73.
 518. Haddad SH, Arabi YM, Memish ZA, Al-Shimemeri AA. Nosocomial infective endocarditis in critically ill patients: a report of three cases and review of the literature. *Int J Infect Dis* 2004;8:210–6.
 519. Mermel LA. Short-term peripheral venous catheter-related bloodstream infections: A systematic review. *Clin Infect Dis* 2017;65:1757–62.
 520. Austin ED, Sullivan SB, Whittier S, Lowy FD, Uhlemann AC. Peripheral intravenous catheter placement is an unrecognized source of *Staphylococcus aureus* bloodstream infection. *Open Forum Infect Dis* 2016;3:ofw072.
 521. Le Moing V, Alla F, Doco-Lecompte T, Delahaye F, Piroth L, Chirouze C, et al. *Staphylococcus aureus* bloodstream infection and endocarditis—a prospective cohort study. *PLoS One* 2015;10:e0127385.
 522. Trevino SE, Kollef MH. Management of infections with drug-resistant organisms in critical care: an ongoing battle. *Clin Chest Med* 2015;36:531–41.
 523. Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, et al. DALI: defining antibiotic levels in intensive care unit patients: are current β -lactam antibiotic doses sufficient for critically ill patients? *Clin Infect Dis* 2014;58:1072–83.
 524. Neuville M, El-Helali N, Magalhaes E, Radjou A, Smonig R, Soubirou JF, et al. Systematic overdosing of oxacillin in severe infections treated in ICU: risk factors and side effects. *Ann Intensive Care* 2017;7:34.
 525. Yuan SM. Infective Endocarditis during pregnancy. *J Coll Physicians Surg Pak* 2015;25:134–9.
 526. Kebed KY, Bishu K, Al Adham RI, Baddour LM, Connolly HM, Sohail MR, et al. Pregnancy and postpartum infective endocarditis: a systematic review. *Mayo Clin Proc* 2014;89:1143–52.
 527. Vizzardi E, De Cicco G, Zanini G, D'Aloia A, Faggiano P, Lo Russo R, et al. Infectious endocarditis during pregnancy, problems in the decision-making process: a case report. *Cases J* 2009;2:6537.
 528. Connolly C, O'Donoghue K, Doran H, McCarthy FP. Infective endocarditis in pregnancy: Case report and review of the literature. *Obstet Med* 2015;8:102–4.
 529. Barth WH Jr. Cardiac surgery in pregnancy. *Clin Obstet Gynecol* 2009;52:630–46.
 530. Eliopoulos GM. Principles of anti-infective therapy. In: Bennett JE, Dolin R, Blaser MJ, editors. *Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases*. 8th ed. Philadelphia: Elsevier Saunders; 2015. p. 224–34.
 531. Mistiaen WP. Infective endocarditis in cancer patients: incidence, mechanisms and approach. *Clin J Heart Dis* 2017;1:1003–4.
 532. Fernández-Cruz A, Muñoz P, Sandoval C, Fariñas C, Gutiérrez-Cuadra M, Pericás Pulido JM, et al. Infective endocarditis in patients with cancer: a consequence of invasive procedures or a harbinger of neoplasm? A prospective, multicenter cohort. *Medicine (Baltimore)* 2017;96:e7913.
 533. Thomsen RW, Farkas DK, Friis S, Sværke C, Ording AG, Nørgaard M, et al. Endocarditis and risk of cancer: a Danish nationwide cohort study. *Am J Med* 2013;126:58–67.
 534. Sun LM, Wu JN, Lin CL, Day JD, Liang JA, Liou LR, et al. Infective Endocarditis and Cancer Risk: A Population-Based Cohort Study. *Medicine (Baltimore)* 2016;95:e3198.
 535. Melenotte C, Million M, Audoly G, Gorse A, Dutronc H, Roland G, et al. B-cell non-Hodgkin lymphoma linked to *Coxiella burnetii*. *Blood* 2016;127:113–21.
 536. Kuruvilla J, Forrest DL, Lavoie JC, Nantel SH, Shepherd JD, Song KW, et al. Characteristics and outcome of patients developing endocarditis following hematopoietic stem cell transplantation. *Bone Marrow Transplant* 2004;34:969–73.
 537. Snygg-Martin U, Rasmussen RV, Hassager C, Bruun NE, Andersson R, Olaison L. Warfarin therapy and incidence of cerebrovascular complications in left-sided native valve en-

- docarditis. *Eur J Clin Microbiol Infect Dis* 2011;30:151–7.
538. Chan KL, Dumesnil JG, Cujec B, Sanfilippo AJ, Jue J, Turek MA, et al. A randomized trial of aspirin on the risk of embolic events in patients with infective endocarditis. *J Am Coll Cardiol* 2003;42:775–80.
 539. Duval X, Leport C. Prophylaxis of infective endocarditis: current tendencies, continuing controversies. *Lancet Infect Dis* 2008;8:225–32.
 540. Glenny AM, Oliver R, Roberts GJ, Hooper L, Worthington HV. Antibiotics for the prophylaxis of bacterial endocarditis in dentistry. *Cochrane Database Syst Rev* 2013;10:CD003813.
 541. Cahill TJ, Harrison JL, Jewell P, Onakpoya I, Chambers JB, Dayer M, et al. Antibiotic prophylaxis for infective endocarditis: a systematic review and meta-analysis. *Heart* 2017;103:937–44.
 542. Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. *Circulation* 2007;116:1736–54.
 543. Gould FK, Elliott TS, Fowleraker J, Fulford M, Perry JD, Roberts GJ, et al. Guidelines for the prevention of endocarditis: report of the Working Party of the British Society for Antimicrobial Chemotherapy. *J Antimicrob Chemother* 2006;57:1035–42.
 544. Daly CG, Currie BJ, Jeyasingham MS, Moulds RF, Smith JA, Strathmore NF, et al. A change of heart: the new infective endocarditis prophylaxis guidelines. *Aust Dent J* 2008;53:196–200.
 545. Naber CK, Al-Nawas B, Baumgartner H, Becker HJ, Block M, Erbel R, et al. Prophylaxe der infektiösen Endokarditis. *Kardiologie* 2007;1:243–50.
 546. Tubiana S, Blotière PO, Hoen B, Lesclous P, Millot S, Rudant J, et al. Dental procedures, antibiotic prophylaxis, and endocarditis among people with prosthetic heart valves: nationwide population based cohort and a case crossover study. *BMJ* 2017;358:j3776.
 547. Chen TT, Yeh YC, Chien KL, Lai MS, Tu YK. Risk of infective endocarditis after invasive dental treatments. *Circulation* 2018;138:356–63.
 548. Janszky I, Gémes K, Ahnve S, Asgeirsson H, Möller J. Invasive procedures associated with the development of infective endocarditis. *J Am Coll Cardiol* 2018;71:2744–52.
 549. Lacassin F, Hoen B, Leport C, Selton-Suty C, Delahaye F, Goulet V, et al. Procedures associated with infective endocarditis in adults. A case control study. *Eur Heart J* 1995;16:1968–74.
 550. Duval X, Alla F, Hoen B, Danielou F, Larrieu S, Delahaye F, et al. Estimated risk of endocarditis in adults with predisposing cardiac conditions undergoing dental procedures with or without antibiotic prophylaxis. *Clin Infect Dis* 2006;42:e102–7.
 551. Lockhart PB, Brennan MT, Sasser HC, Fox PC, Paster BJ, Bahrani-Mougeot FK. Bacteremia associated with toothbrushing and dental extraction. *Circulation* 2008;117:3118–25.
 552. Veloso TR, Amiguet M, Rousson V, Giddey M, Vouillamoz J, Moreillon P, et al. Induction of experimental endocarditis by continuous low-grade bacteremia mimicking spontaneous bacteremia in humans. *Infect Immun* 2011;79:2006–11.
 553. Lee P, Shanson D. Results of a UK survey of fatal anaphylaxis after oral amoxicillin. *J Antimicrob Chemother* 2007;60:1172–3.
 554. Nemoto H, Nomura R, Ooshima T, Nakano K. Distribution of amoxicillin-resistant oral streptococci in dental plaque specimens obtained from Japanese children and adolescents at risk for infective endocarditis. *J Cardiol* 2013;62:296–300.
 555. Thornhill MH, Dayer MJ, Forde JM, Corey GR, Chu VH, Couper DJ, et al. Impact of the NICE guideline recommending cessation of antibiotic prophylaxis for prevention of infective endocarditis: before and after study. *BMJ* 2011;342:d2392.
 556. Dayer MJ, Chambers JB, Prendergast B, Sandoe JA, Thornhill MH. NICE guidance on antibiotic prophylaxis to prevent infective endocarditis: a survey of clinicians' attitudes. *QJM* 2013;106:237–43.
 557. Dayer MJ, Jones S, Prendergast B, Baddour LM, Lockhart PB, Thornhill MH. Incidence of infective endocarditis in England, 2000–13: a secular trend, interrupted time-series analysis. *Lancet* 2015;385:1219–28.
 558. Desimone DC, Tleyjeh IM, Correa de Sa DD, Anavekar NS, Lahr BD, Sohail MR, et al. Incidence of infective endocarditis caused by viridans group streptococci before and after publication of the 2007 American Heart Association's endocarditis prevention guidelines. *Circulation* 2012;126:60–4.
 559. Pasquali SK, He X, Mohamad Z, McCrindle BW, Newburger JW, Li JS, et al. Trends in endocarditis hospitalizations at US children's hospitals: impact of the 2007 American Heart Association Antibiotic Prophylaxis Guidelines. *Am Heart J* 2012;163:894–9.
 560. Pant S, Patel NJ, Deshmukh A, Golwala H, Patel N, Badheka A, et al. Trends in infective endocarditis incidence, microbiology, and valve replacement in the United States from 2000 to 2011. *J Am Coll Cardiol* 2015;65:2070–6.
 561. Alam M, Bastakoti B. Therapeutic guidelines: antibiotic. Version 15. *Aust Prescr* 2015;38:137.
 562. Özveri-Koyuncu B, Kandemir S, Sezer FB, Günbay TB. Physician compliance with American Heart Association guidelines for prevention of bacterial endocarditis in dental procedures. *Turk J Med Sci* 2011;41:851–8.
 563. Peeters B, Herijgers P, Beuselinck K, Verhaegen J, Peetermans WE, Herregods MC, et al. Added diagnostic value and impact on antimicrobial therapy of 16S rRNA PCR and amplicon sequencing on resected heart valves in infective endocarditis: a prospective cohort study. *Clin Microbiol Infect* 2017;23:888.e1–e5.
 564. Lockhart PB, Brennan MT, Thornhill M, Michalowicz BS, Noll J, Bahrani-Mougeot FK, et al. Poor oral hygiene as a risk factor for infective endocarditis-related bacteremia. *J Am Dent Assoc* 2009;140:1238–44.
 565. Lockhart PB. Antibiotic prophylaxis for dental procedures: are we drilling in the wrong direction? *Circulation* 2012;126:11–2.
 566. Periodontal Country Profiles, Oral Health Database, 2018 [Internet]. Geneva: WHO. Available at: <http://www.dent.niigata-u.ac.jp/prevent/perio/perio.html>. Accessed Feb 10, 2020.

567. Baltimore RS, Gewitz M, Baddour LM, Beerman LB, Jackson MA, Lockhart PB, et al. Infective endocarditis in childhood: 2015 update: A scientific statement from the American Heart Association. *Circulation* 2015;132:1487–515.
568. Ekkelenkamp MB, van der Bruggen T, van de Vijver DA, Wolfs TF, Bonten MJ. Bacteremic complications of intravascular catheters colonized with *Staphylococcus aureus*. *Clin Infect Dis* 2008;46:114–8.
569. Ruhe JJ, Menon A. Clinical significance of isolated *Staphylococcus aureus* central venous catheter tip cultures. *Clin Microbiol Infect* 2006;12:933–6.
570. van Eck van der Sluijs A, Oosterheert JJ, Ekkelenkamp MB, Hoepelman IM, Peters EJ. Bacteremic complications of intravascular catheter tip colonization with Gram-negative micro-organisms in patients without preceding bacteremia. *Eur J Clin Microbiol Infect Dis* 2012;31:1027–33.
571. Park KH, Kim SH, Song EH, Jang EY, Lee EJ, Chong YP, et al. Development of bacteraemia or fungaemia after removal of colonized central venous catheters in patients with negative concomitant blood cultures. *Clin Microbiol Infect* 2010;16:742–6.
572. Wertheim HF, van Kleef M, Vos MC, Ott A, Verbrugh HA, Fokkens W. Nose picking and nasal carriage of *Staphylococcus aureus*. *Infect Control Hosp Epidemiol* 2006;27:863–7.
573. Saadatian-Elahi M, Tristan A, Laurent F, Rasigade JP, Bouchiat C, Ranc AG, et al. Basic rules of hygiene protect health care and lab workers from nasal colonization by *Staphylococcus aureus*: an international cross-sectional study. *PLoS One* 2013;8:e82851.
574. Kitten T, Munro CL, Wang A, Macrina FL. Vaccination with FimA from *Streptococcus parasanguis* protects rats from endocarditis caused by other viridans streptococci. *Infect Immun* 2002;70:422–5.
575. Spellberg BJ, Ibrahim AS, Avanesian V, Fu Y, Myers C, Phan QT, et al. Efficacy of the anti-*Candida* rAls3p–N or rAls1p–N vaccines against disseminated and mucosal candidiasis. *J Infect Dis* 2006;194:256–60.
576. Weems JJ Jr, Steinberg JP, Filler S, Baddley JW, Corey GR, Sampathkumar P, et al. Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of *Staphylococcus aureus* bacteremia. *Antimicrob Agents Chemother* 2006;50:2751–5.
577. Rupp ME, Holley HP Jr, Lutz J, Dicipinigitis PV, Woods CW, Levine DP, et al. Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-*Staphylococcus aureus* capsular polysaccharide immune globulin in treatment of *Staphylococcus aureus* bacteremia. *Antimicrob Agents Chemother* 2007;51:4249–54.
578. ClinicalTrials.gov Database. A study of the safety and efficacy of 514G3 in subjects hospitalized with bacteremia due to *Staphylococcus aureus* [Internet]. Bethesda, MD: National Institutes of Health. Available at: <https://clinicaltrials.gov/ct2/show/NCT02357966>. Accessed Feb 10, 2020.
579. Otero A. XBiotech announces top-line results for 514G3 antibody therapy in serious *Staphylococcus aureus* infections [Internet]. Los Angeles, CA: Globe Newswire. Available at: <https://globenewswire.com/news-release/2017/04/03/953500/0/en/XBiotech-Announces-Top-Line-Results-for-514G3-Antibody-Therapy-in-Serious-Staphylococcus-aureus-Infections.html>. Accessed Feb 10, 2020.
580. Benjamin DK, Schelonka R, White R, Holley HP, Bifano E, Cummings J, et al. A blinded, randomized, multicenter study of an intravenous *Staphylococcus aureus* immune globulin. *J Perinatol* 2006;26:290–5.
581. DeJonge M, Burchfield D, Bloom B, Duenas M, Walker W, Polak M, et al. Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants. *J Pediatr* 2007;151:260–5.
582. Weisman LE, Thackray HM, Steinhorn RH, Walsh WF, Lassiter HA, Dhanireddy R, et al. A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis. *Pediatrics* 2011;128:271–9.
583. Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, Ordóñez J, et al. Use of a *Staphylococcus aureus* conjugate vaccine in patients receiving hemodialysis. *N Engl J Med* 2002;346:491–6.
584. Fowler VG, Allen KB, Moreira ED, Moustafa M, Isgro F, Boucher HW, et al. Effect of an investigational vaccine for preventing *Staphylococcus aureus* infections after cardiothoracic surgery: a randomized trial. *JAMA* 2013;309:1368–78.
585. ClinicalTrials.gov Database. Safety and efficacy of SA4Ag vaccine in adults having elective open posterior spinal fusion procedures with multilevel instrumentation (STRIVE) [Internet]. Bethesda, MD: National Institutes of Health. Available at: <https://clinicaltrials.gov/ct2/show/NCT02388165>. Accessed Feb 10, 2020.

Keywords: Consensus report; infective endocarditis.

Anahtar sözcükler: Uzlaşı raporu; infektif endokardit.

*Full text of this report was published in "Klinik Dergisi 2019; 32: Özel Sayı-1: 2-116." <https://www.klinikdergisi.org/tr/infektif-endokarditin-tanisi-tedavisi-ve-onlenmesi-ulusal-uzlasi-raporu-165880>. This is a summary of the original full text article.